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This thesis work sought to develop a biomaterial to further the understanding of affinitybased delivery and to serve as a potential treatment for peripheral nerve injury. The use of an
affinity-based delivery system (ABDS) with growth factors in a nerve guidance conduit (NGC) was
hypothesized to promote nerve regeneration and functional recovery following a critical nerve defect.
Evaluation of affinity-based delivery using peptides with varying binding affinity for heparin
determined that peptide binding affinity for heparin affected the release rate and biological activity of
nerve growth factor (NGF) in vitro. The ABDS presented biologically active NGF, which promoted
neurite extension regardless of peptide binding affinity for heparin. The efficacy of the ABDS in
vivo to promote nerve regeneration in a rat sciatic nerve critical defect was determined through
histomorphometric outcomes. The ABDS with any affinity peptide and NGF was similar to the
isograft in aspects of nerve regeneration including: fiber density, nerve regeneration quality, fiber
maturity, and the fiber organization of the regenerating nerve 6 weeks after treatment. Alternatively,
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the ABDS effectively sequestered and slowed the release of glial-derived growth factor (GDNF) and
promoted neurite extension in vitro. The efficacy of the ABDS and GDNF in vivo to promote nerve
regeneration in a rat sciatic nerve critical defect was determined through histomorphometric
outcomes. Histomorphometric measures revealed that the ABDS and GDNF promoted nerve
regeneration similar to the isograft 6 weeks after treatment in measures of fiber density, nerve
regeneration quality, fiber maturity, and the fiber organization of the regenerating nerve. Functional
recovery and modality specific nerve regeneration were studied with the ABDS and growth factor in
a rat sciatic nerve critical defect 12 weeks after treatment. Behavioral outcomes and
electrophysiological responses including evoked motor responses were similar to functional
outcomes in the isograft with the delivery of NGF, but superior to the isograft with the delivery of
GDNF. Both GDNF and NGF delivery supported the regeneration of motor and sensory neurons
equivalent to the isograft, as assessed by retrograde labeling. Overall, this work indicates that
affinity-based growth factor delivery from fibrin matrices enhances nerve regeneration.
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Chapter 1
Introduction
1.1

Overview
This work seeks to develop a biomaterial to serve as a potential treatment for

peripheral nerve injury. This work also seeks to further the understanding of affinity-based
delivery to treat peripheral nerve injury. The overall objective of this research was to
evaluate the effect of growth factor delivery from fibrin matrices containing an affinity-based
delivery system (ABDS) on peripheral nerve injury. Fibrin is a natural material and
provisional extracellular matrix (ECM) involved in wound healing, is biocompatible, and is
capable of promoting cell migration and axonal growth. Sakiyama-Elbert and Hubbell
previously designed an ABDS containing a bi-domain peptide capable of covalent
incorporation during fibrin polymerization and interaction with heparin, which can interact
with growth factors (Sakiyama-Elbert and Hubbell 2000a; Sakiyama-Elbert and Hubbell
2000b). Further research from Sakiyama-Elbert and colleagues developed bi-domain
peptides that could be covalently incorporated during fibrin polymerization and could
interact with heparin with varying affinity to modulate growth factor release rates. The
heparin-binding domain of these bi-domain peptides was identified from an increasing step
gradient of sodium chloride concentration to modulate interaction with heparin (Maxwell,
Hicks et al. 2005). These peptides that vary in binding affinity for heparin were utilized for a
portion of this thesis work to assess the role of peptide binding affinity for heparin and
release rate on nerve regeneration. Additionally, growth factors were used in the ABDS to
1

promote nerve regeneration and potentially target different neuronal populations during
regeneration. The choice of growth factor was based on its ability to target sensory and
motor neuron populations.
The first study of this thesis work assessed the role of peptide binding affinity for
heparin in modulating the release rate and biological activity of nerve growth factor (NGF).
The ABDS incorporating a peptide with high binding affinity for heparin and NGF
previously demonstrated enhanced biological activity (Sakiyama-Elbert and Hubbell 2000a).
To explore the role of binding affinity, peptide sequences were previously identified that
exhibited “high”, “medium”, and “low” affinity for heparin using an increasing step gradient
of sodium chloride concentration (1.0 M, 1.5 M and 2.0 M NaCl were used to elute the low,
medium and high affinity peptide display phage from a heparin affinity column, respectively)
(Maxwell, Hicks et al. 2005). These peptides were synthesized containing the identified
heparin binding domains along with a transglutaminase substrate to allow crosslinking into
fibrin matrices (Maxwell, Hicks et al. 2005). The first study in this thesis work utilized these
peptides to assess the role of peptide binding affinity for heparin with this ABDS and NGF.
The ratio of peptide to heparin and the peptide binding affinity for heparin were varied to
assess differences in NGF release rates through mathematical modeling and in vitro
experiments. The ratio of peptide to heparin and the peptide binding affinity for heparin
were also modulated to assess differences in biological response. Chick embryo dorsal root
ganglia (DRG) were implanted into fibrin matrices with ABDS to assess the biological
activity of delivered NGF through neurite extension.
The second study extended the previous work of the first study to provide insight
into the effect of peptide binding affinity for heparin on nerve regeneration in vivo. To assess
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how peripheral nerve regeneration in vivo was affected, a rat sciatic nerve critical defect (13
mm) was bridged with a nerve guidance conduit (NGC) containing the ABDS with heparin
binding peptides and NGF previously utilized in the first study. To determine the effect of
modulating peptide binding affinity for heparin on nerve regeneration, regenerated tissue
was harvested after 6 weeks for histomorphometric analysis and compared to the clinical
equivalent in a rat model (isograft).
The third study characterized GDNF delivery from the ABDS in vitro utilizing the
heparin binding peptide that maximized nerve extension in vitro and best promoted nerve
regeneration in vivo based on the results of first and second studies. Release rates were
characterized for varying concentrations of delivery system components to determine which
conditions resulted in sustained growth factor delivery. Dose response studies were
performed to determine the appropriate concentration of GDNF to maximize neurite
extension from chick embryo DRG and determine if the ABDS can enhance neurite
extension.
The fourth study extended the results of the third study to assess the role of affinitybased delivery of GDNF in vivo to promote nerve regeneration. A rat sciatic nerve critical
defect (13 mm) was bridged with a NGC containing the ABDS and GDNF to determine its
efficacy in promoting peripheral nerve regeneration. The effectiveness of nerve regeneration
and histomorphometric measures were assessed on regenerating tissue harvested after 6
weeks following treatment. The results were compared to the clinical equivalent in a rat
model (isograft).
The final study assessed the role growth factors in an ABDS have on peripheral
nerve regeneration modalities (sensory versus motor axonal regeneration) and functional
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recovery. A NGC containing the ABDS and growth factors were used to bridge a rat sciatic
nerve critical defect (13 mm). The growth factors included were known to target different
neuronal populations. Behavioral and electrophysiological measures of regenerating nerves
and innervated muscle were measured. The regenerating nerves were also retrograde labeled
to assess sensory and motor nerve regeneration and compared with the functional recovery
results.
This introduction will discuss characteristics of peripheral nerve injury and factors
known to influence nerve regeneration to better elucidate the reasoning for the studies
described in this thesis work. Additionally, current and past treatments for peripheral nerve
injury including biological grafts, nerve guidance conduits, and growth factor delivery will be
discussed to establish the state of the field.

1.2

Peripheral Nerve Injury and Regeneration
The peripheral nervous system (PNS) facilitates the extension of signals from the

central nervous system (CNS) to limbs and other organs. The PNS is susceptible to injury
particularly due to the long axonal processes that extend throughout the body. The most
common cause of these injuries are motor vehicle accidents, stabbing and gun shot wounds,
and stretch and compression related injuries due to falling and represent a large number of
repair procedures performed annually (Kouyoumdjian 2006). Damage to the nervous
system is catastrophic and results in impaired motor and/or sensory function at denervated
end-organs. The PNS is capable of limited regeneration; however, axonal damage still
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remains clinically challenging to treat. This section will describe peripheral nerve injury and
regeneration and issues involved in nerve regeneration.

1.2.1 Characteristics of Injury and Regeneration
Peripheral nerves consist of fascicles containing a mixture of sensory and motor
axons, some myelinated by Schwann cells (SCs). The nerve fascicle itself is made up of
connective tissue layers: the inner endoneurium, the perineurium surrounding individual
fascicles, and the epineurium that bundles the fascicles into a nerve. Injuries to the
peripheral nervous system can involve secondary damage to any one of these layers, or more
severe injuries such as compression or lacerations resulting in nerve lesions or complete
nerve transection (Burnett and Zager 2004).
Following injury to the nerve, Waller determined that the nerve undergoes
pathological changes due to the separation of the axon from the cell body. The degeneration
of the separated axonal portion and myelin (distal stump) has thus been named Wallerian
degeneration (Waller 1850). Initially, the loss of a significant portion of the axon can result
in ionic imbalances and influx. This imbalance and other pathological conditions result in
chromatolysis or possibly cell death. Cellular death after nerve transection can be as high as
30 – 35% in dorsal root ganglia (Otto, Unsicker et al. 1987; McKay Hart, Brannstrom et al.
2002). However, neurons can survive nerve injury and cell death by upregulating genes
responsible for growth and survival. These genes are signaled through trophic support
provided by neighboring regions to the cell body and within the cell itself due to the injury
(Costigan, Befort et al. 2002).
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Besides the resulting neuronal changes, the distal stump undergoes many significant
changes that prepare it for regenerating axons from the proximal stump to enter. The first
of which is the invasion of glial cells to facilitate phagocytosis of myelin and axonal debris in
the distal stump that are inhibitory to axonal regeneration. These glial cells phagocytose the
axonal and myelin debris in a process that takes approximately a week (Waller 1850; Bruck
1997). Experiments by Friede and colleagues determined that macrophages are the major
cell involved in the phagocytosis of myelin and myelin debris, while SCs play a role in
digesting myelin debris, but to a lesser extent (Beuche and Friede 1984; Scheidt and Friede
1987).
Closely following axonal debris clearance SCs proliferate in part due to signaling
from axonal membrane and myelin debris (Salzer and Bunge 1980) but also due to
stimulation by macrophages. Macrophages in vitro produce a medium that is mitogenic for
SCs (Baichwal, Bigbee et al. 1988), and in vivo macrophages accumulate in the distal stump
prior to SC proliferation possibly indicating a role in signaling SC proliferation (Williams and
Hall 1971). These proliferating SC align themselves to the remaining basal lamina and
endoneurial tubes in the distal stump. These aligned SC tubes are known as the bands of
Büngner and act as natural support for sprouting axons during regeneration in order to
facilitate guidance back to end-organ targets (Waller 1850; Burnett and Zager 2004). Thus,
the distal stump acts as a naturally beneficial scaffold to the regenerating axons.
Following nerve transaction numerous sprouts from the original axon grow toward
the distal stump along the basal lamina and SCs in the endoneurial tubes (Haftek and
Thomas 1968). These sprouts or neurites are guided by cell adhesion molecules and ECM,
which neurites bind via cell-surface receptors. SCs are responsible for the production and
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replacement of basal lamina, which principally consists of laminin, type IV collagen and
fibronectin (Rogers, Letourneau et al. 1983; Fawcett and Keynes 1990). These neurites are
also guided by diffusible trophic factors, primarily secreted by SCs and to an extent by their
end-organ targets, which promote neurite survival, migration , and synapse formation at the
end-organ (Reichardt and Tomaselli 1991). Regenerating axons become myelinated shortly
after migrating through the endoneurial tubes in the distal stump. These axons can
reestablish connections with end-organ targets; for example in the case of muscle, motor
axons reform neuromuscular junctions at the motor endplates. Axons reach maturity with
increased myelination after reinnervation with their appropriate end-organ targets.

1.2.2 Challenges in Peripheral Nerve Regeneration
Although the PNS is capable of regeneration, axonal regeneration generally does not
occur for large defects separating the proximal and distal nerve ends if not treated clinically.
More importantly, axonal regeneration does not necessarily lead to restored function, and
the degree of motor versus sensory regeneration varies based on nerve injury treatment
(Fawcett and Keynes 1990). Consequently axonal migration may follow endoneurial tubes
that lead to incorrect end-organs or the correct end-organ such as muscle, but the incorrect
particular muscle (Wigston and Donahue 1988; Kingham and Terenghi 2006). Alternatively,
axons may innervate muscle endplates that they did not previously innervate. As already
mentioned, numerous sprouts from each axon extend into the distal stump, and these
branches typically are eliminated when improper connections with an end-organ target form
(Aitken 1949); however, muscle endplates can be reinnervated by different motor fibers than
originally found. This improper innervation can result in loss of coordination or complete
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improper functioning of the muscles associated due to insufficient muscle contraction
(Kingham and Terenghi 2006). Additionally, the original arrangement of fast and slow
twitch muscle fibers is no longer preserved as it was before in normal muscle (Burnett and
Zager 2004). Furthermore, even with appropriate muscle reinnervation, full functional
recovery outcomes are difficult due to the lack of proprioception provided by proper
sensory reinnervation of the muscle (Burnett and Zager 2004).
Several theories on motor versus sensory nerve regeneration and axonal guidance
exist. One hypothesis considered is that end-organs, such as muscle, provide primary
support for appropriate axonal pathfinding through diffusible cues or tropic support
(Madison, Robinson et al. 2007). Another theory suggests that SCs and endoneurial tubes
provide guidance cues to axons (Politis 1985; Brushart 1988; Wigston and Donahue 1988).
Regenerating axons in general follow a chemotropism where they grow preferentially toward
the distal nerve segment instead of other tissue (Fawcett and Keynes 1990). Robinson,
Madison and colleagues have extended the role of chemotropism to describe how axons
migrate to their correct end-organ pathways. They demonstrated that motor axons rely on
guidance cues in the form of trophic support, primarily diffusible factors derived from their
end-organ targets, to properly find their reinnervation targets. These discoveries were
demonstrated through a series of experiments in rat femoral nerve by modulating the
distance axons travel to their end-organ after injury (Robinson and Madison 2004; Madison,
Robinson et al. 2007; Uschold, Robinson et al. 2007). This theory is also supported by the
observation that motor and sensory axons contain different cell-surface receptors for these
diffusible factors (Boyd and Gordon 2003). Alternatively, the SCs or endoneurial tubes may
be a guiding force for correct axonal pathfinding. Some evidence for this is based on nerve
crush injuries, which differ from complete or partial transection injuries as the axons that
8

regenerate typically remain in their parent endoneurial tubes and reestablish high levels of
functional recovery following injury (Haftek and Thomas 1968). Based on these results, it
may be that the disruption of the endoneurial tubes in traumatic injury leads to inappropriate
target reinnervation and incomplete regeneration following injury. Additionally, research in
preferential motor reinnervation in the rat femoral nerve model led Brushart and colleagues
to hypothesize that the endoneurial tubes themselves or the Schwann cells within the tubes
may direct axons down their correct pathways (Brushart 1988). Overall, axonal guidance is
likely directed to a degree by all these theories. Therefore, therapies to treat injuries should
consider the inclusion of these components to lead to better functional recovery following
injury.

1.3

Treatment Therapies
As previously mentioned, damage to peripheral nerve can result in a defect

disconnecting the proximal and distal nerve stumps leading to loss of motor or sensory
function. The rate of axonal regeneration can vary but on average is around 1 mm/day
making regeneration a slow process for injuries far from the innervation site (Evans 2001;
Burnett and Zager 2004). However, neural outgrowth cannot occur when a significant
defect separates the proximal stump from the distal stump, and surgical intervention is often
required (Lundborg 2000). In order to promote nerve regeneration, clinical strategies for
repair involve bringing the damaged nerve ends together in order to promote migration of
glial cells and surviving axons to grow from the proximal stump to the distal stump. The
most common method of nerve repair is direct suture of the two severed nerve ends
together; however, this is often not feasible if the defect between the two ends is too large,
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as excessive tension produced by directly reconnecting the two ends would disrupt
regeneration (de Medinaceli, Wyatt et al. 1983). Therefore, a bridge or scaffold must serve to
reconnect the proximal and distal stumps. This section describes materials used to serve as
the bridge between the nerve stumps.

1.3.1 Biological Grafts
Biological grafts using microsurgical techniques to bridge critical nerve defects were
first performed in the 1960’s (Millesi 1973). Despite significant advances in nerve
reconstruction, the nerve autograft still remains the clinical standard of care for critical, long,
peripheral nerve defect repair. The autograft provides a scaffold and trophic support in the
form of basal lamina, endoneurial tubes, and SCs for the regenerating axons guiding nerves
to the distal stump (Belkas, Shoichet et al. 2004). Donor nerves that are commonly used as
autografts include the sural (sensory) nerve or other cutaneous nerves (Meek and Coert
2002). However, disadvantages of autografts include loss of feeling and possible pain or
itching at the donor site due to scarring and morbidity, insufficient donor tissue availability,
risk of disease spread, secondary deformities, and less than optimal dimensions (diameter
and/or length) of the donor tissue to span the injury site (Evans 2001; Belkas, Shoichet et al.
2004). Additionally, functional recovery with autografts varies. For example, less than 25%
of patients who received autograft repair of the median nerve at the wrist level regained full
motor function and only 1-3% recovered normal sensation after 5 years (Beazley, Milek et al.
1984; Dellon and Mackinnon 1988). Even with appropriate matching of fascicles during
autograft surgery, axonal guidance to the original fascicles is not guaranteed, which can lead
to incorrect innervation of muscles (Gordon, Sulaiman et al. 2003). Although the autograft
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needs improvements, the less than optimal results with autografts may be attributed in part
to the donor nerve material. For example, the repair of motor nerve defects with motor
grafts was found to be superior to sensory grafts in measures of nerve density, percent nerve,
and total fiber number, independent of graft cross-sectional area (Brenner, Hess et al. 2006).
Also, the repair of a mixed nerve defect with a mixed or motor graft resulted in superior
regeneration than compared to sensory grafts with respect to nerve fiber number, percent
nerve, and nerve density (Nichols, Brenner et al. 2004). However, donor motor nerves are
difficult, if not impossible, to obtain due to their invaluable current function; therefore,
alternative biological grafts have been considered.
Nerve allografts have been considered as one such alternative; however, their use
requires immunosuppression to avoid rejection and nerve regeneration failure due to their
foreign nature (Evans, Midha et al. 1994). The Mackinnon lab has given considerable study
to the use of nerve allografts as alternatives to autografts. They have tested antibodies to
cell-adhesion molecules to induce antigen-specific tolerance, which allow the allografts to
perform as well as isografts in nerve histomorphometry measures in mice (Nakao,
Mackinnon et al. 1995) and rats (Nakao, MacKinnon et al. 1995). They also utilized a
systemic treatment of anti-CD40 ligand monoclonal antibody in mouse (Brenner, Tung et al.
2004) and primate (Brenner, Jensen et al. 2004) models, which resulted in nerve regeneration
in allografts that were similar to autografts during the drug treatment; however, after the
drug treatment was stopped, the allografts were rejected by the body (Brenner, Jensen et al.
2004; Brenner, Tung et al. 2004). To avoid immune suppression, the company Axogen, Inc
developed technology to decellularize allografts taken from human cadaver tissue. The
Mackinnon lab performed studies with the grafts compared to isografts to determine its
potential effectiveness in peripheral nerve injury. They demonstrated that decellularized
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nerve allografts do not perform as well as isografts in nerve histology, electrophysiology, and
effectiveness in bridging a 14 mm critical defect length. The enhanced nerve regeneration in
the isograft was attributed in part to SCs retained in isografts promoting nerve regeneration,
which are lost in the decellularization process (Whitlock, Tuffaha et al. 2009). Others
researchers have also studied acellular nerve grafts as alternatives and similarly concluded
that the lack of cellular support for long nerve defects resulted in nerve regeneration inferior
to autografts (Gulati 1988).
Other biological tissues to serve as grafts have been investigated due to their greater
availability and dimensions (diameter and/or length). Vein or artery has been used a
biological substitute to nervous tissue due to its similarities to a conduit, which can
encapsulate the regenerating nerves and naturally degrades over time (Foidart-Dessalle,
Dubuisson et al. 1997). Consequently, veins and arteries can present a major obstacle to
regeneration because their mechanical properties are not ideal, where the thin walls can lead
to collapse and excess pressure on regenerating nerves, and the tissue is mismatched
potentially leading to scarring (Belkas, Shoichet et al. 2004). Muscle tissue offers a better
alternative to vein or artery due to basal lamina arrangement that mimics the endoneurial
tubes contained in peripheral nerve and contains collagen and laminin to promote nerve
outgrowth (Belkas, Shoichet et al. 2004). Mechanical dissimilarities and scarring due to
tissue mismatch have been observed when it is used as a graft (Meek and Coert 2002). More
promising results with both vein and muscle grafts have been demonstrated with isogenic
SCs injected into either graft as treatment for nerve injury (Fansa, Keilhoff et al. 1999a;
Fansa, Keilhoff et al. 1999b; Fansa and Keilhoff 2004). Either donor tissue loaded with SCs
performed as well as the isograft in histomorphometric measures of nerve density and gratios while the tissues without cells were inferior in nerve regeneration (Fansa and Keilhoff
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2004). However, the donor tissue would still need to be harvested from the recipient in
order to avoid adverse foreign tissue responses (Fansa, Schneider et al. 2002; Belkas,
Shoichet et al. 2004). Therefore, other materials, such as tubular repair using nerve guidance
conduits (NGCs), have been considered.

1.3.2 Nerve Guidance Conduits (NGCs)
NGCs have been studied for many years as a potential “off the shelf” alternative to
nerve grafts for the treatment of nerve gaps. NGCs typically consist of a hollow conduit
that can be filled with an ECM scaffold. Efforts have been focused on the construction of
biodegradable conduits, which may avoid biocompatibility issues present with permanent
material placement in the body. The main advantage of using conduits is that they isolate
the environment where regeneration is occurring and allow controlled presentation of cues
to examine their effects on nerve regeneration.
Lundborg and colleagues considered using a tube or conduit to bridge a nerve defect;
however, their motivation initially was to study peripheral nerve regeneration, not as
alternative treatment for bridging the nerve defect. They used a psuedosynovial neural
sheath to bridge a nerve defect in the rat sciatic nerve (Lundborg and Hansson 1979;
Lundborg and Hansson 1980), which was shortly followed by silicone conduits. Both
materials led to a convenient method to encapsulate trophic factors associated with nerve
regeneration and to study the time course of nerve regeneration. These experiments
provided knowledge that a cellular scaffold of natural proteins and glial cell migration
followed axonal nerve sprouting into an empty tube, indicating that even in the absence of a
cellular scaffold peripheral nerves are capable of producing their own to support
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regeneration (Lundborg and Hansson 1979; Lundborg and Hansson 1980; Lundborg, Dahlin
et al. 1982a; Lundborg, Dahlin et al. 1982b).
Clinically, silicone conduits have been used in the treatment of small nerve defects in
humans (Lundborg, Dahlin et al. 1991; Lundborg, Rosen et al. 1997; Lundborg, Rosen et al.
2004) due to their biocompatibility and mechanical stability, although there have been
reports of associated morbidities. Silicone conduits have been reported to cause chronic
nerve compression and irritation at the implantation site requiring removal (Merle, Dellon et
al. 1989; Danielsen, Dahlin et al. 1993; Dellon 1994; Battiston, Geuna et al. 2005). The longterm presence of a material surrounding nerve may have presented the pathology; therefore,
alternatives have been suggested to alleviate the permanence of the material, such as a
biodegradable conduit.
To this end numerous groups have constructed and examined the properties of
conduit materials such as poly-L-lactic acid (Hadlock, Elisseeff et al. 1998), poly(lactic-coglycolic acid) copolymer (Hadlock, Elisseeff et al. 1998), poly(L-lactide–co-6-caprolactone)
(Nicoli Aldini, Perego et al. 1996) and vinylidenefluoride-trifluoroethylene copolymer (Fine,
Valentini et al. 1991). These polymer materials were selected due to their range of
degradation, mechanical stability, and in the latter instance, its piezoelectric properties that
may be beneficial to nerve regeneration. Alternatively, natural materials can serve as
biodegradable conduits substitutes to polymers, offer permeability to oxygen and nutrients
and may have biocompatible advantages over polymers. The repair of peripheral nerves
with a conduit fabricated from collagen has demonstrated promise in terms of its ability to
promote nerve regeneration and still provide structural support during the regeneration
process. In a rodent and primate short nerve defect model, these conduits demonstrated
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effectiveness in promoting functional recovery in electrophysiology measures compared to
direct suture repair and autologous nerve graft repair (Archibald, Krarup et al. 1991). These
collagen conduits also worked as effectively as nerve autografts in terms of physiological
recovery of motor and sensory responses in primates in further follow-up studies (Li,
Archibald et al. 1992). Alternatively fibronectin has been oriented into mats in order to
produce conduits that can promote nerve regeneration (Whitworth, Brown et al. 1995), and
more recently, fibrin conduits were constructed that promoted nerve regeneration
(Kalbermatten, Pettersson et al. 2009).
Overall, NGCs provide valuable insight into the nerve regeneration process as well
as potential to treat peripheral nerve defects. Polymer and natural NGC materials generally
support axonal regeneration for small defects, and in some cases large defects. However,
NGCs can be further improved by design of a cellular scaffold to encourage and promote
SC and axonal growth into the conduit.

1.3.3 Scaffolds for a Nerve Guidance Conduit
Stimulation of regeneration through NGCs for large nerve defects (> 3 cm) has
proven difficult, so a number of materials have been studied for use as luminal conduit fillers
(Schmidt and Leach 2003). Initial research with NGCs demonstrated that a scaffold for
cellular migration proceeds glial cellular infiltration and axonal growth into a conduit;
therefore, providing a scaffold for cellular migration could circumvent the need for the body
to construct its own scaffold before nerve regeneration and accelerate the regeneration
process. The focus of this thesis work was directed toward a luminal component for NGCs.
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The ideal scaffold would consist of proteins that naturally reside at the nerve defect
site. SCs’ major function is to produce extracellular matrix, where they provide the basal
lamina for the cell (Bunge, Bunge et al. 1986), therefore besides providing a scaffold for
axonal migration, the support of SC proliferation and migration would also be ideal. In vitro
studies comparing various ECM proteins in axonal development have not demonstrated
dramatic differences due to the material protein used. For example, laminin and type IV
collagen substrates have both increased neurite outgrowth over uncoated surfaces (Sanes
1989; Isahara and Yamamoto 1995; Venstrom and Reichardt 1995). Therefore, in vivo
studies have focused on various natural proteins that could encourage nerve regeneration.
The nerve graft itself is primarily made up of basal lamina protein consisting of
laminin, which is produced by SCs. Laminin for this reason has been incorporated into
conduits to test its capacity on nerve regeneration. Madison et al. increased the rate of
axonal growth in a short rat sciatic nerve defect within a silicone or degradable conduit by
the inclusion of laminin gels (Madison, da Silva et al. 1987). Furthermore, they later
followed this work to determine that the inclusion of collagen or laminin gels enhanced
nerve regeneration and the effectiveness in bridging long nerve defects (> 20 mm) (Madison,
Da Silva et al. 1988).
Fibrin is a provisional ECM and a natural material that has been considered for
nerve regeneration. Initial experiments using a 10 mm gap in the rat sciatic nerve contained
within a silicone conduit revealed that at one week a fibrin matrix spanned the chamber. At
two weeks, SCs, fibroblasts, and endothelial cells had migrated into the matrix and into both
stumps, and axons reached the distal stump by three weeks with a proximal gradient of
myelin advancing (Williams, Longo et al. 1983). Therefore, it was postulated that pre-filling

16

a conduit with fibrin could accelerate the regeneration process. Indeed, filling a silicone
conduit with plasma resulted in increased axonal regeneration and SC migration into the
conduit for a rat critical defect (Williams 1987). Besides being native to the injury site, fibrin
also contains two RGD binding sites that can facilitate binding of cells via integrin receptors
(Thiagarajan, Rippon et al. 1996). SCs contain a specific integrin receptor for binding RGD
on fibrin (αVβ8), which can facilitate their migration through fibrin (Chernousov and Carey
2003).
Other natural protein matrices have been investigated for use as a scaffold to fill the
lumen of a NGC. For example, the Bellamkonda lab demonstrated that agarose gels
containing laminin and NGF were comparable to autografts in functional measures in a 10
mm rat sciatic nerve defect (Yu and Bellamkonda 2003). Collagen-glycosaminoglycan
copolymers are an ECM analog and can encourage rat sciatic nerve regeneration across a 10
mm defect (Chamberlain, Yannas et al. 1998). Additionally, alginate can act as a scaffold to
bridge a 2 – 4 cm gap in the rabbit peroneal nerve (Mohanna, Terenghi et al. 2005), which
can also be covalently modified to incorporate heparin and growth factors for delivery to
treat rat sciatic nerve injuries (Ohta, Suzuki et al. 2004).
While luminal scaffolds have focused on natural and ECM materials, synthetic
polymers have been considered as they offer more degrees of freedom for construction and
chemistry. In particular, much research in synthetic materials has involved the use of aligned
or parallel fibers within a conduit to better represent the organized endoneurial tubes
normally present. Synthetic longitudinally arranged polymer filaments have included:
polyamide (Dahlin and Lundborg 1999; Arai, Lundborg et al. 2000), catgut (Dahlin and
Lundborg 1999; Arai, Lundborg et al. 2000), polydioxanone (Arai, Lundborg et al. 2000),
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poly-glycolide (Lietz, Dreesmann et al. 2006) and polyglactin (Arai, Lundborg et al. 2000),
which all supported nerve regeneration across a nerve gap of 15 mm better than an empty
conduit alone. However, the biocompatibility of such polymer filaments may present a
problem as large numbers of macrophages were found on catgut and polyglactin filaments
(Terada, Bjursten et al. 1997). Furthermore, the biodegradability of polymers is an issue as
polyamide is non-resorbable, while the others investigated are biodegradable but may still
break down into acidic byproducts that may inhibit the nerve regeneration process and
present safety issues, especially in long-term implantation situations (Terada, Bjursten et al.
1997).
An additional aspect of the design of all scaffolds is the dependence of the
concentration of the natural or ECM proteins or polymer stiffness used. Navarro and
colleagues have examined agarose (Labrador, Buti et al. 1995), collagen and laminin gels
(Labrador, Buti et al. 1998) to determine if their concentration, or density/stiffness, affected
neural regeneration. Labrador et al. implanted conduits filled with agarose gels of varying
concentrations to bridge a short defect in the rat sciatic nerve. They found that the gel
concentration or stiffness affected functional recovery following nerve injury, where there
was an optimal concentration that enhanced functional recovery compared to other
concentrations (Labrador, Buti et al. 1995). They also performed followed-up studies using
collagen and laminin gels in both short defect and critical mouse sciatic nerve defects, and
again found that there was an optimal concentration or stiffness for either gel solution that
maximized axonal regeneration. They also determined that there were differences in axonal
regeneration between the two solutions based on the defect length; however, the mechanism
and reason for the differences are not well understood (Labrador, Buti et al. 1998).
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Overall, studies considering scaffolds for nerve regeneration have found that natural
materials or proteins can effectively promote nerve regeneration beyond defect lengths that
would normally be limited in empty NGCs. Scaffolds for nerve regeneration also are not
limited to their inclusion in NGCs and may be included in other materials in future work.
This thesis work utilized a fibrin matrix to act as a luminal scaffold for nerve regeneration
due to its regenerative properties and its ability to be chemically modified for drug delivery,
as described later.

1.4

Growth Factors
Growth factors are known to influence neural regeneration. After nerve injury

growth factors, in particular neurotrophic factors, are upregulated due to a decrease in
trophic support from the deinnervated end-organs (Costigan, Befort et al. 2002). These
factors typically exert their effects via binding to cell membrane surface receptors which lead
to a diverse array of transcriptional effects. Following activation, they regulate neurite
growth, branching and synaptogenesis, as well as adult synaptic plasticity and maturation of
neuronal phenotype. Most importantly, neurotrophic factors promote the survival of
neurons and counteract pathological neuronal cell death. Neurotrophic factors currently are
classified by three major families: the neurotrophins, including nerve growth factor (NGF);
the neurokines; and the GDNF family of ligands (GFL) including, GDNF (Boyd and
Gordon 2003). Biological grafts contain neurotrophic factors naturally to a degree, and the
delivery of neurotrophic factors with alternative therapies, such as NGCs, can enhance and
promote nerve regeneration, as will be discussed later. Two of these neurotrophic factors,
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NGF and GDNF, will be described in detail in this section due to their involvement in this
thesis work.

1.4.1 Nerve Growth Factor (NGF)
NGF was the first discovered neurotrophin (Levi-Montalcini and Hamburger 1951;
Cohen, Levi-Montalcini et al. 1954) and was discovered in mouse sarcoma due to its effects
on chick embryo ganglia (Cohen, Levi-Montalcini et al. 1954). Processed and biologically
active NGF (β-NGF) takes the form of a dimer with 3 disulfide chains to stabilize itself
(Sofroniew, Howe et al. 2001a). NGF’s receptors include p140 or, more commonly, tyrosine
receptor kinase A (TrkA) and p75NTR (p75 or low affinity growth factor receptor). Both are
the two major known receptors for NGF in many neurons, and NGF binds to either
receptor with moderate to low affinity. The co-localization of the two receptors forms an
oligomer leading to a high affinity NGF binding receptor stronger than either receptor alone
(Sofroniew, Howe et al. 2001a). TrkA homodimer and the combination of p75-TrkA
heterdimer receptor signaling promote cell survival and differentiation, while p75
homodimer, a tumor necrosis factor receptor family member (Esposito, Patel et al. 2001),
mediates apoptosis upon binding and activation with NGF (Niederhauser, Mangold et al.
2000).
NGF has a specific role in neural development where it supports the survival and
maturation of a number of neuronal cells. It also is involved in nerve injury, where glial cells
upregulate its expression in response to the injury in both the central nervous system and the
peripheral nervous system (Sofroniew, Howe et al. 2001a). Exogenous delivery of NGF has
proven beneficial in numerous studies of sciatic nerve injury. NGF delivered from a silicone
20

tube protected dorsal root ganglia from injury-induced death after sciatic nerve injury (Otto,
Unsicker et al. 1987). NGF delivered via a subcutaneous silicone reservoir for 12 weeks
after nerve injury promoted improved nerve regeneration more than epineurial repair alone
(Santos, Rodrigo et al. 1998). However, NGF is limited in axonal targeting in the peripheral
nervous system as sensory neurons express the receptors for NGF, mainly TrkA, while
motor neurons do not express TrkA receptors (Boyd and Gordon 2003).

1.4.2 Glial Derived Neurotrophic Factor (GDNF)
GDNF was the first discovered of the GDNF family of ligands (Lin, Doherty et al.
1993; Baloh, Enomoto et al. 2000). GDNF was initially identified for its ability to promote
the survival of dopaminergic neurons (Lin, Doherty et al. 1993). Following peripheral nerve
injury its expression is upregulated in SCs (Hoke, Gordon et al. 2002; Boyd and Gordon
2003; Zhao, Veltri et al. 2004), while its receptors are upregulated in motor neurons (Boyd
and Gordon 2003). GDNF is also upregulated in skeletal muscle after injury (Nagano and
Suzuki 2003; Zhao, Veltri et al. 2004) and regulates presynaptic differentiation and
neuromuscular junction connections (Nagano and Suzuki 2003; Yang and Nelson 2004).
GDNF binding is facilitated through a receptor unit, where the primary receptor subunit is
GDNF receptor α-1, which elicits signaling through its linked partner subunit, c-Ret receptor
tyrosine kinase (Baloh, Enomoto et al. 2000).
Exogenous GDNF has promoted neurite outgrowth and neuronal survival in vitro
(Trupp, Ryden et al. 1995; Matheson, Carnahan et al. 1997; Bennett, Michael et al. 1998;
Gavazzi, Kumar et al. 1999; Tucker, Rahimtula et al. 2006; Leclere, Norman et al. 2007) and
promotes survival of axotimized sciatic neurons in vivo (Matheson, Carnahan et al. 1997).
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While GDNF is recognized to be beneficial to both sensory and motor neuron survival and
regeneration, multiple studies have found GDNF to be a potent motor neuron trophic and
survival factor in vitro and in vivo (Henderson, Phillips et al. 1994; Yan, Matheson et al. 1995;
Oppenheim, Houenou et al. 2000). Studies have also shown GDNF to have increased
ability to promote motor nerve regeneration compared to other neurotrophic factors such as
NT-3 or NGF (Barras, Pasche et al. 2002; Fine, Decosterd et al. 2002). Furthermore, the
effects of GDNF go beyond immediate nerve regeneration effects but also play a role in
promoting maturation of the neuromuscular junction and functional connections. Using
nerve-muscle co-cultures Wang et al. demonstrated that GDNF not only increased the total
length of neurites in the motor neurons, but also facilitated aggregation of synaptic vesicles
in the presynaptic terminals, as well as increased acetylcholine receptors clustering in the
postsynaptic terminal (Wang, Yang et al. 2002). Nguyen et al. used transgenic mice that
overexpress GDNF in muscle to show that increased exposure of GDNF not only
decreased spinal motor neuron death, but also led to hyperinnervation of the neuromuscular
junctions (Nguyen, Parsadanian et al. 1998). Therefore, GDNF appears to play a significant
role in motor nerve regeneration and the reestablishment of neuromuscular junctions in
skeletal muscle at denervation.

1.5

Controlled Protein Delivery
Growth factors can promote nerve regeneration; however, injected and ingested

drugs or proteins have associated problems such as low stability due to degradation, rapid
clearance of the drug, which may affect its potency at the injury site, and more importantly,
systemic effects, which may not be desirable due to adverse side effects in other tissues.
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Osmotic pumps and other implantable reservoirs can effectively produce localized delivery
but can have inflammatory problems due to their permanent nature (Schmidt and Leach
2003). An alternative degradable delivery system can be achieved with NGCs, which can
delivery proteins and other soluble molecules using controlled release mechanisms. The
delivery using NGCs can occur from both the conduit walls and materials within the lumen
of the conduit. Different strategies have been considered for drug delivery where the most
common mechanism is through diffusion-based release. Diffusion-based systems release
drug or protein by modulating the diffusion coefficient of the drug within the material. The
primary control of this modulation is through altering the pore size of the material (Langer
and Folkman 1976; Saltzman and Langer 1989).
Numerous NGCs have employed diffusion-based release systems. Aebischer and
colleagues have constructed ethylene vinyl acetate copolymer (EVA) conduits that prevent
the diffusion of growth factors from the outer portion of the conduit while permitting
release to the inner portion that contains the nerve stumps (Aebischer, Salessiotis et al.
1989). The release of growth factors has an initial drug burst but is followed by weeks of
linear growth factor release (Aebischer, Salessiotis et al. 1989). These conduits have been
used to treat 15 mm defects in rat sciatic nerve with basic fibroblast growth factor (bFGF)
(Aebischer, Salessiotis et al. 1989), GDNF, and NGF (Fine, Decosterd et al. 2002) and to
treat 8 mm defects in rat facial nerve with neurotrophin-3 (NT-3) and GDNF (Barras,
Pasche et al. 2002). Alternatively, Terenghi and colleagues used a conduit constructed from
a natural material, fibronectin, to delivery growth factors. Fibronectin mats impregnated
with NGF and NT-3 effectively delivered either growth factor to enhance nerve
regeneration in a rat sciatic nerve defect (Whitworth, Brown et al. 1996; Sterne, Brown et al.
1997).
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Scaffolds for NGCs have included growth factors to promote nerve regeneration,
but few have used controlled release mechanisms. Commonly the drug is loaded into the
scaffold and is therefore free to diffuse away from the conduit (Yu and Bellamkonda 2003).
Affinity-based delivery offers an alternative to loading free drug or growth factor into a
scaffold by non-covalently sequestering the drug within the scaffold or matrix. Affinitybased release systems control release by modulating the concentration of drug or protein
available for release. This thesis work utilized an ABDS to sequester and deliver growth
factors to promote nerve regeneration.

1.5.1 Affinity-based Delivery
ABDSs differ from diffusion-based delivery systems in that the systems immobilize
drugs within the matrix via non-covalent interactions. These non-covalent interactions allow
the release to be controlled by modulating the diffusible fraction of drug. The fraction of
drug available for release can be specifically modulated by degradation of the matrix that
binds the drug, controlling the quantity of binding sites available for drug within the matrix,
or tailoring the affinity of drug interaction with the matrix.
Heparin is a polysaccharide that is commonly used to sequester growth factors in
ABDSs. Heparin protects growth factors from degradation and contains charged sulfate
groups, which facilitate electrostatic interactions with a variety of growth factors via basic
domains (Yamada 1983; Mach, Volkin et al. 1993; Mulloy 2005). ABDSs utilizing heparin
have been employed in a variety of systems. Edelman and colleagues used heparinconjugated Sepharose beads encapsulated in alginate to immobilize bFGF and protect it
from degradation. They achieved controlled growth factor release which could be
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modulated by enzyme degradation (Edelman, Mathiowitz et al. 1991). This delivery system
was effective enough in vivo to reach human clinical trials for the treatment of myocardium
revascularization (Laham, Sellke et al. 1999). Another system was developed using collagen
matrices that immobilized heparin through crosslinking the collagen. The immobilized
heparin in turn sequestered bFGF within the matrices allowing enhanced endothelial cell
proliferation and reducing the minimum cell seeding density needed for proliferation
(Wissink, Beernink et al. 2000a; Wissink, Beernink et al. 2000b). More recently, heparin was
methacrylated and copolymerized with dimethacrylated poly(ethylene glycol) monomers to
yield hydrogels that sequester bFGF (Benoit and Anseth 2005).
Sakiyama-Elbert and Hubbell developed an ABDS that sequesters proteins in a fibrin
matrix using non-covalent interactions (Sakiyama-Elbert and Hubbell 2000a; SakiyamaElbert and Hubbell 2000b). This system utilizes a bi-domain peptide that is uniquely able to
incorporate into a fibrin matrix and still interact with molecules on its other domain.
Fibrinogen is normally cleaved at acceptor sites by thrombin which permits interactions at
the acceptor sites with other fibrinogen proteins resulting in a non-covalent fibrin mesh.
This is further stabilized by the formation of covalent bonds within the mesh due to
transglutaminase substrates contained on fibrinogen facilitated through the transglutaminase
Factor XIIIa (Loewy, Dunathan et al. 1961). In the ABDS, one domain of the bi-domain
peptide consists of a transglutaminase substrate, based on α2-plasmin inhibitor (Ichinose,
Tamaki et al. 1983; Kimura, Tamaki et al. 1985), which allows it to be crosslinked into fibrin
matrices during polymerization. The other domain consists of a modified version of the
heparin-binding domain from antithrombin III (Tyler-Cross, Sobel et al. 1994; Tyler-Cross,
Sobel et al. 1996; Sakiyama, Schense et al. 1999) allowing non-covalent interactions of
heparin to peptide crosslinked within a fibrin matrix. The heparin-binding domain has the
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capability to sequester various neurotrophic factors due to their ability to interact with
heparin to varying degrees.

1.6

Concluding Remarks
Previously, the aforementioned fibrin-based ABDS was applied to treat peripheral

nerve injury using the delivery of NGF (Lee, Yu et al. 2003a). This study demonstrated the
efficacy of this ABDS to treat peripheral nerve injury; however, additional aspects of the
delivery system were considered of interest: what role peptide binding affinity for heparin
might perform in peripheral nerve injury treatment and whether other growth factors such as
GDNF could be delivered to treat nerve injury, particularly due to the ability of GDNF to
target motor axons which cannot be specifically targeted with NGF due to the lack of
receptors. Therefore, this thesis work first examined the role of each component in vitro and
then applied each to a rat animal model of peripheral nerve injury to assess the role of each
in nerve regeneration.
The rat sciatic nerve has been classically used to study peripheral nerve injury due to
its availability, cost, and nerve size. The rat sciatic nerve has a fair degree of sensitivity to
histological measures of nerve regeneration, as at mid-thigh level the sciatic nerve contains a
mixture of sensory and motor axons (approximately 28,000 axons); of these axons, 8000 are
myelinated and 4000 – 5000 of these myelinated axons are motor fibers (Schmalbruch 1986;
Schmalbruch 1987a; Schmalbruch 1987b; Mackinnon and Dellon 1988). Furthermore, rat
nerve morphology bears similarities to human nerve morphology (Mackinnon and Dellon
1988). Additionally as already discussed, the placement of a silicone conduit between nerve
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stumps results in nerve regeneration in a rat (Williams, Longo et al. 1983); however, the
repair of the rat sciatic nerve with a silicone conduit resulted in nerve regeneration only
when the gap length was 10 mm or less. The use of a defect greater than 10 mm resulted in
dramatically fewer instances of nerve regeneration (Lundborg, Dahlin et al. 1982a).
Therefore, a silicone conduit filled with the ABDS can serve as useful injury model to
observe improvements in nerve regeneration and was thus chosen as the in vivo injury model
used in this thesis work.
This thesis work utilized affinity-based delivery to delivery neurotrophic factors to
promote peripheral nerve regeneration. The first and second studies of this thesis work
utilized peptides with varying binding affinity for heparin to determine whether peptide
binding affinity for heparin or release rate affected peripheral nerve regeneration both in vitro
and in vivo. The third study investigated whether the growth factor GDNF could be
sequestered by the ABDS and how the release rates could be modulated. It also determined
how the ABDS and GDNF might be directed to promote in vivo nerve regeneration by
assessing in vitro neurite extension. The fourth study considered the efficacy of the ABDS
and GDNF in promoting peripheral nerve regeneration following injury in a short-term
animal model through histology measures. The final study utilized the ABDS with both
NGF and GDNF to determine whether the ABDS could promote functional recovery
following injury in a long-term animal model and whether there were differences in sensory
versus motor nerve regeneration. Overall, this thesis work represents an effort toward
designing a material for the potential treatment of peripheral nerve injury.
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Chapter 2
Release rate controls biological activity of nerve growth
factor released from fibrin matrices containing affinitybased delivery systems*
2.1

Abstract
Previously, combinatorial techniques were used to identify peptide sequences

exhibiting high, medium, and low affinity for heparin. Bi-domain peptides were synthesized
containing a transglutaminase sequence for one domain and one of the heparin affinity
sequences for the other domain. A delivery system was made consisting of bi-domain
peptides, heparin, and nerve growth factor (NGF), which binds to heparin with moderate
affinity. The goal of this research was to determine if peptide affinity for heparin and the
molar ratio of peptide to heparin affected the release rate of NGF from the delivery system
and the biological activity of NGF release. This study also explored whether peptide affinity
modulated biological activity independent of release rate. Mathematically modeling the
delivery system confirmed that release could be controlled by both peptide affinity and
molar ratio of peptide to heparin. Experimentally the rate of NGF release from the delivery
system was found to be affected by the affinity and molar ratio. The delivery system
presented biologically active NGF as assayed by embryonic chick dorsal root ganglia (DRGs)
neurite extension, where extension was similar to or increased for DRGs grown in fibrin
matrices containing the delivery system compared to DRGs grown with NGF in the culture
media. Furthermore, by modulating the molar ratio of peptide to heparin in the delivery
*Contents of this chapter were published in J Biomed Mater Res A. 84A (2), 300-312, 2008 and were
reprinted with permission of the publisher
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system, similar release rates of NGF were obtained for different affinity peptides and these
conditions promoted similar levels of neurite extension, demonstrating that release rate
appears to be the main mechanism controlling the biological activity of released NGF.

2.2

Introduction
The peripheral nervous system is capable of limited regeneration after injury,

however in the case of large nerve gaps, surgical intervention is often required (Lundborg
2000). Nerve autografts are commonly used to repair these larger gaps but their limitations
suggest that an alternative is needed (Staniforth and Fisher 1978; Lundborg 2000).
Biomaterial matrices and neurotrophins, such as nerve growth factor (NGF), have been
implicated as potential therapeutics for peripheral nerve injury (Schmidt and Leach 2003;
Bellamkonda 2006), where NGF has been shown to promote neurite extension in vitro
(Conti, Fischer et al. 1997; Macias, Battocletti et al. 2000; Sakiyama-Elbert and Hubbell
2000a; Xu, Yu et al. 2002) and nerve regeneration in vivo when combined with a biomaterial
scaffold (Xu, Yu et al. 2002; Lee, Yu et al. 2003b; Yu and Bellamkonda 2003). A nerve
guidance conduit filled with a biomaterial scaffold and NGF could be used as potential
treatment for peripheral nerve injury, providing a physical bridge between the severed nerve
ends and cues for neuronal survival. In order to maximize their effect on regeneration,
controlled release of the growth factors is needed.
Diffusion-based release from biomaterial scaffolds is a common mechanism of drug
delivery, where release of the drug is controlled by the diffusion coefficient of the drug
within the material. By modulating the pore size of the material, the diffusion coefficient of
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the material can be altered (Langer and Folkman 1976; Saltzman and Langer 1989; Burdick,
Ward et al. 2006). Alternatively, affinity-based delivery systems have been studied, which
differ in that the delivery systems immobilize drugs within the matrix via non-covalent
interactions allowing the release to be controlled by the modulating the fraction of the drug
in the diffusible form.
Affinity-based delivery systems utilizing heparin have been used for a variety of
applications and take advantage of the ability of the sulfated groups on heparin to interact
with proteins, such as growth factors, via basic domains (Mach, Volkin et al. 1993; Mulloy
2005). One such system was developed by Edelman and coworkers and used heparinconjugated Sepharose beads encapsulated in alginate to immobilize basic fibroblast growth
factor (bFGF). This system allowed the growth factors to be released in a controlled process
over time and protected them from degradation within the alginate matrix (Edelman,
Mathiowitz et al. 1991; Laham, Sellke et al. 1999). Another system was developed using
heparinized collagen matrices, made by crosslinking collagen and covalently immobilizing
heparin within the matrices. This system was able to sequester bFGF within collagen
matrices allowing enhanced endothelial cell proliferation and reducing the minimum cell
seeding density required for proliferation (Wissink, Beernink et al. 2000a; Wissink, Beernink
et al. 2000b). More recently, heparin was copolymerized with poly(ethylene glycol) (PEG)
dimethacrylate to yield hydrogels that sequestered bFGF (Benoit and Anseth 2005). While
another group used hyaluronan, gelatin, and heparin modified with thiol groups and
crosslinked these components with PEG diacrylate to make hydrogels that sequestered
vascular endothelial growth factor or bFGF (Pike, Cai et al. 2006).
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We have developed an affinity-based delivery system that sequesters proteins within
a fibrin matrix using non-covalent interactions (Sakiyama-Elbert and Hubbell 2000a;
Sakiyama-Elbert and Hubbell 2000b). This system contains a bi-domain peptide, consisting
of a transglutaminase substrate from α2-plasmin inhibitor (Ichinose, Tamaki et al. 1983;
Kimura, Tamaki et al. 1985), and a heparin-binding domain. Based on the transglutaminase
substrate the peptide is crosslinked into fibrin matrices during polymerization by Factor
XIIIa, leaving the other domain free to interact with heparin. This work demonstrated that
this delivery system is capable of delivering NGF through heparin interactions with NGF,
which binds with modest affinity, creating a ternary complex (peptide, heparin, and NGF)
within the fibrin matrix (Sakiyama-Elbert and Hubbell 2000a).
To modulate the affinity of the heparin-binding domain for heparin, combinatorial
techniques were used to identify peptides with varying affinity for heparin. Peptide
sequences were identified exhibiting “high”, “medium”, and “low” affinity for heparin using
an increasing step gradient of sodium chloride concentration (1 M, 1.5 M and 2.0 M were
used to elute the low, medium and high affinity peptide, respectively). Peptides were
synthesized containing the identified heparin binding domains along with a transglutaminase
substrate to allow crosslinking into fibrin matrices and to bind to heparin (Maxwell, Hicks et
al. 2005).
This system allows the release rate of NGF to be modulated by changing the molar
ratio of peptide to heparin in the delivery system (thus modulating the fraction of NGF in
the diffusible form) or the peptide affinity for heparin. This allows us to test whether
peptide affinity affects NGF biological activity independent of release rate because molar
ratios of peptide to heparin can be identified for two different affinity peptides that result in
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similar release rate. The notion of biological activity being independent of release rate may
seem unconventional; however, in nature there are examples of growth factors with varying
affinity for ECM or cell surface receptors that demonstrate different biological activity. For
example, the different isoforms of transforming growth factor-β demonstrate different
affinity for heparin sulfate and exhibit different biological responses in wound healing (Lyon,
Rushton et al. 1997). Additionally, the neurotrophin NGF binds with different affinity to its
receptors, TrkA and p75, where the ratio of each receptor activated can lead to different cell
responses (survival vs. apoptosis) (Bothwell 1995; Sofroniew, Howe et al. 2001b; Kuruvilla,
Zweifel et al. 2004). Thus biological activity may be affected by affinity in controlled release
systems as well.
The focus of this study was to assess the release rate and biological activity of βNGF released from fibrin matrices containing a heparin-binding delivery system (HBDS)
with peptides of varying affinity for heparin. The release of NGF from matrices was
modeled mathematically as a function of peptide affinity for heparin and the molar ratio of
peptide to heparin to determine if similar release rates of NGF could be obtained for
peptides with different heparin affinity. Additionally, the release of NGF was measured
experimentally over 7 days and the ability of the delivery system to present biologically active
NGF was analyzed using chick embryonic DRGs.

2.3

Materials and Methods
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless specified

otherwise.

32

2.3.1 Mathematical modeling
A mathematical model was developed to understand how varying peptide affinity for
heparin and the molar ratio of peptide to heparin affected the concentrations of species
containing NGF bound within the fibrin matrix at equilibrium. Additionally, the release of
NGF from fibrin matrices to aqueous media was modeled over 24 h to determine the role of
peptide affinity for heparin and molar ratio of peptide to heparin and to reveal if similar
release rates of NGF could be obtained for peptides of different heparin affinity. Therefore,
the equilibrium and release of species containing NGF from fibrin matrices was modeled
after situations similar to those described in the experimental methods below, where a closed
system of reacting species were allowed to reach equilibrium followed by the passive release
of species to aqueous media.
The delivery system was modeled with nine species (five of which contained NGF)
given by: peptide, either matrix bound (PB) or unbound (free, PU) to the fibrin matrix,
heparin (H), NGF (G), peptide-heparin complex, either matrix bound (PHB) or unbound
(PHU), heparin-NGF complex (free, HG), and peptide-heparin-NGF complex, again matrix
bound (PHGB) or unbound (PHGU). This model explored the effects of having both bound
(cross-linked to the fibrin matrix) and unbound peptide present (and capable of binding to)
heparin and in turn bind NGF. These species reacted according to the following chemical
equations governing the network, where all possible complexes between the species (P, H,
and G) were considered:
(2.1)

κ

f


PB + H 
κ r PH B
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κ

(2.2)

f


PU + H 
κ r PH U

(2.3)

kf

 HG
H + G 
kr 

(2.4)

kf

 PHG
PH B + G 
B
kr 

(2.5)

kf

 PHG
PH U + G 
U
kr 

(2.6)

f


PB + HG 
κ r PHG B

(2.7)

f


PU + HG 
κ r PHG U .

κ

κ

It was assumed that the kinetic rates of heparin binding to NGF and peptide binding to
heparin were independent of previous interactions with another species. Additionally,
peptide-containing and heparin-containing species were assumed to contain only one
binding site for interaction with heparin-containing species and NGF-containing species,
respectively. Others have found that heparin can bind multiple sites on acidic fibroblast
growth factor with high affinity interactions due to interactions of basic residues of the
growth factor with the anionic regions of heparin (Mach, Volkin et al. 1993). However,
since a molar excess of heparin was present in all model calculations, it was assumed that
NGF would primarily occupy only one binding site on heparin. The kinetic rate constants
for peptide interacting with heparin were κf for the association rate constant, κr for the
dissociation rate constant, and KD, PH for the equilibrium dissociation constant. The kinetic
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rate constants for heparin interacting with NGF were kf for the association rate constant, kr
for the dissociation rate constant, and KD, HG for the equilibrium dissociation constant.
At the start of release experiments fibrin matrices were assumed to be at equilibrium
in a closed system. Nine equations governing the concentrations of the species at
equilibrium (eqns. 2.8 – 2.12), found from considering the reactions of the species (eqns. 2.1
– 2.7) and the concentrations due to the conservation of mass for a closed system (eqns. 2.13
– 2.16), were evaluated to obtain the starting conditions for release. The equations consisted
of the following:
(2.8)

Κ D, PH =

[P]B [H]
[PH]B

(2.9)

Κ D, PH =

[P]U [H]
[PH]U

(2.10)

Κ D, HG =

[H][G]
[HG]

(2.11)

Κ D, PH =

[P]B [HG]
[PHG]B

(2.12)

Κ D, PH =

[P]U [HG]
[PHG]U

(2.13)

EQ
EQ
[P]EQ
[P]EQ
B, Total =
B + [PH]B + [PHG n ]B

(2.14)

EQ
EQ
[P]EQ
[P]EQ
U, Total =
U + [PH]U + [PHG n ]U
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(2.15)
EQ
EQ
EQ
EQ
[H]Total
=
[H]EQ + [PH]EQ
+ [PHG]EQ
B + [PH]U + [HG]
B + [PHG]U

(2.16)

EQ
[G]Total
=
[G]EQ + [HG]EQ + [PHG]BEQ + [PHG]EQ
U

(2.17)

1 [G]EQ + 1 [HG]EQ + 1 [PHG]EQ + [PHG]EQ
U
B
2
2
,
α= 2
EQ
[G]Total

where the values for the total concentrations of P, H, and G at equilibrium were the same as
those used for experiments (see below). Equations 2.13 and 2.14 assume that not all the
peptide was cross-linked into the fibrin matrix, and matrix bound peptide was estimated to
be approximately 8 moles of peptide per mole of fibrinogen (Sakiyama, Schense et al. 1999;
Schense and Hubbell 1999). Equation 2.17 describes the results of the in vitro equilibrium
study (see below), where α represents the fraction of [G] retained within the matrix.
Equations 2.8 – 2.17 were entered into MATLAB (Mathworks, Inc., Novi, MI) and solved
using a non-linear equation solver to obtain the dissociation constant (KD, HG) for the
interaction of heparin with NGF (the average value for KD, HG is given in Table 2.1) and by
omitting equation 2.17 (KD, HG was kept at the average shown in Table 2.1) to determine the
fraction of bound growth factor as the heparin concentration varied.

Table 2.1: Constants employed in math model
Constant

Value

KD, HG

1.7 ± 2.6 x 10-6 M

KD, PH (Low affinity peptide)

9.0 x 10-5 M (Maxwell, Hicks et al. 2005)

KD, PH (Medium affinity peptide)

6.1 x 10-5 M (Maxwell, Hicks et al. 2005)

KD, PH (High affinity peptide)

3.8 x 10-5 M (Maxwell, Hicks et al. 2005)
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KD, PH (ATIII peptide)

8.78 x 10-8 M (Olson, Srinivasan et al. 1981;
Kridel, Chan et al. 1996)

DP, W (MW ~ 2200 Da.)

1.9 x 10-2 mm2/min

DH, W

9.3 x 10-3 mm2/min

DG, W

1.0 x 10-2 mm2/min

DPH, W

8.9 x 10-3 mm2/min

DHG, W

7.7 x 10-3 mm2/min

DPHG, W

7.6 x 10-3 mm2/min

DP, M

1.9 x 10-2 mm2/min

DH, M

9.1 x 10-3 mm2/min

DG, M

9.7 x 10-3 mm2/min

DPH, M

8.6 x 10-3 mm2/min

DHG, M

7.5 x 10-3 mm2/min

DPHG, M

7.3 x 10-3 mm2/min

The release of species from fibrin matrices was described by the mass balances for
the species given by partial differential equations (PDEs) describing the kinetics of binding
and dissociation and the diffusive transport of the species in the fibrin matrix and in the
aqueous media with time. The delivery system was considered with the following equations:
(2.18)

∂[P]B
=
− κ f ([P]B [H] + [P]B [HG]) + κ r ([PH]B + [PHG]B )
∂t

(2.19)

∂[P]U
=D P,j∇κ2 [P]
([P]
[P]
+ U κ ([PH]
+
U −[H]
f
U [HG])
∂t

(2.20)

∂[H]
= D H,j∇κ2 [H]
([P]
− [H]
[P]
[H])
+ Uκ ([PH]
+ r
f
B
∂t
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r

[PHG]
U +)

U

[PH]
k [H][G]
k [H +
B +)
U − f

r

G]

(2.21)

∂[G]
= DG,j∇ 2 [G] − k f ([H][G] + [PH]B [G] + [PH]U [G]) + k r ([HG] + [PHG]B + [PHG]U )
∂t

(2.22)

∂[PH]B
= κ f [P]B [H] − κ r [PH]B − k f [PH]B [G] + k r [PHG]B
∂t

(2.23)

∂[PH]U
=
D PH,j∇ 2κ[PH]
[P] U[H]
+ f κ [PH]
− rk [PH]
k [PHG]
+
U
U −[G]
f
U
∂t

(2.24)

∂[HG]
κ ([P]
[HG]− [P]
[HG])
=D HG,j∇ 2 [HG] + k f [H][G]
− k r [HG]
+
f
B
∂t
κ+ ([PHG]
+
)U
r
B[PHG]

(2.25)

∂[PHG]B
= k f [PH]B [G] − k r [PHG]
κ [P]B [HG]
+ f Bκ [PHG]
−
∂t

(2.26)

∂[PHG]U
=
D PHG,j∇ 2 [PHG]U + k f [PH]Uκ[G]
[P]− k[HG]
κU[PHG]
+ f
r [PHG]
∂t

r

r

U

U

B

U

−

r

U

,

where [i] is the concentration of the species i given by PB, PU, H, G, PHB, PHU, HG, PHGB,
and PHGU, j is the material in which the species is diffusing, and t represents time. The mass
balances for species not cross-linked to the fibrin matrix included a term for diffusive
transport as well as kinetic terms, while the mass balances for matrix bound species included
only kinetic terms because the peptide was assumed to be immobilized in the fibrin matrix.
The equilibrium dissociation constants (used to estimate the kinetic rate constants) and
diffusion coefficients (Di, j) are given in Table 2.1 where i is the species and j is the material in
which the species is diffusing (matrix (M) or aqueous media (W)).
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The diffusion coefficients for the species diffusing through the aqueous media
(water) were found by the Stokes-Einstein Equation (Einstein 1906; Saltzman 2001) :

(2.27)

D A, W =

k BT
,
6πμa

where kB is Boltzmann’s constant, T is the temperature, μ is the viscosity of water, and a is
the hydrodynamic radius of the species A. The diffusion coefficients for the species
diffusing through the fibrin matrix were found by the Ogston Fiber Matrix Model (Ogston
1958; Ogston, Preston et al. 1973; Saltzman 2001) :

(2.28)

1

=
D A, M D A, W exp  −Φ 2


a
,
r

where Φ is the volume fraction occupied by the fibers (~ 5% (Carr and Hermans 1978;
Diamond 1999; Guthold, Liu et al. 2004)) and r is the radius of the fibrin fibers (~ 5 nm
(Galanakis, Lane et al. 1987; Diamond 1999; Guthold, Liu et al. 2004)). The delivery system
was modeled in one-dimension as a 2 mm fibrin matrix in contact with 5 mm aqueous
media. The interface of the fibrin matrix and the aqueous media were coupled by two
boundary conditions where it was assumed that the concentrations and fluxes of the species
were equal. Since the fibrin matrix was > 95% water, the partition coefficient between the
two interfaces was assumed to be ~ 1, and the mass transfer area between the two interfaces
was equal. At the other end of the fibrin matrix, the flux of species was zero. The other end
of the aqueous media was assumed to have a constant concentration of zero for all species.
The results of the equilibrium modeling for the fibrin matrices were used as the
initial conditions (concentrations of the species in the fibrin matrix), and the concentration
of all species in the aqueous media was assumed to be zero initially. The equations (2.18 –
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2.26), constants, and initial conditions for passive release of NGF were solved using
FEMLAB (COMSOL, Inc., Burlington, MA), a numerical PDE solver. The model was run
replacing the aqueous medium with new aqueous medium, where the concentration of the
species in the entire medium were initially zero, over the course of 24 h in a manner similar
to that described in the experimental methods for the in vitro release assay. While the
aqueous medium were cleared of species at specific times, the concentration of species in the
fibrin matrix remained the same as concentrations in the fibrin matrix before the aqueous
medium species were cleared, similar to the in vitro release assay.

2.3.2 Peptide synthesis
Peptides of varying heparin-binding affinity were synthesized by standard solid phase
Fmoc chemistry (amino acids from Nova Biochem, San Diego, CA; peptide synthesis
solvents from Applied Biosystems, Foster City, CA) using an ABI433A peptide synthesizer
(Applied Biosystems) and were based on amino acid sequences identified previously (Table
2.2) (Tyler-Cross, Sobel et al. 1994; Sakiyama, Schense et al. 1999; Maxwell, Hicks et al.
2005). The peptides denoted high, medium, and low affinity were based on previously
identified 12-mer peptides found from screening a phage display library with heparinSepharose chromatography (Maxwell, Hicks et al. 2005), and the peptide denoted ATIII was
based on a modified version of the antithrombin III-heparin binding domain (Tyler-Cross,
Sobel et al. 1994; Sakiyama, Schense et al. 1999). After synthesis, the peptides were cleaved
from the resin with 95% trifluoroacetic acid, 2.5% water, and 2.5% triisopropylsilane by
volume for 2-3 h using 10 mL of cocktail per 1 g of resin. The mixture was filtered through
glass wool to remove the resin then precipitated in cold diethyl ether. The crude peptide
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filtrates were dried under vacuum and then purified by standard C18 reverse phase liquid
chromatography (Shimadzu, Columbia, MD) and lyophilized. The identity of purified
peptides were verified by matrix-assisted laser desorption ionization (MALDI) mass
spectrometry.

Table 2.2: Heparin-binding peptides synthesized
(Transglutaminase substrate is in Italics)
Peptide Name

Amino Acid Sequence

Low affinity

NQEQVSPGALPNSSKLAPSR (Maxwell, Hicks et al. 2005)

Medium affinity

NQEQVSPGSSANGKKPSTRR (Maxwell, Hicks et al. 2005)

High affinity

NQEQVSPGNSAHRTRGRQRS (Maxwell, Hicks et al. 2005)

ATIII

(AcG)NQEQVSPK(βA)FAKLAARLYRKA (Sakiyama, Schense et
al. 1999)

2.3.3 Fibrin matrix preparation
Fibrin matrices were prepared as previously described (Schense and Hubbell 1999)
by mixing the following components (final concentrations given): human plasminogen-free
fibrinogen containing Factor XIII (4.0 mg/mL), bovine thrombin (2 NIH units/mL), and
CaCl2 (2.5 mM, Fisher Scientific, Pittsburgh, PA). The delivery system was prepared by
incorporating the following additional components: peptide (0.25 mM high, medium, low
affinity, or ATIII, to obtain ~ 8 moles of peptide cross-linked per mole of fibrinogen
(Sakiyama, Schense et al. 1999; Schense and Hubbell 1999)), heparin (sodium salt from
porcine intestinal mucosa 18,000 average MW) added at 62.5, 6.25, and 1.25 μM to obtain
4:1, 40:1, and 200:1 molar ratios of peptide to heparin, respectively, and human β–NGF (100
ng/mL, Peprotech Inc., Rocky Hill, NJ and R&D systems, Minneapolis, MN for the in vitro
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biological activity and release assay, respectively). The components were polymerized in 24well tissue culture plates for 60 min at 37°C and 5% CO2 yielding 400 µL matrices.

2.3.4 In vitro release assay
Fibrin matrices were prepared as described above then incubated with an aqueous
wash consisting of Tris-buffered saline (TBS, 137 mM NaCl, 2.7 mM KCl, 33 mM Tris, pH
7.4, Fisher Scientific) containing 1% bovine serum albumin (BSA) at 37°C. Equilibrium
studies were performed where 400 µL washes were added to the matrices and then collected
after 48 h, which was previously determined to be sufficient time for the NGF concentration
to reach equilibrium between the matrix and wash phases (Willerth, Johnson et al. 2007).
Additionally, a 7-day release study was performed where 1 mL washes were added and
collected 5 times in the first 24 h, followed by collection subsequently every 24 h for the
next 6 days. For both studies all washes were collected in siliconized tubes to reduce NGF
loss due to adsorption on tube walls and stored at -20°C. Upon completion of the release
studies, the remaining NGF was extracted from the fibrin matrices by cutting them into 1
mm cubes and placing them in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl,
1.5 mM KH2PO4, 8.0 mM Na2HPO4, pH 7.4, Fisher Scientific) containing 0.56 mM heparin,
an additional 2 M NaCl (Fisher Scientific), 0.01% Triton-X, and 1% BSA at 4 °C for 48 h,
after which the mixture was stored at -20°C until analysis was performed.
The amount of NGF released and remaining in the fibrin matrices was quantified by
an enzyme-linked immunosorption assay (ELISA) for human β-NGF according to the
manufacturer’s instructions (R&D systems). The absorbance was read at 450 nm with an
optical subtraction at 650 nm using a multi-well plate spectrophotometer (MultiSkan RC,
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Labsystems), and sample concentrations were calculated from a standard curve of known βNGF concentrations. Control matrices were made by omitting the peptide, heparin, and/or
NGF from the fibrin matrices.

2.3.5 In vitro biological activity assay
DRGs were dissected from day-10 white leghorn chick embryos (Specific Pathogen
Free, Sunrise Farms, Catskill, NY). Media consisted of modified neurobasal media (NBM,
Invitrogen, Carlsbad, CA) containing the following: insulin (5 g/mL), transferrin (100
g/mL), progesterone (6.4 ng/mL), putrescine (16.11 g/mL), selenite (5.2 ng/mL), and BSA
(0.1%, Sigma-Aldrich). A positive control for neurite extension consisted of an unmodified
fibrin matrix (no peptide, heparin, or NGF) with NBM containing 20 ng/mL of NGF,
previously found to be an optimal dose (Sakiyama-Elbert and Hubbell 2000a). Fibrin
matrices were prepared as described above then washed 5 times in the first 24 h with 1 mL
of TBS for the first 4 washes and the last wash consisting of 1 mL of modified NBM media
(20 ng/mL of NGF added for the positive control). One DRG was implanted per matrix
using dissection forceps and allowed to adhere to the fibrin matrix for 1 h at 37°C and 5%
CO2. One mL of modified NBM was added after 1 h and left on the fibrin matrices for the
remainder of the experiment.
DRGs were allowed to grow and extend neurites for 48 h upon which images were
captured. Brightfield images with a 2x objective using a CCD camera (Magnifire, Olympus)
were collected and analyzed using Image-Pro Express software (MediaCybernetics, San
Diego, CA) to determine the average neurite extension. The average neurite extension was
calculated as the radius of an annulus between the DRG body and the outer halo of
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extending neurites, as described previously (Herbert, Bittner et al. 1996). All average neurite
extension was normalized to the average neurite extension of the positive control from each
experiment. Additional control matrices were made by omitting the peptide, heparin,
and/or NGF from the fibrin matrices.

2.3.6 Statistical analysis
Statistical analysis was performed using Statistica (Statsoft) with comparative analysis
using Scheffe’s F post-hoc test by analysis of variance at a 95% confidence interval (α =
0.05). The release assays were performed with 3 matrices per replicate; the biological activity
study was performed with 6 matrices per replicate. All studies were performed in at least
triplicate, and reported values are given as mean ± standard deviation (S.D.).

2.4

Results

2.4.1 Mathematical modeling
To explore the effect of varying the peptide affinity for heparin and the molar ratio
of peptide to heparin, the equilibrium concentrations of matrix bound species containing
NGF were calculated for the delivery system, consisting of nine interacting species in a fibrin
matrix, at varying heparin concentrations (while holding peptide and NGF concentrations
constant) (Figure 2.1). At high molar ratios of peptide to heparin (e.g. above 100:1), the
amount of bound NGF decreased because the ratio of heparin to NGF was reduced by the
low heparin concentration required to obtain high peptide to heparin ratios. The amount of
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bound NGF in the delivery system increased to a maximum value as the molar ratio of
peptide to heparin decreased to an optimal molar ratio of peptide to heparin (1:1 – 4:1). As
the molar ratio of peptide to heparin decreased past this optimal molar ratio (<1:1), the
amount of NGF that was bound in the delivery system decreased rapidly. The rapid
decrease was due to an increase in unbound heparin, which resulted in more unbound
heparin-NGF complex formation and the saturation of binding sites on the peptides for
heparin. Additionally, the affinity of the peptide for heparin affected the equilibrium
concentration of bound species. The maximum amount of bound NGF in the delivery
system increased as peptide affinity for heparin increased. Thus, at equilibrium a biphasic
response of bound NGF was observed for all peptides, where an increase or decrease in the
molar ratio of peptide to heparin from the optimal ratio resulted in a decrease of matrix
bound NGF.
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Figure 2.1. Effect of molar ratio of peptide to heparin on the fraction of NGF in the bound
state. At a state of equilibrium, mathematical modeling of the delivery system in the fibrin matrix
demonstrated that the amount of bound NGF was dependent upon the affinity of the peptide for
heparin and the molar ratio of peptide to heparin. The curves displayed a biphasic nature where
there was an optimal molar ratio of peptide to heparin to obtain the maximum amount of available
bound NGF, regardless of affinity.

Using the equilibrium concentrations as the initial conditions within the fibrin
matrix, the amount of NGF released to aqueous media over 24 h was simulated in a manner
similar to the experimental in vitro release study. The presence of the delivery system resulted
in a decrease in NGF release regardless of peptide affinity for heparin or molar ratio of
peptide to heparin (Figure 2.2). At similar molar ratios of peptide to heparin, the total
amount of NGF released decreased as peptide affinity for heparin increased. By changing
the molar ratio of peptide to heparin for the affinity peptides, NGF release was modulated
resulting in increased NGF release as the molar ratio of peptide to heparin increased.
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Additionally, this result demonstrated that peptides with different heparin affinity are
capable of releasing NGF over 24 h at similar rates if the appropriate molar ratios of peptide
to heparin are used. Therefore, the modeling demonstrates the feasibility of using this
delivery system to test whether delivery system affinity affects biological activity independent
of release rate.

Figure 2.2. Fraction of NGF released at 24 h depends on the peptide affinity for heparin and
the molar ratio of peptide to heparin in the delivery system. The amount of NGF released over
24 h was modeled mathematically to mimic the experimental in vitro release study. The presence of
the delivery system resulted in reduced NGF release. Unique release profiles were obtained by
varying the peptide affinity for heparin and the molar ratio of peptide to heparin. Additionally,
different affinity peptides had the ability to retain similar levels of NGF after 24 h (at different
peptide to heparin ratios) demonstrating the feasibility of the in vitro biological activity assay.
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2.4.2 In vitro release assay
The ability of the delivery system to immobilize NGF within fibrin matrices was
assessed in equilibrium release studies by measuring the amount of NGF present within the
matrices after 48 h (previously found to be sufficient time for the NGF concentration to
reach equilibrium) (Willerth, Johnson et al. 2007). The retention of NGF within fibrin
matrices at equilibrium was compared to the amount of NGF present in their corresponding
aqueous washes (equal volumes). The amount of NGF present in fibrin matrices and the
washes without the complete delivery system (fibrin alone, NGF with peptide but no
heparin, or NGF with heparin but no peptide) were equal at ~50-51% of the NGF initially
added to the matrix, demonstrating equal partitioning of NGF in the absence of delivery
system (Table 2.3). However, the presence of the delivery system enhanced the amount of
NGF retained within the fibrin matrices, where the level of enhancement depended upon
the molar ratio of peptide to heparin and the peptide affinity for heparin. The delivery
system containing the low affinity peptide retained at most 55 ± 3% of the initial NGF at all
molar ratios of peptide to heparin, similar to unmodified fibrin. The presence of the delivery
system employing the ATIII, high affinity, or medium affinity peptides increased retention
of NGF in fibrin matrices compared to fibrin alone at peptide to heparin molar ratios of 4:1
and 40:1. The medium affinity peptide retained 64 ± 5% and 68 ± 1%, the high affinity
peptide retained 73 ± 8% and 73 ± 1%, and the ATIII peptide retained 78 ± 3% and 76 ±
1% of the initial NGF (4:1 and 40:1 molar ratios of peptide to heparin, respectively).
However, at a peptide to heparin molar ratio of 200:1 only the delivery system employing the
ATIII or the high affinity peptide retained more NGF than unmodified fibrin, where the
high affinity peptide retained 63 ± 1% and the ATIII peptide retained 71 ± 3% of the initial
NGF.
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Table 2.3: Mass retention of NGF in fibrin matrices with HBDS
* indicates statistical significance compared to fibrin matrices containing only NGF
Molar ratio of peptide to heparin
Peptide

4:1

40:1

200:1

No heparin

None

50 ± 4

51 ± 1

51 ± 1

50 ± 1

Low

53 ± 1

55 ± 3

53 ± 1

51 ± 2

Medium

64 ± 5 *

68 ± 1 *

56 ± 1

51 ± 1

High

73 ± 8 *

73 ± 1 *

63 ± 1 *

51 ± 2

ATIII

78 ± 3 *

76 ± 1 *

71 ± 3 *

51 ± 1

The effect of varying the affinity of heparin-binding peptides for heparin and the
molar ratio of peptide to heparin was investigated by measuring the cumulative release of
NGF from fibrin matrices over 7 days. The release of NGF from fibrin matrices (without
peptide or heparin) was rapid with a large initial burst at 2 h (38 ± 3%) followed by the loss
of 92 ± 3% of the NGF over 24 h (Figure 2.3). By day 7, the delivery system retained only a
fraction of the initial NGF (< 1%). Fibrin matrix controls consisting of any of the peptides
with NGF (but no heparin) were similar to unmodified fibrin matrices with NGF (Figure
3D).
The presence of the delivery system slowed the release of NGF and retained a
greater fraction of NGF over 7 days depending on the peptide affinity for heparin and molar
ratio of peptide to heparin. The initial release (2 h) of NGF was statistically decreased for
the delivery systems incorporating the medium affinity, high affinity, and ATIII peptides at a
4:1 molar ratio of peptide to heparin compared to unmodified fibrin matrices (Figure 2.3A).
A greater fraction of NGF was also retained at 24 h for the medium affinity (35 ± 3%), high
affinity (44 ± 1%), and ATIII (50 ± 4%) peptides. Release began to level off after 6 days
49

with < 2% loss per day, while still retaining more NGF than unmodified fibrin matrices or
fibrin matrices containing an incomplete delivery system (heparin but no peptide) (12 ± 1%
medium affinity, 23 ± 1% high affinity, and 33 ± 1% ATIII). The delivery system
incorporating the low affinity peptide did not show a difference versus unmodified fibrin
matrices or a delivery system incorporating heparin (but no peptide) at 2 h, 24 h, or day 7 (2
± 1% NGF retained).
When the molar ratio of peptide to heparin was increased to 40:1, the initial release
of NGF was decreased compared to unmodified fibrin matrices or a delivery system
incorporating heparin (but no peptide) (Figure 2.3B). Additionally, a higher fraction of
NGF was retained after 24 h for all peptides (29 ± 3% low affinity, 45 ± 1% medium
affinity, 49 ± 1% high affinity, and 55 ± 6% ATIII) compared to unmodified fibrin matrices
or a delivery system incorporating heparin (but no peptide). Release from delivery systems
containing any peptides at the 40:1 molar ratio began to level off after 6 days with < 3% loss
per day, however these systems still retained greater levels of NGF versus unmodified fibrin
matrices or a delivery system incorporating heparin (but no peptide), even in the case of the
low affinity peptide, (9 ± 1% low affinity, 14 ± 1% medium affinity, 20 ± 2% high affinity,
and 32 ± 2% ATIII).
Additionally, when the molar ratio of peptide to heparin was 200:1, an initial burst
release of NGF was observed, similar to that observed for unmodified fibrin matrices that
lacked the delivery system (Figure 2.3C). However, at a 200:1 molar ratio of peptide to
heparin all peptides had similar NGF retention levels at 24 h (27 ± 3% low affinity, 29 ± 2%
medium affinity, 29 ± 1% high affinity, and 30 ± 2% ATIII), which was greater than the
level retained in unmodified fibrin matrices. At day 7, a greater fraction of NGF remained
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for the ATIII (11 ± 1%) peptide compared to unmodified fibrin matrices or a delivery
system incorporating heparin (but no peptide).

Figure 2.3. NGF release in vitro over 7 days depends on the peptide affinity for heparin and
the ratio of peptide to heparin in the delivery system. NGF was released over 7 days from fibrin
matrices with and without the delivery system at a various molar ratios of peptide to heparin
containing varying affinity peptides for heparin. At the 4:1 molar ratio (A), the delivery system
incorporating the medium affinity, high affinity, and ATIII peptides retained higher levels of NGF
after 2 h, 24 h, and 7 days. At the 40:1 molar ratio (B), the delivery system incorporating any peptide
retained higher levels of NGF after 2 h, 24 h, and 7 days. At the 200:1 molar ratio (C), only the ATIII
peptide retained higher levels of NGF after 7 days. The peptides alone were not able to affect the
retention of NGF (D). Data (n ≥ 3) represented by mean ± SD and statistical significance was
considered p<0.05 compared to fibrin matrix alone or delivery system incorporating only heparin at a
similar concentration.

2.4.3 In vitro biological activity assay
In order to assess the biological activity of NGF released by the delivery system,
embryonic chick DRGs were implanted into fibrin matrices with and without the delivery
system, and the average neurite extension was measured. Neurite extension was normalized
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to neurite extension from DRGs grown in unmodified fibrin matrices with NGF in the
culture media at an optimal dose (20 ng/mL) (Sakiyama-Elbert and Hubbell 2000a). Fibrin
matrices containing the delivery system with any affinity peptide at all molar ratios of peptide
to heparin tested exhibited neurite extension that was equivalent to or greater than that
observed for fibrin matrices with NGF in the media (Figure 2.4A). Varying the peptide
affinity for heparin resulted in different biological responses, where a 4:1 molar ratio of
peptide to heparin showed increased neurite extension for the medium affinity (23 ± 17%),
high affinity (19 ± 14%), or ATIII (29 ± 20%) peptides versus NGF in the media, while the
low affinity peptide was similar to NGF in the media.

Figure 2.4. Effect of peptide affinity and peptide to heparin molar ratio on DRG neurite
extension in vitro. Normalized neurite extension from chick DRGs was affected by varying the
peptide affinity or the molar ratio of peptide to heparin in the delivery system. All DRG neurite
extension was normalized to the average neurite extension for unmodified fibrin matrices with 20
ng/mL of NGF added to the media for the same experiment. The delivery system incorporating any
peptide with 100 ng/mL of NGF caused increased or equivalent neurite extension compared to
NGF in the media (A). Additionally, the entire delivery system was required to increase normalized
neurite extension (B). Data (n ≥ 18) represents mean ± S.D. and an asterisk indicates statistical
significance (p<0.05) compared to NGF in the media.

Additionally, the effect of varying the molar ratio of peptide to heparin was explored.
At a molar ratio of 40:1 peptide to heparin, all peptides exhibited increased neurite extension
versus NGF in the media (21 ± 21% low affinity, 15 ± 14% medium affinity, 19 ± 17%
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high affinity, and 20 ± 18% ATIII). In particular, greater neurite extension was observed for
the low affinity peptide found at this molar ratio. Conversely, neurite extension was not
enhanced at the 4:1 molar ratio. However, at a molar ratio of 200:1 peptide to heparin, only
the high affinity (18 ± 15%) and ATIII (19 ± 15%) peptides displayed increased neurite
extension versus to NGF in media, while the medium and low affinity peptides were similar
to NGF in the media.
To assess the contribution of the other components in the delivery system, DRGs
were implanted into fibrin matrices lacking the complete delivery system and the average
neurite extension was measured. The absence of NGF (with heparin at any concentration
and/or any of the peptides) did not promote robust neurite extension and was statistically
decreased from DRGs grown with NGF in the media by ~70% (Figure 2.4B). When NGF
was included, incorporating any of the peptides, heparin at any concentration (data not
shown), or neither peptide nor heparin resulted in neurite extension that was similar to
DRGs grown with NGF in the media.
Additionally, the effect of similar release regimes for peptides of different heparin
binding affinity on the biological activity of NGF was assessed. The NGF release rates of
the low, medium, and high affinity peptides at a 40:1 molar ratio of peptide to heparin were
each compared to other peptides and molar ratios of peptide to heparin with similar NGF
release over the first 24 h. For each peptide at the 40:1 molar ratio of peptide to heparin,
other peptides and molar ratios of peptide to heparin with similar NGF retention at 24 h are
grouped and listed in Table 2.4, where the NGF retained after 24 h was presented as the
average of the group members for each similar release group. Since DRGs were implanted
in fibrin matrices after 24 h of washing during the in vitro biological activity assay, neurite
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extension was compared for all members within a similar release group to assess the effect of
release on biological activity. Neurite extension between members within the same release
group demonstrated similar means, where the average increase in neurite extension (versus
NGF in the media) for each release group is given: low affinity (16 ± 7%), medium affinity
(21 ± 6%), and high affinity (20 ± 5%) peptide groups. This result indicates that the ability
of the delivery system to retain NGF affected biological activity, and there was no effect of
peptide affinity independent of release rate.

Table 2.4: Similar mass retention of NGF at 24 h results in similar normalized neurite
outgrowth regardless of peptide affinity
(Neurite outgrowth was normalized to its respective positive control)
Peptide

Similar

Mass

Average

Normalized

Average normalized

group

peptide

retention

mass

neurite

neurite outgrowth

groups

at 24 h

retention

outgrowth

Low 40:1

29 ± 3 %

30 ± 3 %

121 ± 21

Med 4:1

35 ± 3 %

123 ± 17

ATIII 200:1 30 ± 2 %

119 ± 15

High 200:1

29 ± 1 %

118 ± 15

Med 200:1

29 ± 2 %

107 ± 16

Low 200:1

27 ± 3 %

107 ± 16

Med 40:1

45 ± 1 %

High 4:1

44 ± 1 %

119 ± 14

High 40:1

49 ± 1 %

119 ± 17

ATIII 4:1

50 ± 4 %

129 ± 20

High 40:1

49 ± 1 %

Med 40:1

45 ± 1 %

115 ± 14

High 4:1

44 ± 1 %

119 ± 14

ATIII 4:1

50 ± 4 %

129 ± 20

ATIII 40:1

56 ± 2 %

119 ± 15

Low 40:1

Med 40:1

High 40:1

47 ± 3 %

49 ± 5 %
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115 ± 14

119 ± 17

116 ± 7

121 ± 6

120 ± 5

2.5

Discussion
The drug delivery system investigated in this study used a rational approach to

delivery system design to develop a biomaterial scaffold to sequester and slow the release
rate of NGF. Other affinity-based drug delivery systems incorporating components that
reversibly bind the drug of interest, such as heparin within fibrin (Jeon, Kang et al. 2005;
Jeon, Ryu et al. 2005), collagen (Wissink, Beernink et al. 2000a), and polymer matrices
(Benoit and Anseth 2005; Pike, Cai et al. 2006) can modulate the release of drug through the
strength of affinity interactions. The delivery system investigated in this study demonstrates
two methods to modulate the rate of drug release, the peptide affinity for heparin and the
molar ratio of peptide to heparin, as verified through mathematical modeling and
experimental data.
The mathematical modeling performed predicted that more NGF could be
sequestered within fibrin matrices at equilibrium by increasing peptide affinity for heparin.
Additionally, it predicted that the greatest amount of NGF could be sequestered by
optimizing the molar ratio of peptide to heparin for each peptide. The key component that
emerged from the model results was the fraction of matrix bound heparin, which implied
that the rate of NGF release could be modulated by varying the concentration of heparin (or
the molar ratio of peptide to heparin). To explore this implication, NGF release was
modeled with the removal all species from the aqueous wash media (similar to the changing
of the wash solutions in the experimental studies). This approach allowed us to estimate
what range of molar ratios of peptide to heparin could yield different release rates for each
affinity peptides and similar release rates between different affinity peptides. Based on these
results, the experimental range of molar ratios of peptide to heparin was chosen.
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Experimentally, peptide affinity for heparin and molar ratio of the peptide to heparin
was found to modulate the release rates of NGF, resulting in different release rates for the
delivery system, as predicted by the math model. As the molar ratio of the peptide to
heparin increased from 4:1 or 40:1 to 200:1, NGF release occurred more rapidly for all of
the peptides. Furthermore, as peptide affinity for heparin increased, NGF release was
slowed for all molar ratios of peptide to heparin. The ability of the delivery system to
modulate the release rate through these two parameters provides two mechanisms for
controlling release rate.
NGF released from the delivery system induced neurite extension that was similar to
or greater than that induced by NGF in the media, suggesting that the delivery system did
not have a negative impact on the biological activity of the NGF. Previously, others have
found that localized delivery of neurotrophic factors can enhance neurite extension more
than neurotrophic factors in the media (Sakiyama-Elbert and Hubbell 2000a; SakiyamaElbert and Hubbell 2000b; Taylor, McDonald et al. 2004). This enhancement could be due
to the formation of concentration gradients within the fibrin matrices as extending neurite
locally degrade the fibrin matrix and release the matrix bound growth factor. NGF has been
shown to guide and enhance neurite extension through concentration gradients, but only if
the steepness of the gradient was above a critical value (Cao and Shoichet 2001; Cao and
Shoichet 2003; Rosoff, Urbach et al. 2004). In this study, enhanced neurite extension
compared to NGF in the media was observed for the medium and high affinity and ATIII
peptides at 4:1 and 40:1 molar ratios of peptide to heparin, where enhanced NGF retention
was observed as well. However, enhanced neurite extension compared to NGF in the media
was only observed for the low affinity peptide at a molar ratio of 40:1 as opposed to the 4:1
molar ratio. This result could be due to the larger amount of NGF retained after 24 h for
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the 40:1 molar ratio of peptide to heparin versus the 4:1, establishing the minimum retention
level needed in the fibrin matrices to elicit enhanced neurite extension.
As mentioned previously, the NGF remaining after 24 h for the low affinity peptide
at a 4:1 molar ratio of peptide to heparin was comparable to unmodified fibrin matrices,
while more NGF remained for all the other peptides (medium, high and ATIII), which
resulted in increased neurite extension for the other peptides. When the molar ratio of
peptide to heparin was increased to 40:1, all of the peptides retained more NGF than
unmodified fibrin, and neurite extension was increased for delivery systems containing any
of the peptides (and heparin) indicating that NGF retention was critical for neurite
extension. To confirm that the delivery system components were all necessary to modulate
the release rate of NGF (and thus to elicit neurite extension), one or more components of
the delivery system were removed, which resulted in lower NGF retention and the loss of
enhanced neurite extension.
Apart from modulating neurite extension through altering the release rate of NGF,
the delivery system allowed the ability to test whether the delivery system affinity could
affect biological activity independent of release rate. To test this hypothesis, different
affinity peptides with similar release rates after 24 h (selected molar ratios of peptide to
heparin) were compared. It was found that the neurite extension was similar for all group
members within a group of delivery system conditions that elicited similar rates of NGF
release. These results suggest that when two peptides of different heparin affinity were
combined with heparin concentrations such that they exhibited similar release rate, the
resulting neurite extension (biological activity) elicited by the released NGF was similar, thus
there was no effect of affinity independent of release rate.
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The ability of the delivery system to present biologically active NGF in vitro suggests
it may be useful for the treatment of nerve injury in vivo. In particular, NGF has been
delivered locally to treat peripheral nerve injury (Lee, Yu et al. 2003b), but not in a way that
tests at what rate NGF should be administered. Dinbergs and coworkers discovered that
not all growth factors are best delivered slowly and locally. They found bFGF enhanced
endothelial and smooth muscle cell proliferation through sustained release compared to
bolus administration while transforming growth factor-β1 inhibited endothelial cells more
efficiently in bolus form compared to slow release (Dinbergs, Brown et al. 1996). This
delivery system has the unique ability to allow us to study the effects of how the rate of
growth factor release affects nerve regeneration.
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Chapter 3
Heparin-binding affinity-based delivery systems
releasing nerve growth factor enhance sciatic nerve
regeneration *
3.1

Abstract
The controlled delivery of nerve growth factor (NGF) to the peripheral nervous

system has been shown to enhance nerve regeneration following injury, although the effect
of release rate has not been previously studied with an affinity-based delivery system (DS).
The goal of this research was to determine if the binding site affinity of the DS affected
nerve regeneration in vivo using nerve guidance conduits (NGCs) in a 13 mm rat sciatic nerve
defect. These DSs consisted of bi-domain peptides that varied in heparin-binding affinity,
heparin, and NGF, which binds to heparin with moderate affinity. Eight experimental
groups were evaluated consisting of NGF with DS, control groups excluding one or more
components of the DS within silicone conduits, and nerve isografts. Nerves were harvested
6 weeks after treatment for analysis by histomorphometry. These DSs with NGF resulted in
a higher frequency of nerve regeneration compared to control groups and were similar to the
nerve isograft group in measures of nerve fiber density and percent neural tissue, but not in
total nerve fiber count. In addition, these DSs with NGF contained a significantly greater
percentage of larger diameter nerve fibers, suggesting more mature regenerating nerve
content. While there were no differences in nerve regeneration due to varying peptide

*Contents of this chapter were accepted for publication in J Biomaterials Res Polymer Ed and were reprinted
with permission of the publisher
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affinity with these DSs, their use with NGF enhanced peripheral nerve regeneration through
a NGC across a critical nerve gap.

3.2

Introduction
Despite significant advances in nerve reconstruction, the autograft remains the

clinical standard of care for long gaps in critical peripheral nerves; however, functional
outcomes are still suboptimal and drawbacks exist including donor site morbidity (Lundborg
2000; Schmidt and Leach 2003). Because of these disadvantages, alternatives have been
sought including NGCs (Lundborg 2000; Schmidt and Leach 2003; Bellamkonda 2006). The
use of a NGC offers the advantage of being able to control the microenvironment for
regeneration by modulating the composition and luminal contents of the conduit, in
particular through the inclusion of growth factors and extracellular matrix (ECM) molecules
(Lundborg 2000; Schmidt and Leach 2003; Bellamkonda 2006).
Much of the research has focused on the design of biodegradable conduits (Widmer,
Gupta et al. 1998; Piquilloud, Christen et al. 2007; Pfister, Alther et al. 2008). However, the
ultimate design goal of NGCs may also include a drug delivery matrix within a biodegradable
conduit. Growth factor delivery from biomaterial matrices is often controlled by diffusion
(Yu and Bellamkonda 2003; Mohanna, Terenghi et al. 2005), however, one shortcoming of
this approach is that the release rate cannot be modulated or controlled by cells during
regeneration. One alternative is to use an affinity-based DS that allows the release of growth
factors to be controlled by cell-based degradation of the DS. This study is focused on the
role of affinity-based drug delivery from the conduit lumen.
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Previously, we developed an affinity-based DS incorporating heparin that sequesters
proteins within a fibrin matrix based on non-covalent interactions (Sakiyama-Elbert and
Hubbell 2000a; Sakiyama-Elbert and Hubbell 2000b). Initially, this system consisted of a bidomain heparin-binding peptide (ATIII peptide) where one domain consisted of a
transglutaminase substrate, based on α2-plasmin inhibitor (Ichinose, Tamaki et al. 1983;
Kimura, Tamaki et al. 1985), allowing it to be crosslinked into fibrin matrices during
polymerization by the transglutaminase Factor XIIIa. The other domain consisted of a
modified version of the heparin binding domain from antithrombin III (Tyler-Cross, Sobel
et al. 1994; Tyler-Cross, Sobel et al. 1996; Sakiyama, Schense et al. 1999) allowing noncovalent binding of heparin to peptide crosslinked within a fibrin matrix. With the inclusion
of a protein that interacts with heparin, a ternary complex is formed consisting of peptide,
heparin, and protein bound within the fibrin matrix that effectively sequesters the protein
within the matrix, allowing release by cell-mediated processes.
NGF is well known for its ability to promote neurite extension in vitro (Conti, Fischer
et al. 1997; Macias, Battocletti et al. 2000; Sakiyama-Elbert and Hubbell 2000a; Xu, Yu et al.
2002) and nerve regeneration in vivo (Xu, Yu et al. 2002; Lee, Yu et al. 2003a; Yu and
Bellamkonda 2003). Our lab has determined that the presentation of NGF, e.g. free NGF in
a biomaterial matrix or NGF bound to a biomaterial matrix (such as our DS through a
strong heparin-binding peptide) can affect the biological response to NGF. We previously
demonstrated that our affinity-based DS enhanced nerve regeneration when containing a
strong heparin-binding peptide (ATIII peptide) compared to matrices loaded with NGF
alone (Lee, Yu et al. 2003a). Moreover, others recently have shown that collagen matrices
that can sequester NGF by affinity interactions are more effective than diffusion-based
delivery of NGF at promoting neural regeneration (Sun, Lin et al. 2007). However, the
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effect of binding affinity (the system’s ability to sequester drug) of an affinity-based delivery
system on nerve regeneration in vivo has not been elucidated. Specifically, if binding affinity
and drug release rate for an affinity-based DS is modulated, how is the in vivo biological
activity of the drug that is being released modulated.
To explore the role of binding affinity, we used combinatorial techniques to tailor
the affinity of non-covalent interactions between a heparin-binding peptide and heparin
(Maxwell, Hicks et al. 2005). Peptide sequences were identified that exhibited “high”,
“medium”, and “low” affinity for heparin using an increasing step gradient of sodium
chloride concentration (1.0 M, 1.5 M and 2.0 M NaCl were used to elute the low, medium
and high affinity peptide display phage from a heparin affinity column, respectively)
(Maxwell, Hicks et al. 2005). Peptides were synthesized containing the identified heparin
binding domains along with a transglutaminase substrate to allow crosslinking into fibrin
matrices (Maxwell, Hicks et al. 2005). By utilizing these peptide sequences exhibiting high,
medium, and low affinity for heparin and the previously identified ATIII peptide, which has
the strongest binding-affinity for heparin of the peptides in this study, our DS can release
NGF at different rates. Our previous work in vitro demonstrated that the ability of our DS
to sequester NGF was the factor controlling the ability to enhance neurite extension (Wood
and Sakiyama-Elbert 2008). The current study extends the previous work and provides
insight into the effect of binding affinity on nerve regeneration in vivo.
The focus of this study was to assess whether peptide affinity for heparin affects
nerve regeneration. To test this premise, peptides that previously demonstrated the ability to
modulate the release rate and in vitro biological activity of NGF were used in an affinitybased DS. Fibrin matrices containing the DS were placed within a silicone NGC to
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examine nerve regeneration across a 13-mm rat sciatic nerve defect, which exceeds the
critical defect size for spontaneous regeneration (Lundborg, Dahlin et al. 1982a). The effect
of the DS on nerve regeneration was assessed through histomorphometric analysis of the
nerve in the conduits after 6 weeks.

3.3

Materials and Methods
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless specified

otherwise.

3.3.1 Peptide synthesis
Peptides of varying heparin-binding affinity were synthesized by standard solid phase
Fmoc chemistry (amino acids from Nova Biochem, San Diego, CA; peptide synthesis
solvents from Applied Biosystems, Foster City, CA) using an ABI433A peptide synthesizer
(Applied Biosystems) and were based on amino acid sequences identified previously (Table
3.1) (Tyler-Cross, Sobel et al. 1994; Sakiyama, Schense et al. 1999; Maxwell, Hicks et al.
2005). The peptides denoted high and medium affinity were based on previously identified
12-mer peptides identified by screening a phage display library with heparin-Sepharose
chromatography (Maxwell, Hicks et al. 2005), and the peptide denoted ATIII was based on a
modified version of the antithrombin III-heparin binding domain and has the highest
binding affinity for heparin of all the peptides used in the study (Tyler-Cross, Sobel et al.
1994; Sakiyama, Schense et al. 1999). After synthesis, the peptides were cleaved from the
resin with 95% trifluoroacetic acid, 2.5% water, and 2.5% triisopropylsilane by volume for 263

3 h using 10 mL of cocktail per 1 g of resin. The mixture was filtered through glass wool to
remove the resin then precipitated in cold diethyl ether. The crude peptide filtrates were
dried under vacuum and then purified by standard C18 reverse phase liquid chromatography
(Shimadzu, Columbia, MD) and lyophilized. The identity of purified peptides were verified
by matrix-assisted laser desorption ionization (MALDI) mass spectrometry.

Table 3.1: Heparin-binding peptides with equilibrium dissociation constants of peptide
interaction with heparin
(Transglutaminase substrate in italics)
Peptide Name

Amino Acid Sequence

→H )
KD ( P ←

Medium affinity NQEQVSPGSSANGKKPSTRR
High affinity
ATIII

6.1 x 10-5 M (Maxwell, Hicks et

(Maxwell, Hicks et al. 2005)

al. 2005)

NQEQVSPGNSAHRTRGRQRS

3.8 x 10-5 M (Maxwell, Hicks et

(Maxwell, Hicks et al. 2005)

al. 2005)

(AcG)NQEQVSPK(βA)FAKLAARLY

8.78 x 10-8 M (Olson,

RKA (Sakiyama, Schense et al. 1999)

Srinivasan et al. 1981; Kridel,
Chan et al. 1996)

3.3.2 Fibrin matrix preparation
Fibrin matrices were prepared as previously described (Lee, Yu et al. 2003a) by
mixing the following components (final concentrations given): human plasminogen-free
fibrinogen containing Factor XIII (4.0 mg/mL), bovine thrombin (2 NIH units/mL), and
CaCl2 (2.5 mM, Fisher Scientific, Pittsburgh, PA). Fibrin matrices including DS were
prepared by incorporating the following additional components: peptide (0.25 mM of
medium affinity, high affinity, or ATIII to obtain ~ 8 moles of peptide cross-linked per mole
of fibrinogen (Sakiyama, Schense et al. 1999; Schense and Hubbell 1999)), heparin (Sigma-
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Aldrich product no. H9399, sodium salt from porcine intestinal mucosa 18,000 average MW)
added at 62.5 μM to obtain a 4:1 molar ratio of peptide to heparin, and 50 ng/mL human βNGF (Peprotech Inc., Rocky Hill, NJ).
Silicone tubing (SF Medical, Hudson, MA; 0.058 in. inside diameter x 0.009 in. wall
thickness) was cut into 15-mm segments and autoclaved. Prior to filling, the tubes were
rinsed with sterile saline solution. The fibrin solution was drawn into the silicone tube using
a pipette (~22 μL/conduit). The fibrin matrix was allowed to polymerize for 10 minutes
prior to implantation of the conduit.

3.3.3 Experimental animals
Adult male Lewis rats (Harlan Sprague-Dawley, Indianopolis, IN), each weighing
250-300g were used in this study. All surgical procedures and peri-operative care measures
were performed in strict accordance with the National Institutes of Health guidelines and
were approved by the Washington University Animal Studies Committee. All animals were
housed in a central animal facility, given a rodent diet (PicoLab Rodent Diet 20 #5053, PMI
Nutrition International) and water ad libitum.

3.3.4 Experimental Design
Ninety-six animals were randomized into eight groups (n = 12) as shown in Table
3.2. An additional six animals served as nerve graft donors. Group I served as a negative
control group and received an empty conduit. Groups II – IV were additional controls
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receiving conduits containing fibrin alone, fibrin with the ATIII peptide used in the DS (but
no growth factor) or fibrin with the growth factor but no DS, respectively. These groups
examined the effects of the components of the DS. Groups V – VII were implanted with
conduits containing complete DS with one of three varying affinity peptides and 50 ng/mL
β-NGF (dose selected based on a previous study (Lee, Yu et al. 2003a)). Group VIII served
as a positive control receiving reversed nerve isografts from syngeneic donor animals.

Table 3.2: Experimental Design
(n = 12 for all groups)
Group

Group

Peptide used in

Nerve Growth

Fibrin

Rats with

Name

delivery system

Factor (NGF)

Regeneration

(DS)

Dose (ng/mL)

(out of 12)

I

Empty

None

0

No

3

II

Fibrin Alone

None

0

Yes

5

III

ATIII DS

ATIII

0

Yes

3

None

50

Yes

4

(no NGF)
IV

NGF (no
DS)

V

Med DS

Medium affinity

50

Yes

5

VI

High DS

High affinity

50

Yes

6

VII

ATIII DS

ATIII

50

Yes

7

VIII

Isograft

None

0

No

12

3.3.5 Operative Procedure
Operative procedures were performed using aseptic technique and microsurgical
dissection and repairs. Using 4% isoflurane gas (Vedco Inc., St Josephs, MO) anesthesia, the
hind leg of the rat was prepped and the sciatic nerve was exposed through a dorsolateral-
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gluteal muscle splitting incision. A 5 mm nerve segment was excised proximal to the
trifurcation of the sciatic nerve and a 15 mm silicone tube containing fibrin matrices, with or
without DS and NGF, was sutured to the transected proximal and distal stumps,
incorporating 1 mm of nerve on either end, creating a total regeneration gap of 13 mm
(Figure 3.1). Four 9-0 nylon interrupted microepineurial sutures were used to secure the
conduit (two per side). In animals receiving the isograft control, a 13 mm segment of sciatic
nerve was harvested from a syngeneic donor animal and inserted into the recipient animal
using no more than four 10-0 nylon microepineurial sutures per side to secure the graft.
Wounds were irrigated with saline, dried with a q-tip, and closed with a running 5-0 vicryl
suture in muscle fascia, and then interrupted 4-0 nylon skin sutures. Animals were recovered
in a warm aseptic environment and returned to the housing facility.
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Figure 3.1. Schematic representation of surgical implantation of nerve guidance conduit
containing the affinity-based delivery system. A 13 mm nerve gap was repaired with a 15 mm
silicone conduit containing fibrin matrices with or without DS and growth factor and sutured to the
transected proximal and distal stumps, incorporating 1 mm of nerve on either end. The DS
consisted of a bi-domain peptide cross-linked into the fibrin matrix at one domain while the other
binds heparin by electrostatic interactions. The NGF can then bind to the bound heparin, creating a
matrix-bound, non-diffusible complex, which can be retained for cell mediated degradation of the
fibrin matrix (modified from Wood et al. (Wood, Moore et al. 2009)).

At the 6-week end point, all animals were re-anesthetized and nerve harvests were
performed by reopening the prior muscle splitting incision. The nerve conduit or graft and a
5 mm portion of native nerve both proximally and distally were harvested. The specimens
were marked with a proximal suture and stored in 3% glutaraldehyde in phosphate buffer at
4°C until histomorphometric analysis was performed.
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3.3.6 Histomorphometric Evaluation
Tissues, harvested and fixed as described above, were post-fixed with 1% osmium
tetroxide, ethanol dehydrated and embedded in Araldite 502 (Polyscience Inc., Warrington,
PA). Thin (1-µm) sections were made from the tissue using a LKB II Ultramicrotome
(LKB-Produckter A.B., Broma, Sweden) and then stained with 1% toluidine blue for
examination under a light microscope.
Midline cross sections from the host nerve through the conduit or graft were
evaluated using methods detailed previously (Hunter, Moradzadeh et al. 2007). Briefly, at
1000X magnification, six representative fields per nerve were evaluated with an automated
digital image-analysis system linked to histomorphometry software. The system digitized and
displayed the microscope image on a video monitor with a resolution of 0.125 µm/pixel.
Total fascicular area, fiber diameter and density were measured using at least 80% of the
nerve area contained within 4 – 6 intrafascicular field areas. From these primary
measurements the following morphometric indices were calculated: total number of nerve
fibers (nerve fiber density x total fascicular area), nerve fiber density (fiber
number/intrafascicular area), percent neural tissue (100 x neural area/intrafascicular area),
and nerve fiber width. For animals with nerve regeneration, the nerve fiber width was used
to assess fiber maturity for the range of fiber widths. Morphometric indices from
experimental groups were compared to the isograft control.
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3.3.7 Statistical analysis
All conduits and grafts were included in histomorphometric analysis, except the fiber
distribution analysis, even when no axons were found in the midline cross section. All
results are reported as mean ± standard error of the mean (S.E.M.). Statistical analyses were
performed using Statistica version 6 (Statsoft Inc., Tulsa, OK). All data were evaluated for
differences between groups using the Kruskal-Wallis analysis of variance (ANOVA) and
median test. Post hoc Mann-Whitney U-tests were used for determining which groups
differed with significance set at α = 0.05. Additionally, fiber width data was evaluated for
differences between groups using ANOVA and post hoc LSD tests were used for
determining which groups differed with a significance set at α = 0.05. Groups with a p>0.05
were considered statistically similar, while groups with a p<0.05 were considered statistically
different. All statements in the text considering whether groups were different or similar to
one another utilize these statistics to support the statements.

3.4

Results

3.4.1 Nerve guidance conduit harvest
The effectiveness of the DS and/or NGF in promoting nerve regeneration across a
critical nerve gap was evaluated in vivo after sciatic nerve transection and NGC implantation.
To assess whether heparin-binding peptide affinity affects nerve regeneration, peptides with
varying affinity for heparin (ATIII (KD = 8.78 x 10-8 M), high (KD = 3.8 x 10-5 M), and
medium peptides (KD = 6.1 x 10-5M), in order of highest to lowest affinity, respectively) were
examined with the DS and NGF. After 42 days, groups with the DS and NGF resulted in a
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higher percentage of animals with a neural cable spanning the 13 mm gap. Seven of 12
conduits utilizing the ATIII peptide (ATIII DS, group VII), 6 of 12 conduits using the high
affinity peptide (High DS, group VI), and 5 of 12 using the medium affinity peptide (Med
DS, group V) contained regenerated nerve cables when used in the DS with NGF (Table
3.2). Five of 12 conduits from the group containing fibrin alone (group II), 4 of 12 conduits
from the group with NGF with no DS (NGF (no DS), group IV), and 3 of 12 from the DS
alone with no NGF (DS alone (no GF), group III) group and the empty group (group I)
contained regenerated nerve cables. All 12 animals in the isograft group demonstrated had
nerve cables after 6 weeks. The gross appearance of the regenerating nerve cables in the DS
with NGF groups exhibited a larger, more robust nerve cable in comparison to the other
groups (lacking DS and/or NGF). The nerve cable was centered compactly in the conduit,
away from the walls, in all conduit specimens. All conduit specimens had the proximal and
distal sciatic nerve still sutured into the conduit at 6 weeks, regardless of the presence of a
nerve cable spanning the conduit.

3.4.2 Histology
Qualitative examination of sections from the midline of the conduits or isografts by
light microscopy revealed differences in nerve architecture as reflected by the arrangement of
the regenerating axons (Figure 3.2). In particular, the rat sciatic nerve normally contains
myelinated fibers in a packed, semi-symmetrical, uniform arrangement with fibers that are
relatively similar in shape to one another. Overall, this arrangement can be described as
“organized” architecture. The isograft and groups with a DS and NGF reflect this organized
appearance, while the fibrin alone group demonstrated more random spacing and had less
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symmetrically shaped myelinated fibers. In addition, groups incorporating DS and NGF
appeared to have more tightly packed fibers than the isograft, which was likely due to the
compact area for neural regeneration in the silicone tube. No inflammatory response or
residual fibrin was observed.
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Figure 3.2 Histological sections of regenerating nerves at the midline of the conduit (or
graft). (A) Isograft; (B) DS incorporating the ATIII peptide and NGF; (C) DS incorporating the
high affinity peptide and NGF; (D) DS incorporating the medium affinity peptide and NGF; (E)
fibrin with NGF alone; (F) DS with the ATIII peptide and no NGF; (G) fibrin alone; (H) empty
conduit. Thin (1 µm) sections of sciatic nerve specimens were stained with 1% toluidine blue for
qualitative examination of the midline of the conduits by light microscopy. Groups with NGF
demonstrated more organized neural architecture, closely approximating the isograft, in comparison
to the fibrin alone or empty conduit groups. Scale bar, 10 µm.

3.4.3 Histomorphometry
At six weeks, all sections from the midline of the conduits and isografts were
assessed by histomorphometry, regardless of the extent of nerve regeneration. The average
total myelinated fiber number, a measure of the effectiveness of neural regeneration, was
12,000 ± 600 fibers (n = 12) for the isograft, while groups receiving NGCs and NGF had
~2000 fibers (n = 12 per group) and groups receiving NGCs without NGF had ~1700
fibers (n = 12 per group). The average number of fibers in a normal rat sciatic nerve is
approximately 7100 ± 400 (Mackinnon, Dellon et al. 1991). None of the conduit treated
groups were able to match the isograft in total myelinated fiber numbers (Figure 3.3A)
largely due to the smaller cable area (fascicular area) observed for these groups.
Nerve fiber density is another measure of nerve regeneration, and percent neural
tissue is a measure that provides insight into the quality of the regenerating nerve. Neither
of these measures is dependent on the area of the regenerating nerve cable. The nerve fiber
density at the midline of the graft was ~20,000 fibers/mm2 for the isograft, which was
similar to groups with the DS and NGF (ATIII, High and Med DS, ~11,000-15,000
fibers/mm2) at the midline of the conduit, but not to groups lacking the DS and/or NGF
(Figure 3.3B). For normal rat sciatic nerve, the fiber density is ~12,000 fibers/mm2
(Mackinnon, Dellon et al. 1991). The isograft also had ~19% neural tissue in the
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regenerating nerve at the midline of the graft, which was similar to groups with the DS and
NGF (ATIII, High and Med DS, ~12 – 16%) at the midline of the conduit, but greater than
groups lacking the DS and/or NGF (Figure 3.3C). These assessments suggest that one
aspect of nerve regeneration (nerve fiber density) and the quality of nerve regeneration
(percentage neural tissue) was equivalent to an isograft for groups with the DS incorporating
any heparin-binding affinity peptide (ATIII, High or Med) and NGF.

Figure 3.3. Histomorphometric analysis of nerves at the midline of the conduit (or graft).
The total number of myelinated nerve fibers, density, and percent neural tissue were measured by
quantitative histomorphometry. No groups approximated the nerve regeneration of an isograft (A),
but groups with the DS incorporating any affinity peptide and NGF were comparable in nerve fiber
density (B) and percent neural tissue (C) to an isograft. Data (n = 12) represents mean ± S.E.M. and
* indicates statistical significance (p<0.05) compared to isograft.

The myelinated nerve fiber width was assessed as a measure of maturity of the
regenerating nerve fibers for animals with nerve regeneration, and groups that were most
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efficient in promoting nerve regeneration (at least 5 conduits contained nerve cables) were
assessed for their fiber width distribution. All conduit groups contained fewer smaller nerve
fibers (2 – 3 μm) compared to isograft controls (Figure 3.4A); furthermore, the High DS
group also contained fewer nerve fibers than the isograft in the 3 – 4 μm distribution. All
conduit groups demonstrated a higher percentage of larger nerve fibers (4 – 5 μm) compared
to the isograft, but only groups with a DS and NGF (ATIII, High or Med DS) promoted a
higher percentage of nerve fibers in the 5 – 6 μm width range (p< 0.05) compared to the
isograft, suggesting more mature regenerating fibers. Overall, the average fiber width for
conduit groups with nerve regeneration were greater than isografts (Figure 3.4B). The
normal median nerve fiber width of a rat is ~6.5 μm (Mackinnon, Dellon et al. 1991). No
differences between groups were observered for the 1-2 μm or the 6-7 μm range, both of
which contained a low percentage of fibers in all groups. No functional gains were observed
as assessed by Walking Track Analysis with Sciatic Functional Index scoring (data not
shown).
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Figure 3.4. Myelinated fiber width distribution of regenerating nerves at the midline of the
conduit (or graft). The nerve fiber width distributions (A) and averages (B) were measured by
quantitative histomorphometry. The percentage of large regenerating nerve fibers (4 – 5 µm) was
larger in the conduit groups compared to the isograft group. The DS with any affinity peptide and
NGF promoted the greatest percentage of larger fibers (5 – 6 µm). Overall, average fiber width for
conduit groups were greater than isografts. Data represents mean ± S.E.M. and * indicates statistical
significance (p<0.05) compared to the isograft.

3.5

Discussion
Complete clinical recovery after peripheral nerve injury is rare suggesting that

alternatives to the current standards of care are needed. One alternative examined in this
study was the use of a NGC filled with a biomaterial matrix capable of delivering growth
factors with an affinity-based DS. The affinity-based DS allows the release of growth factor
by cells, which activate proteases allowing the degradation of the fibrin matrix and other DS
components via the activation of plasminogen to plasmin (Kalderon 1984; Krystosek and
Seeds 1984; Alvarez-Buylla and Valinsky 1985; Pittman and Buettner 1989; Pittman, Ivins et
al. 1989; Herbert, Bittner et al. 1996).
In this study, we found that drug delivery from a fibrin matrix improved the
effectiveness of nerve regeneration (the number of conduits with a nerve cable spanning the
defect). A fibrin matrix naturally forms within an empty silicone conduit over a one week
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period when the severed nerve ends of rat sciatic nerve are connected to the conduit
(Williams, Longo et al. 1983). Therefore, we hypothesize that an exogenous fibrin matrix
could facilitate bridging a critical nerve defect by eliminating the need to wait one week for
the bridge to form. Fibrin has been used previously as a scaffold to support nerve
regeneration within a NGC (Lee, Yu et al. 2003a; Galla, Vedecnik et al. 2004; Marcol,
Kotulska et al. 2005) and can promote cell adhesion because it contains binding sites for
integrins (Thiagarajan, Rippon et al. 1996) and Schwann cells (Chernousov and Carey 2003).
Additionally, NGF is known to facilitate and enhance nerve regeneration (Xu, Yu et al. 2002;
Lee, Yu et al. 2003a; Yu and Bellamkonda 2003), therefore, incorporation of NGF into
fibrin matrices would likely have a synergistic effect. The use of fibrin was needed to
improve the effectiveness of sciatic nerve regeneration. However, the addition of NGF and
its method of delivery, whether free or bound in the affinity based DS, also affected its
effectiveness in promoting nerve regeneration.
Simple, polymer NGCs can bridge small nerve gaps with high effectiveness;
however, nerve regeneration effectiveness decreases beyond a 10 mm defect size (critical
defect length) without the addition of other components, such as extracellular matrix
molecules, Schwann cells, plasma, or neurotrophic factors to the conduit. Furthermore,
these larger defects may require a luminal matrix that utilizes a different method of drug
delivery than diffusion or loading free drug for enhanced nerve regeneration. For example,
Yu et al. found that agarose matrices incorporating laminin or freely-diffusible NGF
promoted nerve regeneration across the conduit in only half the animals (Yu and
Bellamkonda 2003). When the gap length was increased past the critical defect length,
Dodla et al. determined that agarose matrices with free or unbound ECM or growth factor
were unable to effectively promote sciatic nerve regeneration across a 20 mm defect.
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However, anisotropic matrices with concentration gradients of NGF and laminin, were more
effective in bridging the gap and enhanced nerve regeneration compared to isotropic
matrices (Dodla and Bellamkonda 2008).
Similarly in our study, a critical nerve defect was bridged more effectively with the
inclusion of an affinity-based DS sequestering NGF. This result could be due to loss of
NGF by diffusion from the conduit when there is no DS in the fibrin matrix, resulting in a
limited supply of NGF available to promote nerve regeneration. We previously
demonstrated in vitro that an affinity-based DS sequestered NGF. NGF release rates were
observed to decrease as peptide affinity increased, which increased DRG neurite outgrowth
compared to free NGF (Sakiyama-Elbert and Hubbell 2000a; Maxwell, Hicks et al. 2005;
Wood and Sakiyama-Elbert 2008).
The use of an affinity-based DS and NGF promoted enhanced regeneration as
assessed by one aspect of nerve regeneration, nerve fiber density, and the quality of nerve
regeneration, as assessed by percent neural tissue. Both measures were found to be similar
to nerve isograft. The DS and NGF did not promote total nerve fiber counts that were
similar to the isograft; however, a lower fiber count was likely due to the small crosssectional area of the regenerating nerve cables that were found in the silicone conduits. This
effect of silicone conduits has been noted by others (Williams, Longo et al. 1983; Lloyd,
Luginbuhl et al. 2007). Additionally, DS with NGF improved nerve fiber maturity, as
assessed by the number of large diameter fibers. Nerve fiber diameter is a commonly used
measure of maturity (Aitken, Sharman et al. 1947; Young 1949; Williams and Wendell-Smith
1971; Fraher and Dockery 1998; Lee, Yu et al. 2003a) and larger diameter fibers promote
better conduction velocity and return of function (Williams and Wendell-Smith 1971; Fraher
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and Dockery 1998). Our findings suggest that although it did not promote an equivalent
fiber number, the delivery of NGF from the DS produces more mature nerve fibers and a
similar nerve fiber density and neural tissue percentage compared to an isograft.
Other affinity-based drug DSs have incorporated components that reversibly bind
the drug of interest, such as heparin within fibrin (Jeon, Kang et al. 2005; Jeon, Ryu et al.
2005), collagen (Wissink, Beernink et al. 2000a), and polymer matrices (Benoit and Anseth
2005; Pike, Cai et al. 2006), but have not specifically looked at how the cellular response is
affected by difference in release rates in these DSs in vivo. Diffusion-based DSs were found
to promote differences in nerve regeneration due to varied release rates of growth factor,
and therefore affinity-based DSs could have similar effects due to varied binding affinity
leading to different release rates. For example, when GDNF release kinetics are varied from
a NGC used to treat a sciatic nerve defect, higher nerve fiber counts but lower functional
recovery result with a higher GDNF release rate (Piquilloud, Christen et al. 2007). We have
previously examined NGF release from this DS and found that release of NGF from the DS
increased myelinated nerve fiber sprouting and outgrowth compared to free NGF and fibrin
matrices alone in vivo (Lee, Yu et al. 2003a). Therefore, in this study, we focused on the role
of heparin-binding peptide affinity on nerve regeneration by utilizing an affinity-based DS.
This DS is designed to release growth factors (such as NGF) at different rates by using
different peptide sequences to modulate the affinity of the heparin-binding domain
(Maxwell, Hicks et al. 2005; Wood and Sakiyama-Elbert 2008). There were no statistical
differences in measures of nerve regeneration when peptide affinity was varied, although we
noticed a general trend toward increased nerve regeneration with increasing heparin-binding
affinity. Specifically, as heparin-binding affinity increased, the efficiency of regeneration and
histomorphometric measures generally increased. Previously, the DS demonstrated trends in
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vitro where as heparin-binding affinity increased, neurite extension generally increased and
the ability of the DS to retain NGF directly correlated with increased neurite extension
(Wood and Sakiyama-Elbert 2008).
In our study, we used the DS within a silicone NGC. Silicone NGCs possess a
degree of biocompatibility, a known critical defect length for the rat sciatic nerve injury
model, and are mechanically stable. Clinically, silicone conduits are not ideal and have
associated morbidities (Merle, Dellon et al. 1989; Dellon 1994; Battiston, Geuna et al. 2005),
therefore, the combination of a drug DS with a biodegradable conduit would be more
desirable for clinical peripheral nerve repair. Future studies directed toward this goal would
be of benefit in translating our DS into clinical practice. Additionally, future work with this
DS will likely focus on the use of the ATIII peptide, since it was found in previous studies to
be the most effective at sequestering NGF (Wood and Sakiyama-Elbert 2008) and
demonstrated the strongest trends toward enhanced nerve regeneration within this study. In
nerve regeneration, the ability of an affinity-based DS to retain NGF appears to be key to
enhancing regeneration (Wood and Sakiyama-Elbert 2008). However, other biomaterial
applications may see a benefit in an affinity-based DS that is capable of more passive growth
factor release with less growth factor sequestered, for example, to signal distant cells for
recruitment to the implantation site.

3.6

Conclusions
In summary, the goal of this study was to evaluate the efficiency of our affinity-based

DS in vivo and determine if the affinity of the heparin-binding peptide in the DS affected
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nerve regeneration in a critical defect rat sciatic nerve model. We examined the effect on
histological outcomes of NGF delivery and compared it to controls for the DS and to the
equivalent of the clinical standard of care, an isograft. Our DS enhanced one aspect of
nerve regeneration and the quality of nerve regeneration, as well as nerve fiber maturity and
the organization of the regenerating nerve. We did not observe differences in nerve
regeneration due to heparin-binding affinity with this DS. We hypothesize delivery of NGF
from an affinity-based DS offers a potential future alternative for the treatment of peripheral
nerve injuries.

82

Chapter 4
Controlled release of glial-derived neurotrophic factor
from fibrin matrices containing an affinity-based
delivery system *
4.1

Abstract
This research evaluated the controlled release of glial-derived neurotrophic factor

(GDNF) from an affinity-based delivery system (ABDS) as potential treatment for
peripheral nerve injury. The ABDS consisted of a bi-domain peptide containing a
transglutaminase substrate, allowing crosslinking into fibrin matrices, and a heparin-binding
domain based on the antithrombin-III heparin-binding domain, heparin, and GDNF, which
was sequestered based on its heparin-binding affinity. The objective of this research was to
determine the release rate and biological activity of GDNF released from the ABDS in vitro.
The ratio of peptide to heparin was found to modulate the rate of GDNF release. The
biological activity of GDNF released from the ABDS was assayed using chick dorsal root
ganglia (DRGs) neurite extension. Neurite extension was equivalent for fibrin matrices
containing the ABDS for all concentrations of GDNF tested versus DRGs grown with
GDNF in the media. Furthermore, neurite extension was enhanced in fibrin matrices
containing 100 ng/mL of GDNF with the ABDS versus matrices with GDNF at a simliar
dose but no ABDS. These results suggest that GDNF can be retained and released in a
biologically activity form from the ABDS, and thus this approach may prove useful for the
treatment of peripheral nerve injury.
*Contents of this chapter were published in J Biomed Mater Res A. 89A(4), 909-918, 2009 and were
reprinted with permission of the publisher
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4.2

Introduction
Peripheral nerve injury due to a complete transection of the nerve fibers results in

loss of function and neuropathic pain (Lundborg 2000). The peripheral nervous system is
capable of limited regeneration when the two ends of the severed nerve can be rejoined. In
the case of clean transections or small gaps, the ends are typically sutured back together. In
longer gaps, suturing would generate excess tension; therefore, the gap is typically bridged by
a non-critical donor sensory nerve autograft. Despite significant advances in nerve
reconstruction, autografting remains the clinical standard of care for critical long nerve gap
repair. However, the functional recovery following autografting remains incomplete, and the
resulting donor site morbidity has led investigators to seek alternative therapies (Lundborg
2000; Schmidt and Leach 2003). In particular, a conduit filled with a biomaterial matrix and
neurotrophic growth factors has been studied as an alternative repair strategy that could
serve to bridge the gap and enhance axonal regeneration (Schmidt and Leach 2003;
Bellamkonda 2006).
Drug delivery from biomaterial matrices often involves diffusion-based release,
where release is controlled by diffusion of the drug within the pores of the material.
Alternatively, affinity-based delivery systems immobilize drug within matrices via noncovalent interactions, controlling release by limiting the fraction of drug in the diffusible
form. Of the affinity-based delivery systems studied, many of them utilize heparin, taking
advantage of the ability of negatively-charged sulfated groups on heparin to interact with
proteins, such as growth factors, typically via exposed basic domains (Mach, Volkin et al.
1993; Mulloy 2005). Some previous methods to incorporate heparin into biomaterial
matrices have included heparin-conjugated Sepharose beads encapsulated in alginate
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(Edelman, Mathiowitz et al. 1991; Laham, Sellke et al. 1999), heparinized collagen matrices
(Wissink, Beernink et al. 2000a; Wissink, Beernink et al. 2000b), and use of poly(ethylene
glycol) (PEG) linkers in various forms to covalently incorporate heparin into the system
(Benoit and Anseth 2005; Pike, Cai et al. 2006; Tae, Scatena et al. 2006).
Previously, we have developed an affinity-based delivery system incorporating
heparin that sequesters proteins within a fibrin matrix using non-covalent interactions
(Sakiyama-Elbert and Hubbell 2000a; Sakiyama-Elbert and Hubbell 2000b). This system
contains a bi-domain peptide with one domain consisting of a transglutaminase substrate,
based on α2-plasmin inhibitor (Ichinose, Tamaki et al. 1983; Kimura, Tamaki et al. 1985),
allowing it to be crosslinked into fibrin matrices during polymerization by the
transglutaminase Factor XIIIa. This process leaves the other peptide domain free to interact
with heparin, via a modified version of the antithrombin III-heparin binding domain (TylerCross, Sobel et al. 1994; Tyler-Cross, Sobel et al. 1996; Sakiyama, Schense et al. 1999). With
the inclusion of a heparin-binding protein (e.g. heparin-binding growth factor), a bound
ternary complex within the fibrin matrix is formed consisting of peptide, heparin, and
protein, effectively sequestering the protein within the fibrin matrix leaving it available for
cell-mediated processes.
This delivery system has been employed using a variety of growth factors that
interact non-covalently with heparin, such as platelet-derived growth factor-BB (PDGF-BB)
(Gelberman, Thomopoulos et al. 2007), neurotrophin-3 (NT-3) (Taylor, McDonald et al.
2004; Taylor and Sakiyama-Elbert 2006), and nerve growth factor (NGF) (Sakiyama-Elbert
and Hubbell 2000a; Lee, Yu et al. 2003a; Wood and Sakiyama-Elbert 2008) for a variety of
potential treatment applications, which include flexor tendon repair (Gelberman,
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Thomopoulos et al. 2007), spinal cord injury (Taylor, McDonald et al. 2004; Taylor and
Sakiyama-Elbert 2006), and peripheral nerve injury (Lee, Yu et al. 2003b). In particular for
the potential treatment of peripheral nerve injury, release of NGF has been characterized
with this delivery system (Sakiyama-Elbert and Hubbell 2000a; Lee, Yu et al. 2003a; Wood
and Sakiyama-Elbert 2008). However, NGF has been found to promote sensory neuronal
survival and recovery, and motor neurons do not express or upregulate NGF or its receptors
after injury (Boyd and Gordon 2003). Therefore, additional growth factors that target motor
neurons are desired for use in this delivery system.
Glial-derived neurotrophic factor (GDNF) has been implicated as a potential
therapeutic agent for peripheral nerve regeneration. GDNF was initially identified for its
ability to promote the survival of dopaminergic neurons (Lin, Doherty et al. 1993), but
following peripheral nerve injury its expression is upregulated in Schwann cells (Hoke,
Gordon et al. 2002; Boyd and Gordon 2003; Zhao, Veltri et al. 2004), while its receptors are
upregulated in motor neurons (Boyd and Gordon 2003). Furthermore, GDNF promotes
neurite outgrowth and neuronal survival in vitro (Trupp, Ryden et al. 1995; Matheson,
Carnahan et al. 1997; Bennett, Michael et al. 1998; Gavazzi, Kumar et al. 1999; Tucker,
Rahimtula et al. 2006; Leclere, Norman et al. 2007) and promotes survival of axotomized
sciatic neurons in vivo (Matheson, Carnahan et al. 1997), making it a good candidate for
promoting motor nerve recovery. GDNF is also ideal for controlled delivery from our
delivery system because it binds to heparin with moderately high affinity (Rickard, Mummery
et al. 2003; Rider 2003; Rider 2006; Silvian, Jin et al. 2006; Alfano, Vora et al. 2007),
specifically at a basic amino-acid-rich sequence near the N-terminal to the first cysteine of
the transforming growth factor β domain of GDNF (Alfano, Vora et al. 2007).
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The focus of this study was to assess the release rate and biological activity of
GDNF released from fibrin matrices containing an affinity-based delivery system (ABDS).
The release of GDNF was measured over 7 days, where the delivery system component
ratios and the ratio of peptide to heparin were modulated to control release. Additionally,
neurite extension from chick embryonic dorsal root ganglia (DRGs) was measured to assess
the presence of biologically active GDNF.

4.3

Materials and Methods
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless specified

otherwise.

4.3.1 Fibrin matrix preparation
Fibrin matrices were prepared as previously described (Schense and Hubbell 1999)
by mixing the following components (final concentrations given): human plasminogen-free
fibrinogen containing Factor XIII (4.0 mg/mL), bovine thrombin (2 NIH units/mL), and
CaCl2 (2.5 mM, Fisher Scientific, Pittsburgh, PA). For the delivery system, a bi-domain
peptide (ATIII) based on a modified version of the antithrombin III-heparin binding
domain ((AcG)NQEQVSPK(βA)FAKLAAR-LYRKA, where AcG denotes N-acetyl-glycine
and the tranglutaminase substrate is given in italics) (Tyler-Cross, Sobel et al. 1994; Sakiyama,
Schense et al. 1999) was synthesized as described previously (Wood and Sakiyama-Elbert
2008). Briefly, the peptide was synthesized by standard solid phase Fmoc chemistry (amino
acids from Nova Biochem, San Diego, CA; peptide synthesis solvents from Applied
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Biosystems, Foster City, CA) using an ABI433A peptide synthesizer (Applied Biosystems).
After synthesis, the peptide was cleaved from the resin with 95% trifluoroacetic acid, 2.5%
water, and 2.5% triisopropylsilane by volume for 2-3 h, filtered through glass wool to
remove the resin, and then precipitated in cold diethyl ether. The crude peptide filtrates
were dried under vacuum, purified by standard C18 reverse phase liquid chromatography
(Shimadzu, Columbia, MD) and lyophilized. The identity of the ATIII peptide was verified
by matrix-assisted laser desorption ionization (MALDI) mass spectrometry.
Fibrin matrices including the delivery system were prepared by incorporating the
following additional components: peptide (0.25 mM to obtain ~ 8 moles of peptide crosslinked per mole of fibrinogen (Sakiyama, Schense et al. 1999; Schense and Hubbell 1999)),
heparin (Sigma-Aldrich product no. H9399, sodium salt from porcine intestinal mucosa
18,000 average MW) added at 62.5 and 6.25 μM to obtain 4:1 and 40:1 molar ratios of
peptide to heparin, respectively, and human GDNF (Peprotech Inc., Rocky Hill, NJ and
R&D systems, Minneapolis, MN for the in vitro biological activity and release assay,
respectively). Fibrin matrices with or without the delivery system were polymerized in 24well tissue culture plates for 1 h at 37°C and 5% CO2 yielding 400 µL matrices.

4.3.2 In vitro release assay
To measure the release of GDNF, fibrin matrices were prepared as described above
then incubated with an aqueous wash consisting of Tris-buffered saline (TBS, 137 mM NaCl,
2.7 mM KCl, 33 mM Tris, pH 7.4, Fisher Scientific) containing 1% bovine serum albumin
(BSA) at 37°C. Equilibrium studies were performed where 400 µL washes were added to the
matrices and then collected after 48 h, which was previously determined to be sufficient time
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for NGF to reach equilibrium between the matrix and wash phases in a similar experiment
(Willerth, Johnson et al. 2007). Additionally, a 7-day release study was performed where 1
mL washes were added and collected 5 times in the first 24 h, followed by collection
subsequently every 24 h for the next 6 days. For both studies all washes were collected in
silconized tubes to reduce GDNF loss and stored at -20°C. Upon completion of the release
studies, the remaining GDNF was extracted from the fibrin matrices by cutting them into 1
mm cubes and placing them in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl,
1.5 mM KH2PO4, 8.0 mM Na2HPO4, pH 7.4, Fisher Scientific) containing 0.56 mM heparin,
an additional 2 M NaCl (Fisher Scientific), 0.01% Triton-X, and 1% BSA at 4 °C for 48 h,
after which the mixture was stored at -20°C until analysis was performed.
The amount of GDNF released and remaining in the fibrin matrices was quantified
by an enzyme-linked immunosorption assay (ELISA) for human GDNF according to the
manufacturer’s instructions (R&D systems). The absorbance was read at 450 nm with an
optical subtraction at 650 nm using a multi-well plate spectrophotometer (MultiSkan RC,
Labsystems), and sample concentrations were calculated from a standard curve of known
GDNF concentrations. Control matrices were made by omitting the peptide, heparin,
and/or GDNF from the fibrin matrices.

4.3.3 In vitro biological activity assay
Fibrin matrices were prepared as described above then washed 5 times in the first 24
h with 1 mL of TBS for the first 4 washes and the last wash consisting of 1 mL of modified
neurobasal media (10 ng/mL of GDNF added for the positive control, see below).
Modified neurobasal media (NBM, Invitrogen, Carlsbad, CA) consisted of the following:
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insulin (5 g/mL), transferrin (100 g/mL), progesterone (6.4 ng/mL), putrescine (16.11
g/mL), selenite (5.2 ng/mL), and BSA (0.1%). DRGs were dissected from day-10 white
leghorn chick embryos (Specific Pathogen Free, Sunrise Farms, Catskill, NY). One DRG
was implanted per matrix using dissection forceps and allowed to adhere to the fibrin matrix
for 1 h at 37°C and 5% CO2. One mL of modified NBM was added after 1 h and left on the
fibrin matrices for the remainder of the experiment. The concentrations of peptide, heparin,
and GDNF and their corresponding molar ratios used in the delivery system for experiments
are contained in Table 4.1.

Table 4.1: Concentrations of delivery system components employed for in vitro biological
activity assay
GDNF

Peptide

Heparin

Molar ratio of

Molar ratio of

(ng/mL)

(mM)

(µM)

peptide : heparin

heparin : GDNF

10

0.25

62.5

4

200000

25

0.25

62.5

4

80000

100

0.25

62.5

4

20000

100

0.25

6.25

40

2000

250

0.25

62.5

4

8000

500

0.25

62.5

4

4000

DRGs were allowed to grow and extend neurites for 48 h upon which images were
captured. Brightfield images with a 2x objective using a CCD camera (Magnifire, Olympus)
were collected and analyzed using Image-Pro Express software (MediaCybernetics, San
Diego, CA) to determine the average neurite extension. The average neurite extension was
calculated as the radius of an annulus between the DRG body and the outer halo of
extending neurites, as described previously (Herbert, Bittner et al. 1996). All average neurite
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extension was normalized to the average neurite extension of a positive control consisting of
DRGs grown in 10 ng/mL of GDNF in the media (dose resulting in largest neurite
extension for soluble GDNF doses tested) from each experiment. Additional control
matrices were made by omitting the GDNF and/or peptide and heparin from the fibrin
matrices.

4.3.4 Immunocytochemistry
DRGs were mechanically dissociated, seeded to fibrinogen-coated 24 well plates (4.0
mg/mL) and given neurobasal media supplemented with 10% fetal bovine serum
(Invitrogen) and 10 ng/mL GDNF, and allowed to extend neurites for 24 h. The cells were
fixed in 2% formalin (pH 7.4) in PBS for 1 h at 37°C, permeabilized with 0.1% Triton X-100
and blocked with 3% BSA in PBS. These cultures were incubated with GDNF receptor α-1
(GFRα-1) primary antibody (1 μg/mL, Neuromics, Edina, MN) at 4°C for 24 h, followed by
Alexa Fluor 488 tagged secondary antibody (1 μg/mL, Invitrogen) detection for 2 h.
Fluorescence light microscopy images were captured using a CCD camera, where DRGs
with only the addition of the secondary antibody served as a threshold control to remove
excess background staining.

4.3.5 Statistical analysis
Statistical analysis was performed using Statistica (Statsoft, Tulsa, OK) with
comparative analysis using Scheffe’s F post-hoc test by analysis of variance at a 95%
confidence interval (α = 0.05). The release assays were performed with 3 matrices per
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replicate; the biological activity study was performed with 6 matrices per replicate. All
studies were performed in at least triplicate, and reported values are given as mean ±
standard deviation (S.D.).

4.4

Results

4.4.1 In vitro release assay
To understand how the delivery system would release GDNF over time, the system
was analyzed for its potential to bind GDNF. The ability of the delivery system to sequester
GDNF was assessed by incubating fibrin matrices (with or without delivery system)
containing GDNF with an equal volume of wash buffer and allowing the system to come to
equilibrium for 48 h (previously found to be sufficient time for growth factor concentrations
to reach equilibrium between the aqueous media and matrix (Willerth, Johnson et al. 2007)).
The amount of GDNF present within the matrices and the aqueous wash media was
measured to determine the concentration of free and matrix bound GDNF by assuming that
the concentration of free GDNF was the same in both phases. The amount of GDNF
present in fibrin matrices and their aqueous media without the complete delivery system
(fibrin alone, GDNF with peptide but no heparin, or GDNF with heparin but no peptide)
was equal to ~50% of the GDNF initially added to the matrix, demonstrating equal
partitioning of GDNF in the absence of delivery system (Figure 4.1). However, fibrin
matrices with the complete delivery system at both 4:1 and 40:1 molar ratios of peptide to
heparin retained more GDNF compared to matrices with no delivery system (62 ± 5% and
66 ± 1%, respectively versus ~50%).
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Figure 4.1. GDNF retention in vitro at 48 h is enhanced by the delivery system. GDNF was
released from fibrin matrices with or without delivery system (DS) over 48 h to an equal volume of
aqueous media to assess how much GDNF was retained in the fibrin matrices. The delivery system
at either molar ratio of peptide to heparin enhanced GDNF retention in the fibrin matrices, while the
inclusion of GDNF with peptide or heparin alone did not affect the retention. Data (n ≥ 3)
represented by mean ± SD where the parentheses contains the peptide to heparin molar ratio.
Statistical significance was considered p<0.05 compared to fibrin matrix alone or fibrin matrix with
either peptide or heparin.

The dynamic release of GDNF from fibrin matrices over 7 days was assessed by
measuring the concentration in aqueous wash media collected 5 times in the first 24 h and
once every 24 h for the following 6 days. GDNF was released rapidly from matrices lacking
the complete delivery system (matrices containing only GDNF, GDNF and heparin, or
GDNF and peptide), with 27-30% released in the initial burst and 79-85% released after 24
h (Figure 4.2). By day 3 all groups lacking the complete delivery system had released 90% of
their initial GDNF, and at the end of the study (day 7) these matrices retained little GDNF
(< 3%).
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Figure 4.2. GDNF release in vitro over 7 days is controlled by the ratio of peptide to heparin
in the delivery system. GDNF was released over 7 days from fibrin matrices with and without the
delivery system (DS) at various molar ratios of peptide to heparin. At the either molar ratio, the
delivery system retained a greater fraction of GDNF over all 7 days compared to no delivery system.
Additionally, at the 40:1 molar ratio, a greater fraction of GDNF was retained after the initial 24 h
until the end of the release at 7 days. GDNF with either peptide or heparin alone did not slow the
release of GDNF. Data (n ≥ 3) represented by mean ± SD where the parentheses contains the
peptide to heparin molar ratio, and statistical significance was considered p<0.05.

The presence of the complete delivery system slowed the release of GDNF and
resulted in the retention of a greater fraction of GDNF over 7 days. The initial burst of
GDNF from matrices with the delivery system during the first 24 h was reduced compared
to matrices lacking the complete delivery system, while 19 ± 2% and 14 ± 5% were released
for 4:1 and 40:1 peptide to heparin molar ratios, respectively. After 24 h, the matrices
containing the complete delivery system retained more GDNF than controls again with only
56 ± 5% and 51 ± 2% GDNF released (4:1 and 40:1 molar ratios respectively). By day 4
both ratios released less than 2% of the total GDNF per day demonstrating a relatively
stable state of retention, and at day 7 matrices with the delivery system had retained 29 ± 3%
for a 4:1 ratio and 37 ± 2% for a 40:1 ratio. Additionally, the molar ratio of peptide to
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heparin in the delivery system affected the fraction of GDNF retained. The 40:1 ratio
released less GDNF than the 4:1 ratio after 24 h, which was sustained for the remainder of
the experiment.

4.4.2 In vitro biological activity assay
To assess the feasibility of DRGs for the biological activity assay, DRGs in fibrin
matrices were stained for the primary ligand-binding subunit (GDNF receptor α-1), which
elicits signaling through its linked partner subunit, c-Ret receptor tyrosine kinase (Baloh,
Enomoto et al. 2000). While DRGs contain a majority of sensory neurons, a population of
the total neurons are responsive to GDNF (Trupp, Ryden et al. 1995; Matheson, Carnahan
et al. 1997; Bennett, Michael et al. 1998; Tucker, Rahimtula et al. 2006), where DRG neurite
extension can be measured from treatment with GDNF (Gavazzi, Kumar et al. 1999; Fine,
Decosterd et al. 2002; Tucker, Rahimtula et al. 2006; Leclere, Norman et al. 2007).
Dissociated DRGs demonstrated robust staining for GDNF receptor α-1 (Figure 4.3),
validating their use and sensitivity for quantitative assessment of neurite extension in
response to GDNF delivered from our delivery system.
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Figure 4.3. GDNF receptor α-1 is expressed by chick embryo DRGs. Dissociated DRGs plated
on fibrinogen-coated wells demonstrated robust staining for GDNF receptor α-1. While the
biological activity assay utilized whole DRGs implanted into 3-D fibrin matrices, this staining
validates their use for quantitative assessment of neurite extension in response to GDNF delivered
from our delivery system.

In order to assess the biological activity of GDNF released from the affinity-based
delivery system, embryonic chick DRGs were implanted into fibrin matrices with and
without the delivery system that had been previously washed 5 times over 24 h (analogous to
the first day of the in vitro release assay). The average neurite extension was measured after
48 h and was normalized to neurite extension from DRGs grown in unmodified fibrin
matrices with GDNF in the culture media at a dose of 10 ng/mL (Figure 4.4). This dose
promoted the greatest level of neurite extension (optimal dose) from comparison to other
doses ranging from 1 – 100 ng/mL of GDNF. Additionally, ranges of concentrations of
GDNF were tested at a single peptide to heparin molar ratio (4:1) to identify an optimal
dose (Figure 4.5). At this optimal dose, multiple delivery system formulations were tested by
varying the peptide to heparin molar ratio (through altering the heparin concentration) in the
delivery system to determine if the delivery system component ratio modulated biological
activity.
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Figure 4.4. Photomicrographs of DRG cultured containing different GDNF concentrations
with and without the delivery system. A) 10 ng/mL GDNF in the culture media, B) 100 ng/mL
GDNF with the delivery system at a 4:1 molar ratio of peptide to heparin, C) 100 ng/mL GDNF
without the delivery system, D) 250 ng/mL GDNF without the delivery system, E) 10 ng/mL
GDNF with the delivery system, F) fibrin matrix with no GDNF added. These results represent
sample images demonstrating DRG neurite extension resulting from the variations in the
concentration of GDNF used in the assay.

In the absence of GDNF (with or without heparin and peptide) robust neurite
extension was not observed, and neurite extension was significantly decreased from the
positive control by ~75%. Normalized neurite extension through fibrin matrices containing
10 ng/mL of GDNF with the delivery system was similar to 10 ng/mL of GDNF in the
media (positive control), while the 10 ng/mL of GDNF in fibrin matrices lacking the
delivery system (GDNF and fibrin alone) resulted in decreased neurite extension versus the
positive control (Figure 4.5). At other doses tested (25, 100, 250, and 500 ng/mL in fibrin
matrices) neurite extension was similar to the positive control for both matrices containing
the delivery system and matrices lacking the delivery system. However, at a GDNF dose of
100 ng/mL, the presence of the delivery system resulted in enhanced normalized neurite
extension compared to fibrin matrices without the delivery system at this same dose.
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Figure 4.5. Effect of GDNF concentration on DRG neurite extension in vitro. Neurite
extension from chick DRGs was affected by the concentration of GDNF in fibrin matrices with (DS
with GDNF 4:1) or without the delivery system (GDNF alone). The delivery system at a peptide to
heparin molar ratio of 4:1 at any concentration of GDNF promoted neurite extension similar to
GDNF in the media at 10 ng/mL (optimal dose), while the lack of delivery system resulted in
decreased neurite extension at the lowest GDNF concentration (10 ng/mL). The delivery system
with 100 ng/mL of GDNF promoted enhanced neurite extension compared to GDNF at the same
dose with no delivery system. Additionally, neurite extension was biphasic in response to the GDNF
concentration both with and without the delivery system. All DRG neurite extension was
normalized to the average neurite extension for 10 ng/mL GDNF in the media for the same
experiment. Data (n ≥ 18) represents mean ± S.D., N.T. indicates a dose of GDNF in the media
that was not tested, * indicates statistical significance (p<0.05) compared to 10 ng/mL GDNF in the
media, # indicates statistical significance (p<0.05) compared to GDNF alone, and + indicates
statistical significance (p<0.05) compared to 10 ng/mL GDNF under similar conditions
(with/without the delivery system).

A biphasic response was exhibited where neurite extension increased or decreased
depending on the concentration of GDNF. At doses of 100 and 250 ng/mL of GDNF,
neurite extension increased compared to a dose of 10 ng/mL of GDNF with the delivery
system present, while 25 and 500 ng/mL of GDNF resulted in neurite extension similar to
10 ng/mL of GDNF. Also, when the delivery system was not present, all doses but 250
ng/mL of GDNF resulted in neurite extension comparable to a dose of 10 ng/mL of
GDNF, where neurite extension was increased at 250 ng/mL of GDNF.
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Based on these results, it was determined that at 100 ng/mL the delivery system at a
peptide to heparin molar ratio of 4:1 enhanced normalized neurite extension compared to
the matrices containing a similar dose of GDNF without the delivery system. Therefore, at
this optimal dose the effect of the molar ratio of peptide to heparin was examined, and the
effect of individual delivery system components was examined in a systematic manner to
assess their contribution to the biological response. The use of the delivery system at a 40:1
peptide to heparin molar ratio resulted in enhanced normalized neurite extension compared
to GDNF in the media at an optimal dose (10 ng/mL) by 32 ± 26% but was not different
from the response of the delivery system at a ratio of 4:1 (Figure 4.6). The elimination of
components of the delivery system resulted in similar neurite extension as was found from
fibrin matrices with GDNF alone, which were again decreased versus the complete the
delivery system.
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Figure 4.6. Delivery system components affect DRG neurite extension in vitro. Neurite
extension from chick DRGs was affected by the molar ratio of peptide to heparin at 100 ng/mL of
GDNF. The delivery system at a peptide to heparin molar ratio of 40:1 promoted enhanced neurite
extension compared to 10 ng/mL GDNF in the media. Additionally, the entire delivery system was
required to increase normalized neurite extension. All DRG neurite extension was normalized to the
average neurite extension for unmodified fibrin matrices with 10 ng/mL of GDNF added to the
media for the same experiment. Data (n ≥ 18) represents mean ± S.D., # indicates statistical
significance (p<0.05) compared to the GDNF with no delivery system or with an incomplete delivery
system, and * indicates statistical significance (p<0.05) compared to 10 ng/mL GDNF in the media.

4.5

Discussion
This study utilized an affinity-based delivery system to sequester GDNF and control

its release from fibrin matrices. Non-covalent interactions served to sequester the growth
factor, limiting the fraction of GDNF in the diffusible form, thus slowing its diffusion from
fibrin matrices. In cases of slow diffusion-based release, cell-mediated processes, such as
neurite outgrowth induced protease activation (e.g. plasmin), could potentially serve as
alternative mechanisms for regulating growth factor release from fibrin matrices. GDNF
has been administered locally at the site of injury via passive diffusion (Yan, Matheson et al.
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1995; Barras, Pasche et al. 2002; Fine, Decosterd et al. 2002) and systemically via
subcutaneous injections (Yan, Matheson et al. 1995), both resulting in the rescue of motor
neuron cell bodies from death. Furthermore, when GDNF release kinetics from a nerve
guidance conduit are varied, greater nerve fiber counts but slower functional recovery result
for higher rates of delivery (Piquilloud, Christen et al. 2007); therefore, it is still unclear
which route is the best method for delivery. The affinity-based delivery system releases
growth factor via a cell-mediated manner. Specifically, as neurites from the neuron extend
their processes within the fibrin, proteases are activated by the growth cone allowing the
breakdown of fibrin and other delivery system components. For example, the growth cone
is known to facilitate the activation of plasminogen to plasmin, which can cleave fibrin into
smaller fragments (Pittman and Buettner 1989; Pittman, Ivins et al. 1989; Herbert, Bittner et
al. 1996), and cells releasing heparinase have been shown to liberate heparin-binding growth
factors from extracellular matrix (ECM) (Vlodavsky, Fuks et al. 1991). In order to retain
growth factor in the matrix and available for cell-mediated release, the ratio of delivery
system components can be modulated to slow the passive diffusion-based release of growth
factor from the matrices, as evidenced by the increased fraction of GDNF found in the
matrix at 7 days with the delivery system versus without delivery system.
As the molar ratio of the peptide to heparin increased from 4:1 to 40:1, less GDNF
was released over 7 days from fibrin matrices with the delivery system. Previously, when this
delivery system was utilized to delivery neurotrophin-3 (NT-3), a heparin to growth factor
molar ratio of 800:1 was more effective in slowing the release of growth factor versus a ratio
of 8000:1 (Taylor, McDonald et al. 2004). These ratios correspond to approximate peptide
to heparin ratios of 40:1 and 4:1 for the 800:1 and 8000:1 ratios, respectively (see Table 4.1).
This previous result with NT-3 agrees well with release data from our present experiments
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with a different growth factor, GDNF, used in the same delivery system. While the heparin
to growth factor ratios differ between this previous result and the present data (chosen based
on the relative affinity of the growth factors for heparin), the concentrations of heparin and
peptide used in both were similar and previous mathematical modeling (Wood and
Sakiyama-Elbert 2008) predicts that heparin to growth factor ratios above 100:1 would
contain a vast majority of heparin-growth factor binary complexes. Therefore, the
differences in the ratios of heparin to growth factor are not as important as the ratios of
peptide to heparin, which were similar between both results. Additionally, mathematical
modeling of this delivery system at a state of binding equilibrium between peptide, heparin,
and growth factor within the fibrin matrix utilizing the growth factors NT-3 (Taylor,
McDonald et al. 2004) and NGF (Wood and Sakiyama-Elbert 2008) found a range of
delivery system component ratios that maximized bound growth factor within the matrices.
The molar ratios tested in this study for the growth factor GDNF predict a dissociation
constant (KD) on the order of 1 – 3 x 10-7 M (Wood and Sakiyama-Elbert 2008), which is
within the range predicted by others studying GDNF’s affinity for heparin (~1 x 10-7 M
(Rickard, Mummery et al. 2003; Rider 2003; Rider 2006)). This KD would place both peptide
to heparin molar ratios used in this study within the range of delivery components that
would maximize bound growth factor in a ternary complex within the fibrin matrix (Wood
and Sakiyama-Elbert 2008). However, a molar ratio of 4:1 is closer to the range of
suboptimal equilibrium binding which could result in more release due to unbound heparin
interacting with GDNF resulting in an unbound heparin-GDNF complex that would be
washed away via passive diffusion.
The delivery system did not have a negative effect on the biological activity of
GDNF as evidenced by similar or enhanced neurite extension to GDNF in the cell culture
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media. Additionally, the delivery system’s ability to retain GDNF strongly influenced
GDNF biological activity. The presence of the delivery system provided the ability to retain
more GDNF in the fibrin matrices after washing resulting in better neurite extension
compared to GDNF loaded in the fibrin matrices without the delivery system for certain
doses. Moreover, when individual components of the delivery system were eliminated at a
dose of 100 ng/mL of GDNF, less GDNF was retained and neurite extension was again
decreased compared to the complete delivery system. Furthermore, at this dose the delivery
system was capable of enhancing the biological activity of GDNF over the positive control
by modulating the number of binding sites for peptide and growth factor or concentration
of delivery system components, represented by the molar ratio of peptide to heparin.
Previously, others have found that localized delivery of neurotrophic factors can
enhance neurite extension more than neurotrophic factors in the media (Sakiyama-Elbert
and Hubbell 2000a; Sakiyama-Elbert and Hubbell 2000b; Taylor, McDonald et al. 2004). In
this study, enhanced neurite extension compared to GDNF in the media was observed for a
peptide to heparin molar ratio of 40:1 but not for 4:1. This increase could be due to a
decrease in GDNF released from the system at a peptide to heparin molar ratio of 40:1
compared to a ratio of 4:1. Previously it was determined that the ability of this delivery
system to retain mass was crucial in enhancing the biological activity of DRGs in response to
the growth factor NGF (Wood and Sakiyama-Elbert 2008). Our results agree with this since
at 24 h both ratios retained similar mass, but after 24 h the 40:1 ratio retained more GDNF
than the 4:1 ratio.
Additionally, the results from the biological activity assay suggested a biphasic
response of DRGs to GDNF, where at a low dose of GDNF (10 ng/mL) neurite extension
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was decreased from higher doses of GDNF, both with and without the delivery system. At
doses higher than those doses that maximized neurite extension there was not an increase in
neurite extension, but instead a decrease in neurite extension from these optimal doses
resulting in neurite extension similar to a low dose of GDNF (10 ng/mL), indicative of a
saturation response. Biphasic behavior has been demonstrated in vitro for neurotrophic
growth factors administered in the media alone (Conti, Fischer et al. 1997) and when it is
sequestered in a biomaterial matrix (Sakiyama-Elbert and Hubbell 2000a; Maxwell, Hicks et
al. 2005; Willerth, Johnson et al. 2007), similar to our results. The response of DRGs to
these doses is useful when considering potential doses for in vivo applications towards
treatment of peripheral nerve injury, where an effective dose that encourages regeneration is
desired.
The ability of the delivery system to present biologically active GDNF in vitro
suggests it may be useful for the treatment of nerve injury in vivo. In peripheral nerve
regeneration, when a guidance conduit is placed between the distal and proximal nerve
stumps at the injury site, a fibrin bridge naturally forms between the separated nerve
segments serving as a scaffold for the regeneration process (Williams, Longo et al. 1983).
Therefore, a delivery system filling the lumen of a nerve guidance conduit incorporating
both native ECM and beneficial neurotrophic factors could promote peripheral nerve
regeneration. In addition, this delivery system allows the exploration of factors affecting
local delivery of growth factors that influence regeneration. Sequestering NGF within this
biomaterial matrix promoted better regeneration than free NGF in the matrix at a similar
dose (Lee, Yu et al. 2003b). As mentioned above, less is known about the optimal delivery
method for GDNF, but others have seen promising results when it is delivered slowly
during the regeneration process. For example, transected sciatic nerves repaired with neural
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conduits that slowly released GDNF supported better axonal regeneration, a greater number
of myelinated axons and higher numbers of retrograde-labeled motorneurons than untreated
or NGF-treated conduits (Fine, Decosterd et al. 2002). Furthermore, when the release of
GDNF from a nerve guidance conduit was varied, the resulting regeneration was dependent
on the rate of delivery (Piquilloud, Christen et al. 2007). Therefore, future studies will focus
on the delivery of GDNF utilizing this heparin-based delivery system in vivo for the potential
treatment of peripheral nerve injury to investigate the role of cell-mediated release in the
regeneration process.
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Chapter 5
Affinity-based Release of Glial-Derived Neurotrophic
Factor from Fibrin Matrices Enhances Sciatic Nerve
Regeneration *
5.1

Abstract
Glial-derived neurotrophic factor (GDNF) promotes both sensory and motor

neuron survival. The delivery of GDNF to the peripheral nervous system has been shown
to enhance regeneration following injury. In this study we evaluated the effect of affinitybased delivery of GDNF from a fibrin matrix in a nerve guidance conduit on nerve
regeneration in a 13 mm rat sciatic nerve defect. Seven experimental groups were evaluated
consisting of GDNF or nerve growth factor (NGF) with the delivery system within the
conduit, control groups excluding one or more components of the delivery system, and
nerve isografts. Nerves were harvested 6 weeks after treatment for analysis by
histomorphometry and electron microscopy. The use of the delivery system (DS) with either
GDNF or NGF resulted in a higher frequency of nerve regeneration versus control groups,
as evidenced by a neural structure spanning the 13 mm gap. The GDNF DS and NGF DS
groups were also similar to the nerve isograft group in measures of nerve fiber density,
percent neural tissue, and myelinated area measurements, but not in terms of total fiber
counts. In addition, both groups contained a significantly greater percentage of larger
diameter fibers with GDNF DS having the largest in comparison to all groups, suggesting
more mature neural content. The delivery of GDNF via the affinity-based delivery system
*Contents of this chapter were published in Acta Biomaterialia. 5(4), 959-968, 2009 and were reprinted with
permission of the publisher
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can enhance peripheral nerve regeneration through a silicone conduit across a critical nerve
gap and offers insight into potential future alternatives to the treatment of peripheral nerve
injuries.

5.2

Introduction
Despite recent advances in the understanding of peripheral nerve injury and

regeneration, functional outcomes are still suboptimal. In nerve transection injuries, the
current standard of care is a primary end to end repair. In nerve gap injuries, when tension
precludes a primary repair, an autograft is used to provide a scaffold for the regenerating
nerve. This procedure, however, has limitations due to donor site availability and morbidity
(Meek and Coert 2002; Chen, Zhang et al. 2006) . One alternative to autografting is the use
of a nerve guidance conduit (NGC). NGCs facilitate bridging the gap between a proximal
and distal nerve, protect regenerating axons from infiltrating scar tissue, and allow the
microenvironment of the regenerating nerve to be manipulated by controlling biochemical
and physical contents (Meek and Coert 2002; Battiston, Geuna et al. 2005).
A variety of materials have been investigated for use as scaffolds to fill the lumen of
a NGC, including the extracellular matrix proteins collagen (Chamberlain, Yannas et al.
1998; Labrador, Buti et al. 1998), fibronectin (Chen, Hsieh et al. 2000), and laminin
(Labrador, Buti et al. 1998) as well as naturally-derived matrices such as agarose (Labrador,
Buti et al. 1995; Yu and Bellamkonda 2003) and alginate (Ohta, Suzuki et al. 2004; Mohanna,
Terenghi et al. 2005). Fibrin also has been used as a biomaterial scaffold to support neural
regeneration within a NGC (Lee, Yu et al. 2003a; Galla, Vedecnik et al. 2004; Marcol,
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Kotulska et al. 2005) and may offer an advantage over other materials because it naturally
forms within an empty silicone conduit connecting the damaged ends of rat sciatic nerve
(Williams, Longo et al. 1983). Furthermore, fibrin contains sites for cell binding via integrin
receptors (Thiagarajan, Rippon et al. 1996), including cell binding sites for Schwann cells
(Chernousov and Carey 2003) that may facilitate cellular migration.
Numerous drug delivery methods have also been used with NGCs (Barras, Pasche et
al. 2002; Fine, Decosterd et al. 2002; Whittlesey and Shea 2004; Piquilloud, Christen et al.
2007; Dodla and Bellamkonda 2008; Pfister, Alther et al. 2008). However, diffusion-based
release of growth factors from degradable polymers is the most common delivery method
(Barras, Pasche et al. 2002; Fine, Decosterd et al. 2002; Burdick, Ward et al. 2006). One
shortcoming of this approach is that the release rate cannot be modulated or controlled by
cells during regeneration. One alternative is to use an affinity-based delivery system (DS) that
allows the release of growth factors to be controlled by cell-based degradation of the delivery
system (Sakiyama-Elbert and Hubbell 2000a). Our lab has developed an affinity-based
delivery system that sequesters heparin-binding proteins within a fibrin matrix using noncovalent interactions (Sakiyama-Elbert and Hubbell 2000a; Sakiyama-Elbert and Hubbell
2000b). This system contains a bi-domain peptide containing a transglutaminase substrate
domain and a heparin-binding domain. Based on the α2-plasmin inhibitor substrate
(Ichinose, Tamaki et al. 1983; Kimura, Tamaki et al. 1985), the peptide is able to crosslink
into the fibrin matrix during polymerization via the transglutaminase activity of Factor XIIIa,
leaving the other domain free to interact (Sakiyama, Schense et al. 1999; Schense and
Hubbell 1999). This heparin-binding domain has the capability to sequester various
neurotrophic factors due to their ability to bind to heparin via the sulfated domains on the
heparin (Yamada 1983). This delivery system has been used with a variety of growth factors
108

in many potential treatment applications (Sakiyama-Elbert and Hubbell 2000a; Lee, Yu et al.
2003a; Taylor, McDonald et al. 2004; Taylor and Sakiyama-Elbert 2006; Gelberman,
Thomopoulos et al. 2007; Wood and Sakiyama-Elbert 2008). Specifically, we have
characterized the effect of affinity-based delivery of nerve growth factor (NGF) on
peripheral nerve regeneration (Lee, Yu et al. 2003a).
Glial-derived neurotrophic factor (GDNF) has shown promise in the treatment of
peripheral nerve injuries. While GDNF is has been found to promote the survival of both
sensory and motor neurons, multiple studies report it to be the most potent motor neuron
trophic and survival factor (Henderson, Camu et al. 1993; Li, Wu et al. 1995; Oppenheim,
Houenou et al. 1995; Yan, Matheson et al. 1995; Oppenheim, Houenou et al. 2000; Hoke,
Gordon et al. 2002). GDNF expression in peripheral nerves is also upregulated significantly
in the distal stump of injured sciatic nerve, as well as in the corresponding muscle (Trupp,
Ryden et al. 1995; Naveilhan, ElShamy et al. 1997). Given the ability of GDNF to enhance
peripheral nerve regeneration (Barras, Pasche et al. 2002; Fine, Decosterd et al. 2002;
Piquilloud, Christen et al. 2007), we chose to examine controlled delivery of GDNF from
our affinity-based delivery system in vitro and found that GDNF could be retained and
released from the delivery system in a biologically active form (Wood, Borschel et al. 2009).
In the present study, we evaluated the effects of controlled release of GDNF from a
fibrin matrix containing our affinity-based delivery system within a NGC on nerve
regeneration in vivo using a rat sciatic nerve injury model. We included NGF in the current
study for comparison to our previous study. We hypothesized that controlled delivery of
GDNF would enhance nerve regeneration and have histomorphometric equivalence to a
nerve isograft.
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5.3

Materials and Methods

5.3.1 Experimental animals
Adult male Lewis rats (Harlan Sprague-Dawley, Indianapolis, IN), each weighing
250-300 g were used in this study. All surgical procedures and peri-operative care measures
were performed in strict accordance with the National Institutes of Health guidelines and
were approved by the Washington University Animal Studies Committee. All animals were
housed in a central animal facility, given a rodent diet (PicoLab Rodent Diet 20 #5053, PMI
Nutrition International) and water ad libitum. After surgical procedures, animals recovered in
a warm environment and were closely monitored for 2 hours. Animals were then returned
to the animal facility and monitored for weight loss, infection, and other morbidities.

5.3.2 Experimental Design
Eighty-four animals were randomized into seven groups (n = 12) as shown in Table
5.1. An additional six animals served as sciatic nerve isograft donors. In all experimental
groups, the sciatic nerve was transected and a 5 mm segment was excised just proximal to
the trifurcation of the nerve. The nerve was repaired with a 15 mm silicone conduit
containing fibrin matrices with or without delivery system and growth factor. One
millimeter of nerve was incorporated into each end of the conduit to create a 13 mm nerve
gap, exceeding the “critical gap” of spontaneous rat sciatic regeneration through silicone
conduits by 3 mm (Lundborg, Dahlin et al. 1982a; Williams, Longo et al. 1983) (Figure 5.1).
Group I served as the untreated control group and received an empty conduit. Group II, III,
and IV were additional control groups receiving conduits containing fibrin alone, fibrin with
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the delivery system (no growth factor) or fibrin with the growth factor, but no delivery
system. These groups examined the isolated effects of the delivery system components.
The remaining groups (V, VI) were implanted with conduits containing the fibrin matrix
containing the delivery system with doses of GDNF or NGF, which were selected based
upon in vitro DRG dose studies and preliminary data obtained from dose-response pilot
studies in the sciatic nerve model (test doses included 25, 50, 100, and 250 ng/mL GDNF
with the delivery system). Group VII served as a positive control receiving reversed nerve
isografts from syngeneic donor animals.

Table 5.1: Experimental Design
Group

GF dose

Delivery

Fibrin

Number

Number of rats with

(ng/ml)

System (DS)

Matrix

of rats

neural regeneration

I

0

No

No

12

3

II

0

No

Yes

12

5

III

0

Yes

Yes

12

3

IV

100 – GDNF

No

Yes

12

1

V

100 – GDNF

Yes

Yes

12

6

VI

50 - NGF

Yes

Yes

12

7

VII

Isograft

No

No

12

12

Abbreviations: GF, Growth Factor; GDNF, glial-derived neurotrophic factor; NGF, nerve growth factor.
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Figure 5.1. Schematic representation of surgical implantation of nerve guidance conduit
containing the affinity-based delivery system. A 13 mm nerve gap was repaired with a 15 mm
silicone conduit containing fibrin matrices with or without delivery system and growth factor and
sutured to the transected proximal and distal stumps, incorporating 1 mm of nerve on either end.
The delivery system consisted of a bi-domain peptide cross-linked into the fibrin matrix at one
domain while the other binds heparin by electrostatic interactions. The growth factor can then bind
to the bound heparin, creating a matrix-bound, non-diffusible complex, which can be retained for
cell mediated degradation of the fibrin matrix.

5.3.3 Preparation of fibrin matrices
Fibrinogen solutions were prepared by dissolving human plasminogen-free
fibrinogen in deionized water at 8 mg/mL for 1 h and dialyzing versus 4L of Tris-buffered
saline (TBS) (33 mM Tris, 8 g/L NaCl, 0.2 g/L KCl) at pH 7.4 overnight to exchange salts
present in the protein solution. The resulting solution was sterilized by filtration through 5.0
μm and 0.22 μm syringe filters, and the final fibrinogen concentration was determined by
measuring absorbance at 280 nm. For the delivery system, a bi-domain peptide (ATIII)
based on a modified version of the antithrombin III-heparin binding domain
((AcG)NQEQVSPK(βA)FAKLAAR-LYRKA, where AcG denotes N-acetyl-glycine and the
tranglutaminase substrate is given in italics) (Tyler-Cross, Sobel et al. 1994; Sakiyama,
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Schense et al. 1999) was synthesized as described previously (Wood, Borschel et al. 2009).
Fibrin matrices were prepared as previously described. Components were mixed to obtain
the following final solution concentrations: 4 mg/mL fibrinogen, 2.5 mM Ca++, 2 NIH
units/mL of thrombin, 0.25 mM peptide (which results in 8 moles of cross-linked peptide
per mole fibrinogen (Sakiyama, Schense et al. 1999; Schense and Hubbell 1999)), 62.5 µM
heparin (sodium salt), and recombinant human GDNF or NGF (at proper dose, Peprotech,
Table 5.1).
Silicone tubing (SF Medical, Hudson, MA) (1.5 mm inside diameter x 0.3 mm wall
thickness) was autoclaved overnight, cut into 15 mm segments, and soaked in 70% ethyl
alcohol. Prior to filling, the tubes were rinsed with sterile saline solution. The fibrinogen
solution was drawn into the silicone tube using a pipette and allowed to polymerize for 10
minutes prior to implantation.

5.3.4 Operative Procedure
All surgical procedures were performed using aseptic technique and microsurgical
dissection and repairs. Under subcutaneous anesthesia with ketamine (75 mg/kg) and
medetomidine (0.5 mg/kg), the hind leg of the rat was prepped and the sciatic nerve was
exposed through a dorsolateral gluteal muscle splitting incision. A 5 mm nerve segment was
excised proximal to the trifurcation of the sciatic nerve and a 15 mm silicone tube, with the
fibrin matrices with or without delivery system and growth factor, was sutured to the
transected proximal and distal stumps, incorporating 1 mm of nerve on either end as
described above (Figure 5.1). Four 9-0 nylon interrupted microepineurial sutures were used
to secure the conduit. In animals receiving the isograft control, a 13 mm segment of sciatic
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nerve was harvested from a syngeneic donor animal and inserted into the recipient animal.
Wounds were irrigated with saline, dried, and closed with a running 5-0 vicryl suture in
muscle fascia, and then interrupted 4-0 nylon skin sutures.
Anesthesia in experimental animals was then reversed with a subcutaneous injection
of atipamezole HCl (1mg/kg) (Pfizer Animal Health, Exton, PA), and the animals recovered
in a warm environment. After recovery, the animals were returned to the housing facility.
Six weeks postoperatively, all animals were re-anesthetized and nerve harvests were
performed by reopening the prior muscle splitting incision. The nerve conduit and a 5 mm
portion of native nerve both proximally and distally were harvested. The specimens were
marked with a proximal suture and stored in 3% glutaraldehyde in 0.1 M phosphate buffer
(pH 7.2) at 4°C until histomorphometric analysis was performed. Under anesthesia, the
animals were then euthanized with intracardiac injection of Euthasol (150mg/kg) (Delmarva
Laboratories, Des Moines, IA).

5.3.5 Histomorphometric and Electron Microscopic Evaluation
The tissues were post-fixed with 1% osmium tetroxide, ethanol dehydrated and
embedded in Araldite 502 (Polyscience Inc., Warrington, PA). Thin (1 µm) sections were
made from the tissue using a LKB II Ultramicrotome (LKB-Produckter A.B., Broma,
Sweden) and then stained with 1% toluidine blue for examination by light microscopy. The
slides were evaluated by an observer blinded to the experimental groups for overall nerve
architecture, quantity of regenerated nerve fibers, degree of myelination, and the presence of
Wallerian degeneration (Hunter, Moradzadeh et al. 2007).
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Proximal and distal cross sections from the host nerve, and sections through the
conduit or graft were evaluated. At 1000X magnification, six representative fields per nerve
were evaluated with an automated digital image-analysis system linked to morphometry
software using previously described methods to measure nerve morphometry (Hunter,
Moradzadeh et al. 2007). Briefly, total fascicular area and total fiber number were measured.
At least 80% of the nerve area was measured to determine the fiber diameters and density.
From these primary measurements the following morphometric indices were calculated: total
number of nerve fibers, nerve fiber density (fiber number/mm2), percent neural tissue (100 x
neural area/intrafascicular area), and nerve fiber width. Morphometric indices from
experimental neural specimens were compared to the isograft controls.
For electron microscopy, ultrathin 70 nm sections of the embedded tissues were cut
by a LKB III Ultramicrotome and stained with uranyl acetate-lead citrate. These sections
were examined with a Zeiss 902 electron microscope (Zeiss Instruments, Chicago, IL).
Quality of myelination, relative prevalence of unmyelinated fibers, and the area of myelinated
and unmyelinated fibers were evaluated.

5.3.6 Statistical analysis
All results are reported as mean ± standard error of the mean. Statistical analyses
were performed using Statistica version 6 (Statsoft Inc., Tulsa, OK). All data were evaluated
for differences between groups using the Kruskal-Wallis analysis of variance (ANOVA) and
median test. Post hoc Mann-Whitney tests were used for determining differences between
groups with significance set at α = 0.05. Additionally, fiber width data was evaluated for
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differences between groups using ANOVA, and post hoc LSD tests were used for
determining which groups differed with a significance set at α = 0.05.

5.4

Results

5.4.1 Nerve guidance conduit harvest
The effectiveness of GDNF in promoting nerve regeneration across a critical nerve
gap was evaluated in vivo after sciatic nerve transaction and NGC implantation. After 42
days, groups with the delivery system and growth factor resulted in more successful
regeneration as demonstrated by a neural structure spanning the 13 mm gap with higher
frequency. Six of 12 conduits from the 100 ng/mL GDNF with delivery system (GDNF
DS) and 7 of 12 conduits from 50 ng/mL NGF with DS (NGF DS) groups contained
regenerated nerve cables. Five of 12 conduits from the group containing fibrin, 3 of 12
conduits from DS alone with no growth factor (DS alone (no GF)) group, 1 of 12 of the 100
ng/mL GDNF (GDNF (no DS)) group, and 3 of 12 from the empty group demonstrated
nerve regeneration (Table 5.1). All 12 animals in the isograft group demonstrated
regeneration. The gross appearance of the regenerated nerves in the GDNF DS group
exhibited a larger, more robust nerve cable in comparison to the other experimental groups.
The neural structure was centered compactly in the conduit, away from the walls, in all
conduit specimens. All conduit specimens demonstrated intact connections to the proximal
or distal sciatic nerve, despite variability in regeneration.
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5.4.2 Histology
Qualitative examination of the midline of the conduits or grafts by light microscopy
revealed differences in nerve architecture as reflected by the arrangement and description of
the regenerating axons (Figure 5.2). In particular, the normal rat sciatic nerve contains
myelinated fibers in a packed, semi-symmetric, uniform arrangement with fibers that are
relatively similar in size and shape to one another. Overall, this arrangement can be
described as “organized” architecture. The isograft, GDNF DS and NGF DS, reflect this
organized appearance, while the fibrin alone group demonstrated more random spacing and
swirling of fibers, as well as, less symmetric shape of the individual myelinated fibers. In
addition, groups with growth factor and the delivery system appeared to have more tightly
packed fibers than the isograft, which was likely due to the compact area for neural
regeneration in the silicone tube. No inflammatory response or residual fibrin was
appreciated.
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Figure 5.2. Histological sections of regenerating nerves at the midline of the conduit (or
graft). (A) Fibrin alone; (B) Isograft; (C) delivery system incorporating GDNF (GDNF DS); (D)
delivery system incorporating NGF (NGF DS); (E) normal uninjured nerve. Thin (1 µm) sections of
sciatic nerve specimens were stained with 1% toluidine blue for qualitative examination of the
midline of the conduits by light microscopy. GDNF DS and NGF DS groups demonstrated more
organized neural architecture, closely approximating the isograft, in comparison to the fibrin alone
group. Scale bar, 10 µm.
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5.4.3 Histomorphometry
At six weeks, the average total myelinated fiber count, one measure of the
effectiveness of neural regeneration, was 12,000 ± 600 fibers (n = 12) for the isograft, while
the conduits with GDNF DS contained 3500 ± 1500 fibers (n = 12) (Figure 5.3A). The
NGF DS group had 2000 ± 770 fibers (n = 12), and the fibrin alone group had 1700 ± 800
fibers. The GDNF alone, DS alone (no GF), and empty conduit groups had little
regeneration and resulted in fiber counts less than 1700. The isograft had significantly more
fibers than all other groups. The average number of fibers in a normal rat sciatic nerve is
approximately 7200 ± 410 (Mackinnon, Dellon et al. 1991).
Nerve fiber density is another measure of neural regeneration. The nerve fiber
density at the midline for the GDNF DS (~13,000 fibers/mm2) and NGF DS (~15,000
fibers/mm2) groups were not significantly different from the isograft controls (~20,000
fibers/mm2) (Figure 5.3B). For normal sciatic nerve, the fiber density is ~12,000
fibers/mm2 (Mackinnon, Dellon et al. 1991). Both groups incorporating the delivery system
and growth factors also had similar percentages of neural tissue at the midline of the conduit
(15 – 16 %) compared to the isografts (~19 %) (Figure 5.3C). This assessment provides a
measure of quality of the regenerating nerve and suggests that the quality of nerve
regeneration is better in groups containing both the delivery system and growth factor
compared to control groups.
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Figure 5.3. Histomorphometric analysis of nerves at the midline of the conduit (or graft).
The total number of myelinated nerve fibers, density, and percent neural tissue were measured by
quantitative histomorphometry. No groups were similar to the isograft group in terms of total
number of nerve fibers (A), but the delivery system with GDNF (GDNF DS) or NGF (NGF DS)
was similar to the isograft in terms of fiber density (B) and percent neural tissue (C). Data (n = 12)
represents mean ± S.E.M. and * indicates statistical significance (p<0.05) compared to the isograft.

The myelinated nerve fiber width was assessed as a measure of maturity of the
regenerating nerve fibers, and groups that were most effective in promoting neural
regeneration were assessed for their fiber width distribution in regenerating nerves. All
groups utilizing fibrin within conduits for regeneration contained fewer smaller nerve fibers
(2 – 3 μm) compared to isograft controls (Figure 5.4A); furthermore, the GDNF DS group
also contained fewer nerve fibers than the isograft in the 3 – 4 μm distribution. Both groups
containing the delivery system and growth factor demonstrated higher percentages of larger
nerve fibers (4 – 5, 5 – 6 μm) compared to the isograft, but only the GDNF DS group
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promoted the higher percentages of large caliber nerve fibers (6 – 7 μm) compared to the
isograft, suggesting more mature regenerating fibers. Overall, conduit groups contained
larger average fiber widths compared to the isograft (Figure 5.4B). The normal median rat
sciatic nerve fiber width is ~6.5 μm (Mackinnon, Dellon et al. 1991).

Figure 5.4. Myelinated fiber size distribution of regenerating nerves at the midline of the
conduit (or graft). The nerve fiber width distributions (A) and averages (B) were measured by
quantitative histomorphometry. The percentage of large regenerating nerve fibers (4-5, 5-6 µm) were
larger in the GDNF DS and NGF DS groups compared to the isograft group. GDNF DS had
significantly the greatest percentage of the largest fibers (6-7µm) compared to the isograft. Overall,
conduit groups average fiber widths were larger than isografts. Data represents mean ± S.E.M. and *
indicates statistical significance (p<0.05) compared to the isograft.

5.4.4 Electron microscopy
Electron microscopy was performed to evaluate the regenerative nerve
ultrastructure. Representative sections from groups that were most effective in promoting
nerve regeneration (GDNF DS, NGF DS, fibrin alone and isograft) are shown in Figure 5.5.
The myelinated and unmyelinated fiber areas were determined from randomly selected
specimens from each group by a researcher blinded to the groups (n = 3). Qualitatively, the
GDNF DS group again appeared to have more organized structure and more uniform fiber
shape with larger myelinated fibers than the other experimental groups including the isograft,
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while fibrin alone had the most disorganized appearance and less uniform fiber shapes. The
myelinated area of the GDNF DS (27 ± 2.4 µm2) and NGF DS (23 ± 5.1 µm2) groups were
equivalent to the isograft (25 ± 5.5 µm2), whereas fibrin alone (19 ± 1.4 µm2) had
significantly less myelinated fiber area (Figure 5.6A). There were no differences among
groups for unmyelinated fiber area (Figure 5.6B).
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Figure 5.5. Electron micrographs of regenerating nerves at the midline of the conduit (or
graft). (A) Fibrin alone; (B) Isograft; (C) delivery system incorporating GDNF (GDNF DS); (D)
delivery system incorporating NGF (NGF DS); (E) normal uninjured nerve. Ultrathin 70 nm
sections of the embedded tissues were cut and stained with uranyl acetate-lead citrate. Qualitatively,
GDNF DS and NGF DS appeared to have more uniform fiber structures with larger myelinated
fibers than fibrin alone, which had the most disorganized fiber appearance. Scale bar, 5 µm.
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Figure 5.6. Myelinated and unmyelinated fiber areas of regenerating nerves at the midline of
the conduit (or graft). The myelinated and unmyelinated fiber areas were determined from
randomly selected specimens by electron microscopy from each group. The myelinated areas of for
groups with the delivery system incorporating GDNF (GDNF DS) or NGF (NGF DS) were
equivalent to the isograft, whereas the fibrin alone group had a lower myelinated fiber area (A).
There were no differences among groups in unmyelinated fiber area (B). Data (n = 3) represents
mean ± S.E.M. and * indicates statistical significance (p < 0.05) compared to the isograft.

5.5

Discussion
Peripheral nerve injuries are devastating and alternatives to standard repairs of nerve

gaps rarely lead to complete clinical recovery. In this study we examined the effect of
growth factor delivery using a NGC to bridge and enhance nerve regeneration across a
critical nerve gap length. We used an affinity-based delivery system within a fibrin matrix to
immobilize growth factors, slow their diffusion from the matrix, and allow release by cellmediated degradation of the matrix, thus, controlling their delivery to the regenerative site.
This “cell-mediated” matrix degradation and subsequent growth factor release may be
facilitated through the processes of axonal outgrowth and cell-induced protease activation
(e.g. plasmin activation on the growth cone) (Kalderon 1984; Krystosek and Seeds 1984;
Alvarez-Buylla and Valinsky 1985; Pittman and Buettner 1989; Herbert, Bittner et al. 1996).
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We have previously examined controlled release of NGF with this delivery system in
vivo and found that affinity-based release of NGF increased myelinated nerve fiber sprouting
and outgrowth compared to diffusion-based release from fibrin matrices alone (Lee, Yu et al.
2003a). In the present study, we focused on the controlled delivery of another neurotrophic
factor, GDNF, to investigate its effect on peripheral nerve regeneration in a sciatic nerve
injury model. We found that controlled delivery of GDNF was superior to controls in
aspects of nerve regeneration including neural fiber size and organized nerve architecture,
suggesting more mature neural content. The use of our affinity-based delivery system
directly affected regeneration across a 13 mm gap and the inclusion of the delivery system
sequestering GDNF had a greater effect in eliciting neural regeneration than providing
GDNF in an unbound form to the regenerative site. This effect may be explained by the
delivery’s system’s ability to sequester GDNF and avoid an initial burst of drug release, as
found in vitro (Wood, Borschel et al. 2009). Others have cited initial bursts of GDNF release
to be detrimental to nerve regeneration (Barras, Pasche et al. 2002).
We anticipated the ability of an exogenous fibrin matrix, with or without an affinitybased delivery system, to facilitate bridging a critical nerve defect because a fibrin matrix
naturally forms within an empty silicone conduit connecting the damaged ends of rat sciatic
nerve over a one week period (Williams, Longo et al. 1983). However, we were surprised to
see three out of twelve empty conduits had regeneration across this critical defect, although
the neural content was histologically poorly organized. Nerve regeneration has been shown
to be inconsistent beyond a 10 mm defect without the addition of other components, such
as extracellular matrix molecules, Schwann cells, plasma, or neurotrophic factors (Lundborg,
Dahlin et al. 1982a; Williams, Longo et al. 1983). The regeneration in our empty conduits
may be a result of superior neural regeneration for rats, as it has been shown that the rat is
125

able to spontaneously regenerate into an unfilled 4.5 cm nerve gap to a distance of 2.4 cm
after 5 months (Mackinnon, Hudson et al. 1985). Despite the regeneration in some of the
controls, the inclusion of our affinity-based delivery system incorporating GDNF or NGF
more closely approximated neural regeneration of an isograft across a critical gap defect.
The efficacy of affinity-based delivery of GDNF or NGF to the regenerative site was
also observed in the histomorphometry and electron microscopy results. Both groups
containing the delivery system and neurotrophic factors were not statistically different from
the isograft controls with regards to fiber density and percent neural tissue, both measures of
nerve quality. Beyond enhancing the quality of regeneration, we found that the delivery of
GDNF and NGF from the affinity-based delivery system improved the maturity of the
regenerating fibers. It is well known that axon size and myelin thickness are measures of
maturity (Aitken, Sharman et al. 1947; Young 1949; Williams and Wendell-Smith 1971;
Fraher and Dockery 1998). Both growth factors increased fiber maturity, as seen in
histomorphometric fiber distributions as well as myelinated fiber area from electron
microscopy. Our findings suggest that although not equivalent in fiber number, the delivery
of GDNF by our delivery system produces larger, mature nerve fibers. Of particular
importance, the GDNF group had more 6-7 µm diameter fibers than all other groups
including the isograft. In the normal, uninjured sciatic rat nerve, the average myelinated
fiber width is 6-7 µm. Furthermore, studies have shown that larger axon diameter and
myelination results in larger conduction velocity and can be correlated to greater function as
compared to smaller, less myelinated fibers (Williams and Wendell-Smith 1971; Fraher and
Dockery 1998). Although we did not look at functional outcomes in this study, parallel
studies are underway to explore if these larger diameter fibers result in greater return of
function.
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Our study corroborates previous findings in the literature on the effect of GDNF on
peripheral nerve regeneration. Barras et al. evaluated the effects of GDNF delivery from an
ethylene vinyl acetate polymer rod across an 8 mm rat facial nerve defect. Similar to our
results, they found that GDNF delivery increased myelination and fiber size. In this pure
motor model, they also found that GDNF promoted increased motor neuron labeling in
comparison to neurotrophin-3, suggesting that GDNF has a significant role in motor nerve
regeneration (Barras, Pasche et al. 2002). Given the strong evidence of GDNF in motor
neuron survival and enhancement of peripheral nerve regeneration, further studies looking at
the affinity-based delivery of GDNF to specific motor and sensory nerves will be performed
to elucidate this neurotrophic factor’s impact on modality specific regeneration.
In addition, Fine et al. evaluated axonal regeneration across a 15 mm long gap in the
rat sciatic nerve in the presence of GDNF or NGF provided by synthetic nerve guidance
channels continuously releasing the neurotrophic factors. They found that the average
number of myelinated axons at the midpoint of the regenerated nerves was greater in the
presence of GDNF than NGF. The GDNF group also had significantly greater numbers of
retrograde labeled motoneurons. Thus, these authors report GDNF to have greater efficacy
than NGF in overall regeneration (Fine, Decosterd et al. 2002). In contrast, we did not find
significant differences between GDNF and NGF, except in fiber size distribution. The
difference in our findings may be attributed to our method of delivery. In particular, Fine et
al. used diffusion-based delivery of GDNF or NGF from a biodegradable conduit where the
dose delivered to the regenerating nerve was constant for a period of time. Our delivery
method relies on cell-mediated release of sequestered growth factor from a luminal matrix,
which allows the release rate to vary based on the presence of cells and position within the
NGC. This result suggests that this method of growth factor delivery may play a role in
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regeneration. The effect of delivery rate has been noted by others, such as Piquilloud et al.
who used a resorbable conduit that released GDNF at three different delivery rates and
found differences in neural regeneration due to release rate (Piquilloud, Christen et al. 2007).
We have examined our delivery system with a silicone NGC because of the
biocompatibility of the product, its mechanical stability, and well known critical defect length
in our surgical model. However, clinically, silicone conduits are not ideal and have
associated morbidities. Silicone conduits have been reported to cause chronic nerve
compression, irritation at the implantation site requiring removal, and inflammatory and
fibrotic reactions impacting nerve regeneration (Merle, Dellon et al. 1989; Dellon 1994;
Battiston, Geuna et al. 2005). Thus, the combination of our drug delivery system with a
biodegradable conduit would be more desirable for clinical peripheral nerve injury repairs.
Future studies directed toward this goal would be of certain benefit in translating our
delivery system into clinical practice.
Lastly, previous studies have demonstrated that both NGF and GDNF can enhance
peripheral nerve regeneration (Fine, Decosterd et al. 2002; Boyd and Gordon 2003).
However, NGF has been shown to primarily promote sensory nerve regeneration in the
peripheral nervous system (Terenghi 1999; Boyd and Gordon 2003) as motor neurons do
not express NGF or its receptors (Boyd and Gordon 2003). Our study further confirms the
assertion that the delivery of these neurotrophic factors enhances peripheral nerve
regeneration in a sciatic nerve model, a model that contains both sensory and motor fibers.
Given that that GDNF and NGF affect different cell populations (Boyd and Gordon 2003)
and in vitro work demonstrates increased neurite outgrowth with the combination of the two
factors more than either alone (Deister and Schmidt 2006), an interesting investigation
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would be to evaluate the possible synergistic effects of delivering a combination of both
neurotrophic factors on peripheral nerve regeneration.

5.6

Conclusions
In summary, the goal of this study was to evaluate and elucidate the efficacy of

affinity-based delivery of GDNF to the regenerative site in a critical size defect model. We
examined histological outcomes of this neurotrophic factor and compared it to controls as
well as NGF. Given the increased maturity and organized architecture of the regenerating
nerve under the influence GDNF, we believe affinity-based delivery of GDNF offers insight
into potential future alternatives for the treatment of peripheral nerve injuries.
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Chapter 6
Fibrin Matrices with Affinity-based Delivery Systems
and Neurotrophic Factors Promote Functional Nerve
Regeneration
6.1

Abstract
Glial-derived neurotrophic factor (GDNF) and nerve growth factor (NGF) have

both been shown to enhance peripheral nerve regeneration following injury and target
different neuronal populations. Therefore, the delivery of either growth factor may result in
differences in motor and sensory nerve regeneration and functional recovery. In this study
we evaluated the effect of affinity-based delivery of GDNF or NGF from a fibrin matrix in a
nerve guidance conduit (NGC) on modality specific nerve regeneration and functional
recovery in a 13 mm rat sciatic nerve defect. Seven experimental groups were evaluated
consisting of GDNF or NGF and the delivery system (DS) within the conduit, control
groups excluding the DS and/or growth factor, and nerve isografts. The DS with either
GDNF or NGF resulted in a higher frequency of nerve regeneration versus control groups
with a nerve cable spanning the 13 mm gap within the conduit. All groups with a fibrin
matrix and growth factor in the conduit performed similar to the isograft in behavioral
measures and had similar relative muscle mass at 12 weeks, while the GDNF DS group had
better behavioral outcomes than the isograft. While no differences were observed in nerve
compound nerve action potentials, groups with GDNF had greater extensor digitorum
longus twitch and tetanic specific muscle force. Modality specific regeneration assessed by
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retrograde labeling revealed the number of labeled ventral horn neurons in the GDNF and
NGF DS groups were similar to the isograft; however, these counts were greater than those
of groups without growth factor. Only the empty conduit group had a lower number of
labeled DRG neurons and all other groups showed no differences. Overall, the ability of the
GDNF DS group demonstrated better functional recovery and equivalent motor nerve
regeneration compared to the isograft, suggesting it has potential as a treatment for motor
nerve injury.

6.2

Introduction
Despite significant advances in the treatment of peripheral nerve injury, complete

clinical recovery is rare suggesting that an alternative to the current standard of care (nerve
autograft) is needed. Critical nerve defects treated by nerve autograft suffer from donor site
morbidity and remain deficient in positive functional outcomes (Beazley, Milek et al. 1984;
Dellon and Mackinnon 1988). An alternative repair strategy involves a nerve guidance
conduit (NGC), which can be filled with a biomaterial matrix and growth factors, to bridge
the defect and enhance axonal regeneration (Schmidt and Leach 2003; Bellamkonda 2006).
NGCs have demonstrated similarities to autografts by histological measures, but data
supporting their role in motor nerve regeneration and functional recovery is limited.
Therefore, alternative strategies such as NGCs should focus not only on promoting nerve
regeneration but also improving functional recovery.
Functional recovery following peripheral nerve injury has been difficult to achieve
because the biology of modality specific nerve regeneration (sensory versus motor nerve
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regeneration) and the requirements for stimulating proper muscle reinnervation are not well
understood. One hypothesis is that trophic support acts as a cue to promote the specificity
of nerve regeneration (Uschold, Robinson et al. 2007). Through a series of experiments,
Madison and colleagues demonstrated that motor axons regenerated to their correct parent
branch due to trophic support derived from their end-organ targets (Robinson and Madison
2004; Madison, Robinson et al. 2007; Uschold, Robinson et al. 2007). Alternatively, others
have suggested that the nerve branches may be a source of modality specific trophic support.
For example, the use of ventral root (motor) nerve segments in silicone conduits stimulated
better muscle reinnervation compared to dorsal root (sensory) nerve segments in a sciatic
nerve defect, possibly due to cues for motor nerve regeneration contained in the ventral root
nerve segments (Lago, Rodriguez et al. 2007). Recent work by Hoke et al. demonstrated that
Schwann cells (SCs) within the nerve branches may be the source of the modality specific
trophic support. They observed differences in growth factor expression levels before and
after injury when comparing motor and sensory nerve branches (Hoke, Redett et al. 2006).
Additionally, motor and sensory neurons express varying levels of growth factor receptors
(Boyd and Gordon 2003). For example, motor neurons and their axons express receptors
for glial-derived neurotrophic factor (GDNF (GDNFRα1 and RET) but not NGF (TrkA)
(Boyd and Gordon 2003). Therefore, the inclusion of growth factors that target motor
neurons in a conduit may better stimulate motor nerve regeneration and in turn better
promote functional recovery.
Differences in nerve regeneration modalities have been observed with growth factor
delivery from NGCs that target different neuronal populations. Fine et al. found that the
controlled delivery of GDNF from synthetic conduits stimulated more motor neurons to
regenerate versus NGF as assessed by retrograde labeling of the regenerating ventral horn
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axons (Fine, Decosterd et al. 2002). Additionally, Barras et al. found that a greater number of
axons regenerated with controlled delivery of GDNF from synthetic conduits compared to
neurotrophin-3 (NT-3) in a rat facial nerve injury model, which is a primarily motor nerve
(Barras, Pasche et al. 2002). Both studies utilized diffusion-based release of growth factors
from the NGC. Based on these studies we hypothesized that an alternative approach,
affinity-based delivery, could potentially stimulate modality specific nerve regeneration due to
growth factor release.
In contrast to diffusion-based release, an affinity-based DS allows the release of growth
factors to be controlled by cell-based degradation of the DS (Sakiyama-Elbert and Hubbell
2000a). Our lab has developed an affinity-based DS that sequesters the drug of interest into
a fibrin matrix using non-covalent interactions (Sakiyama-Elbert and Hubbell 2000a;
Sakiyama-Elbert and Hubbell 2000b). This system consists of a bi-domain heparin-binding
peptide, where one domain is a transglutaminase substrate, based on α2-plasmin inhibitor
(Ichinose, Tamaki et al. 1983; Kimura, Tamaki et al. 1985), allowing the peptide to be
crosslinked into fibrin matrices during polymerization by the transglutaminase Factor XIIIa.
The other domain consists of a modified version of the heparin-binding domain from
antithrombin III (Tyler-Cross, Sobel et al. 1994; Tyler-Cross, Sobel et al. 1996; Sakiyama,
Schense et al. 1999), that allows non-covalent immobilization of heparin to peptide
crosslinked within a fibrin matrix. The heparin-binding domain has the ability to sequester
various growth factors based on their interaction with heparin via the sulfate groups
(Yamada 1983).
Delivery of NGF and GDNF from our affinity-based DS has previously been found
to promote nerve regeneration in short-term studies (Lee, Yu et al. 2003a; Wood, Hunter et
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al. 2009; Wood, Moore et al. 2009). In the present study, we evaluated the effects of the
controlled release of GDNF and NGF from a fibrin matrix containing our affinity-based DS
within a NGC on modality specific nerve regeneration and functional recovery in vivo using a
rat sciatic nerve injury model.

6.3

Materials and Methods
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless specified

otherwise.

6.3.1 Experimental animals
Adult male Lewis rats (Harlan Sprague-Dawley, Indianapolis, IN), each weighing
250-300 g were used in this study. All surgical procedures and peri-operative care measures
were performed in strict accordance with the National Institutes of Health guidelines and
were approved by the Washington University Animal Studies Committee. All animals were
housed in a central animal facility, given a rodent diet (PicoLab Rodent Diet 20 #5053, PMI
Nutrition International) and water ad libitum. After surgical procedures, animals recovered in
a warm environment and were closely monitored for 2 hours. Animals were then returned
to the animal facility and monitored for weight loss, infection, and other morbidities.
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6.3.2 Experimental Design
One hundred twelve animals were randomized into seven groups (n = 16) as shown
in Table 6.1. Fifty-six of those animals were distributed equally by group to the evoked
motor response portion of the study, while the remaining animals were distributed to the
retrograde labeling portion of the study. An additional eight animals served as sciatic nerve
isograft donors. Empty conduits served as the untreated control group. Additional control
groups received conduits containing fibrin with the DS (no growth factor) or fibrin with
growth factor, but no DS. These groups examined the effects of the incomplete DS. The
remaining groups were implanted with conduits containing fibrin with the DS and GDNF or
NGF. Doses of GDNF and NGF were selected based upon previous in vivo studies (Wood,
Moore et al. 2009). Reversed nerve isografts from syngeneic donor animals served as a
positive isograft control.

Table 6.1: Experimental Design
Motor Response Study

Retrograde Study

Group

Number

Number with

Number

Number with

Description

of Rats

Regeneration

of Rats

Regeneration

Isograft

Isograft

8

8

8

8

GDNF DS

Fibrin + DS

8

5

8

5

8

2

8

0

8

5

8

6

8

4

8

1

Group Name

+ GDNF
GDNF (no DS)

Fibrin +
GDNF

NGF DS

Fibrin + DS
+ NGF

NGF (no DS)

Fibrin +
NGF
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DS (no GF)

Fibrin + DS

8

3

8

3

8

3

8

2

(no GF)
Empty

Empty

Abbreviations: DS, Delivery System; GF, Growth Factor; GDNF, glial-derived neurotrophic factor (100 ng/mL);
NGF, nerve growth factor (50 ng/mL).

6.3.3 Preparation of fibrin matrices
Fibrinogen solutions were prepared by dissolving human plasminogen-free
fibrinogen in deionized water at 8 mg/mL for 1 h and dialyzing versus 4L of Tris-buffered
saline (TBS, 33 mM Tris, 8 g/L NaCl, 0.2 g/L KCl; Fisher Scientific, Pittsburgh, PA) at pH
7.4 overnight to exchange salts present in the protein solution. The resulting solution was
sterilized by filtration through 5.0 μm and 0.22 μm syringe filters, and the final fibrinogen
concentration was determined by measuring absorbance at 280 nm. For the DS, a bidomain peptide (ATIII) based on a modified version of the antithrombin III-heparin
binding domain ((AcG)NQEQVSPK(βA)FAKLAARLYRKA, where AcG denotes N-acetylglycine and the transglutaminase substrate is given in italics) (Tyler-Cross, Sobel et al. 1994;
Sakiyama, Schense et al. 1999) was synthesized as described previously (Wood, Borschel et
al. 2009). Fibrin matrices were prepared as previously described (Sakiyama-Elbert and
Hubbell 2000a). Components were mixed to obtain the following final solution
concentrations: 4 mg/mL fibrinogen, 2.5 mM Ca++, 2 NIH units/mL of thrombin, 0.25 mM
peptide (which results in 8 moles of cross-linked peptide per mole fibrinogen (Sakiyama,
Schense et al. 1999; Schense and Hubbell 1999)), 62.5 µM heparin (sodium salt), and
recombinant human GDNF or β-NGF (100 ng/mL and 50 ng/mL, respectively; Peprotech
Inc., Rocky Hill, NJ).
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Silicone tubing (SF Medical, Hudson, MA) (1.5 mm inside diameter x 0.3 mm wall
thickness) was autoclaved overnight, cut into 15 mm segments, and soaked in 70% ethyl
alcohol. Prior to filling, the tubes were rinsed with sterile saline solution. The fibrinogen
solution was drawn into the silicone tube using a pipette and allowed to polymerize for 10
minutes prior to implantation.

6.3.4 Operative Procedure
All surgical procedures were performed using aseptic technique and microsurgical
dissection and repairs. Four percent isoflurane gas (Vedco Inc., St Josephs, MO) anesthesia
was used for animal induction followed by 2% isoflurane gas to maintain anesthesia. The
hind leg of the rat was prepped and the sciatic nerve was exposed through a dorsolateralgluteal muscle splitting incision. A 5 mm nerve segment was excised proximal to the
trifurcation of the sciatic nerve and a 15 mm silicone tube, containing fibrin with or without
DS and growth factor, was sutured to the transected proximal and distal stumps,
incorporating 1 mm of nerve on either end (resulting in a 13 mm gap). Four 9-0 nylon
interrupted microepineurial sutures were used to secure the conduit. In animals receiving
the isograft control, a 13 mm segment of sciatic nerve was harvested from a syngeneic donor
animal and inserted into the recipient animal in reverse orientation. Wounds were irrigated
with saline, dried, and closed with a running 5-0 vicryl suture in muscle fascia, and then
interrupted 4-0 nylon skin sutures. Experimental animals were recovered in a warm
environment, and after recovery the animals were returned to the housing facility.
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6.3.5 Behavioral Analysis
Two behavioral tests were performed to assess functional recovery in experimental
groups before any surgical procedures and every 4 weeks before the experimental end point
at 12 weeks. Walking track analysis, as developed by de Medinaceli et al., was utilized to
assess the recovery of hindlimb function (de Medinaceli, Freed et al. 1982). The rats’ hind
feet were coated with nontoxic finger paint and the rats walked down a closed, narrow path
on construction paper. The footprints were assessed for toe spread, intermediate toe spread,
and print length as according to de Medinaceli et al. (de Medinaceli, Freed et al. 1982) and
scored using the sciatic functional index (SFI) previously developed by Bain et. al (Bain,
Mackinnon et al. 1989).
Additionally, a grid-grip test modified from Johnson et al. was utilized to measure
functional recovery in the hindlimb (Johnson, Parker et al. 2009). For this test, rats were
observed walking on a fixed grid of bars spaced 1.5 inches apart for 3 min. Successful grips
of the grid, defined as 2 or more toes of the injured foot griping the bar and successful
movement to another bar without slipping, and the total number of steps with the injured
foot were counted during the allotted time period. The percentage of successful grid-grips
was recorded and improvement in the percentage of successful grid-grips was indicative of
functional recovery.
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6.3.6 Measurement of compound neural action potentials (CNAPs) and
evoked motor responses
Twelve weeks postoperatively, sciatic nerve function was assessed by examining
CNAPs of the peroneal branch of the sciatic nerve and the motor response in reinnervated
EDL muscle upon stimulation of the sciatic nerve. All animals were re-anesthetized and
following isolation of the nerve branches and immersion of tissue in a mineral oil bath,
cathodic, biphasic electrical impulses (duration = 50 µsec, variable amplitudes) were
generated by a single-channel isolated pulse stimulator (Model 2100, A-M Systems Inc.,
Carlsborg, WA) and delivered to the sciatic nerve proximal to the regenerated nerve segment
via bipolar silver wire hook electrodes (7 mil, California Fine Wire, Grover Beach, CA).
Using similar wire hook electrodes, CNAPs were recorded and the resulting signal was
amplified (gain = 1000X) using an instrumentation amplifier (AD620, Analog Devices Inc.,
Norwood, MA) powered by a constant voltage source before being recorded on a desktop
PC (Dell Computer Corp., Austin, TX) equipped with a data acquisition board
(DT3003/PGL, Data Translations, Marlboro, MA) and custom Matlab software (The
MathWorks Inc., Natick, MA). Stimulation with a 1 msec delay and recording were
synchronized through custom software such that electrical stimulation coincided with the
initiation of a 500 msec recording period, wherein data was sampled at 40 kHz for an
average of 25 trials per current amplitude tested. Current amplitudes were varied to
determine the maximum CNAP and the threshold at which a CNAP and foot twitch (motor
response) were observed.
Following measurements of CNAPs, the distal portion of the EDL muscle was
separated from the leg by severing the distal tendons on the dorsum of the foot and
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fastening the tendons to a stainless steel S-hook at the musculotendinous junction using 5-0
nylon suture. Animals were subsequently placed in a custom-designed force measurement
jig where the leg was immobilized by anchoring the femoral condyles. The stainless steel Shook attached to the EDL muscle was connected to a 5 N thin film load cell (S100, Strain
Measurement Devices Inc., Meriden, CT) supported on an adjustable mount. Cathodic,
monophasic electrical impulses (duration = 200 µsec, frequency = single-200 Hz, amplitude
= 0-3 V) were generated and delivered to the sciatic nerve proximal to the regenerated nerve
segment via bipolar silver wire electrodes. Resulting force output at the EDL muscle tendon
was transduced via the load cell and the resulting signal was amplified (gain = 1000X) before
being recorded as before on a desktop PC with custom Matlab software. This software
calculated the passive force and active force for each recorded force trace.
Twitch contractions measured using the custom force recording system were utilized
to determine the optimal stimulus amplitude (Vo) and optimal muscle length (Lo) for
isometric force production in the EDL muscle. Stimulus amplitude was incrementally
increased while muscle length was held constant to determine the largest active force (Vo).
Muscle length was then increased in 1 mm increments from a relaxed state while the
stimulation amplitude was fixed at Vo until the largest active force produced was determined
(Lo). Lo was directly measured as the length of the EDL muscle from proximal to distal
musculotendinous junction. All subsequent isometric force measurements were made at Vo
and Lo. Single twitch contractions were recorded, and peak twitch force (Ft) was calculated.
Tetanic contractions were recorded by delivering 300 µsec bursts of increasing frequency (5200 Hz) to the sciatic nerve, while allowing two minute periods between stimuli for muscle
recovery. Maximum isometric tetanic force (Fo) was calculated from the active force plateau.
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Physiological cross-sectional area (PCSA) of the EDL muscle was calculated
according to the following (Urbanchek, Chung et al. 1999):

(6.1)

PCSA =

M × cos θ
(ρ )(Lo )(0.44) ,

where PCSA = physiological muscle cross-sectional area (cm2), M = EDL muscle mass (g),
cos θ = angle of pinnation for EDL muscle (0o), ρ = density of mammalian skeletal muscle
(1.06 g/cm3), Lo = optimal muscle length (cm), 0.44 = Lf/Lm ratio for EDL muscle fiber
length to the muscle belly length. Maximum specific isometric force was calculated as the
maximum isometric force normalized to muscle PCSA. Healthy, uninjured sciatic nerves
and EDL muscles were similarly tested and evaluated. The muscle mass of both the injured
and uninjured EDL muscles were harvested after testing and weighed. The injured muscle
mass was normalized to the uninjured muscle mass to determine the relative muscle mass
and level of muscle atrophy following injury.

6.3.7 Retrograde labeling of spinal cord and DRG neurons
Retrograde labeling distinguishes and allows quantification of regenerating sensory
and motor neurons. Twelve weeks postoperatively, the surgical site was reopened under
general anesthesia. The trifurcation of the sciatic nerve 5 mm distal to the conduit or graft
was transected, and the proximal portion was immediately placed in a silicone well
containing 4% Fluorogold solution (Sigma-Aldrich, St. Louis, MO). The nerve was allowed
1 h to bath in the solution. The silicone well and solution were removed and the wound
irrigated with saline, dried, and closed with a running 5-0 vicryl suture in muscle fascia, and
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then interrupted 4-0 nylon skin sutures. The contralateral side was labeled in the same
manner immediately following the experimental side as a control for the retrograde tracing.
Animals were recovered in a warm environment, and after recovery the animals were
returned to the housing facility.
Ten days following the procedure animals were euthanized and perfused in 4%
paraformaldehyde, and the spinal cord (Lumbar regions L3 – L6) and DRG (L4 & L5)
harvested. Twenty µm axial sections of the DRG and lumbar spinal cord were obtained on a
cryostat (Leica Microsystems). The number of labeled cell bodies on the control and
experimental side of each ventral horn spinal cord and DRG section were counted using an
optical dissector technique facilitated by MicroBrite Field stereology software (MBF
Bioscience StereoInvestigator version 7.0, Williston, Vermont), where count estimates were
accepted if the Gundersen coefficient of error was less than 0.08. Values were reported as
the percentage of cell bodies labeled relative to the contralateral, uninjured side.

6.3.8 Statistical analysis
All results are reported for animals with nerve regeneration (nerve cable present in
conduit/isograft) as mean ± standard error of the mean. Statistical analyses were performed
using Statistica version 6 (Statsoft Inc., Tulsa, OK). All data were evaluated for differences
between groups using the Analysis of Variance (ANOVA) with post hoc LSD tests with
Bonferroni correction used for determining differences between groups with significance set
at α = 0.05 (p<0.05).
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6.4

Results

6.4.1 Nerve guidance conduit harvest
The effectiveness of NGF or GDNF in promoting nerve regeneration across a
critical nerve gap was evaluated in vivo after sciatic nerve transection and NGC implantation.
After 12 weeks, groups with the DS and growth factor resulted in higher nerve regeneration
effectiveness (a neural structure spanning the 13 mm gap, Table 6.1). Combining animals
used in both portions of the study (evoked motor response and retrograde labeling), 10 of 16
conduits from the GDNF with DS (GDNF DS) and 11 of 16 conduits from NGF DS
groups contained regenerated nerve cables. Only 2 of 16 conduits from the GDNF (no DS)
group, 5 of 16 conduits from the NGF (no DS) group, 6 of 16 conduits from the DS alone
with no growth factor (DS (no GF)) group, and 5 of 16 conduits from the empty group
demonstrated nerve regeneration, representing a frequency of less than half the animals
regenerating any neural tissue. All 16 animals in the isograft group had regeneration. The
regenerated nerves in the NGF DS and GDNF DS groups exhibited a larger, more robust
nerve cable in comparison to the other experimental conduit groups by gross observation.
The neural structure was centered compactly in the conduit, away from the walls, in all
conduit specimens and had a smaller cross-sectional area than the isograft group. All
conduit specimens demonstrated intact connections to the proximal or distal sciatic nerve,
despite variability in regeneration.
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6.4.2 Behavioral testing
All animals regardless of nerve regeneration were assessed for functional recovery
using noninvasive behavioral testing over the course of 12 weeks. Only animals with nerve
regeneration, as determined at nerve harvest, were included in the behavioral analysis, which
include animals pooled from the entire study, both the evoked motor response and
retrograde labeling of SC and DRG neurons. The average preoperative SFI score was -7.3 ±
1.1 for experimental groups with no differences between groups, demonstrating normal
function before injury. No experimental animals demonstrated improved functional
recovery 4, 8 or 12 weeks after injury as SFI scores did not differ between weeks (Figure
6.1). Toe and ankle contractures (abnormal distortions in the toes and ankles) were
observed at 8 and 12 weeks after injury, which disqualified these animals for use in walking
track analysis testing since clear toe spreads and/or print lengths were unobtainable.
However, animals without contractures did not exhibit differences in SFI scores between
groups at 4, 8, or 12 weeks after injury.
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Figure 6.1. Walking track analysis for groups with nerve regeneration 12 weeks after injury.
Animal hind limb foot tracks were recorded and scored for the sciatic functional index (SFI). No
experimental groups demonstrated improved behavioral recovery at any time point and no
differences were found between groups at any time point. Data represents mean ± S.E.M.

Animals were also placed on a wire grid every 4 weeks, and the number of times the
animal successful used its toes to grip the wire mesh without slipping and with visible toe
curling were recorded to measure return to normal, uninjured behavior. All groups
preoperatively averaged high successful grid-grips percentages (79 ± 13%) with no
differences between experimental groups. Four weeks after injury, all experimental groups
demonstrated poor grid-gripping ability with successful grid-grip percentages at nearly zero
for all groups, and no differences were found between groups (Figure 6.2). At 8 weeks, the
isograft had improved functional recovery compared to all other groups with an average
successful grid-grip of 6.8 ± 1.4%, indicating possible earlier neural reinnervation of muscles.
However, at 12 weeks the GDNF DS group surpassed the isograft in functional recovery
with a higher successful grid-grip (13 ± 2%) compared to the isograft (5.9 ± 1%). All other
experimental groups except the empty conduit group (0.4 ± 0.4%) were similar to the
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isograft at 12 weeks in successful grid-grip percentages. Additionally, all experimental
groups except GDNF (no DS) had improved functional recovery compared to the empty
conduit group.

Figure 6.2. Successful grid-grip percentages for groups with nerve regeneration 12 weeks
after injury. Animals were placed on a wire mesh to assess the number of times the animal
successful placed its toes to grip the wire mesh without slipping and the total number of steps taken
with the injured foot. The isograft had improved recovery compared to all groups at 8 weeks;
however, GDNF with the delivery system (GDNF DS) had more successful grid-grips compared to
the isograft at 12 weeks. All other experimental groups performed equal to the isograft except the
empty conduit group at 12 weeks. Data represents mean ± S.E.M., * indicates statistical significance
(p<0.05) compared to the isograft, and # indicates statistical significance (p<0.05) compared to
empty.

6.4.3 Evoked Motor Response
The sciatic nerve was stimulated proximal to the injury site to determine functional
recovery in the peroneal branch by measuring CNAPs for animals with nerve regeneration
across the conduit. Normal, uninjured peroneal nerve produced maximum CNAPs of 12 ±
1.3 mV and first elicited a motor response (foot twitch) with CNAP at 42 ± 4 µA. The
number of animals with regeneration and tested for this portion of the study is summarized
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in Table 6.1. The DS (no GF) and empty groups contained inferior regeneration that
complicated measurements, where neither group had more than one animal with nerve
regeneration with recordable CNAPs; therefore, these groups were omitted from the analysis
as statistics could not be performed for these groups. Groups with growth factor (with or
without the DS) and isografts demonstrated similar CNAPs (1.5 – 0.4 mV) and similar
elicited motor response thresholds (400 – 180 µA), which were different than normal nerve
(Figure 6.3A & B). Data tended to have high variance due to variability in neural
regeneration in combination with tissue scarring and bleeding, which complicated
measurements.

Figure 6.3. Maximum CNAPs and current thresholds to elicit motor responses for groups
with nerve regeneration 12 weeks after injury. The peroneal nerve was stimulated proximal to the
graft or conduit at variable current amplitudes to measure CNAPs (A) and to elicit motor responses
(B). The maximum CNAP and current threshold amplitudes to elicit motor responses were not
different between experimental groups. Data represents mean ± S.E.M.

The sciatic nerve was stimulated proximal to the graft or conduit to measure whole
force production in the EDL. These data were normalized to the cross-sectional area of the
muscle to obtain the specific force, which measures deficits in force capacity and is
independent of muscle mass. Normal, uninjured nerve produced twitch and tetanic specific
forces of 5.0 ± 0.48 N/cm2 and 16 ± 1.6 N/cm2, respectively. No experimental group
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matched the normal nerve in either measure. All groups except GDNF groups produced
similar twitch and tetanic specific forces compared to the isograft, including groups without
growth factor, the empty and DS (no GF) conduits (Figure 6.4); however, groups without
growth factor tended to have high variance due to low number of animals with nerve
regeneration, which diminished power for statistical comparisons. Both twitch and tetanic
specific forces increased for the GDNF DS (3.4 ± 0.36 N/cm2 and 8.9 ± 1.2 N/cm2,
respectively) and GDNF (no DS) (3.6 ± 0.25 N/cm2 and 11 ± 0.14 N/cm2, respectively)
groups compared to the isograft (1.4 ± 0.4 N/cm2 and 4.0 ± 0.8 N/cm2, respectively).
These groups were also increased compared to empty (1.1 ± 1.1 N/cm2 and 2.3 ± 2.3
N/cm2, respectively) and DS (no GF) (0.98 ± 0.74 N/cm2 and 3.2 ± 2.0 N/cm2,
respectively) groups. Overall, the GDNF delivery results possibly indicate superior muscle
reinnervation.
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Figure 6.4. Specific force measurements of EDL for groups with nerve regeneration 12 weeks
after injury. EDL muscles were stimulated proximal to the graft or conduit to the produce maximal
twitch and tetanic muscle force, which were normalized to the muscle cross sectional area. All
groups, except GDNF groups, produced similar specific forces compared to the isograft. Specific
twitch and tetanic forces increased for GDNF groups, compared to empty and DS (no GF) groups
and the isograft. Data represents mean ± S.E.M., * indicates statistical significance (p<0.05)
compared to the isograft, and # indicates statistical significance (p<0.05) compared to empty or DS
(no GF) groups.

EDL muscles (experimental and contralateral sides) were harvested and weighed
after evoked motor response testing and normalized to the contralateral (uninjured side)
muscle mass to assess the level of muscle atrophy due to loss of nerve innervation. Groups
with growth factor (53 – 63%) were similar to the isograft (~ 62%), while groups without
growth factor, empty (~ 30%) and DS (no GF) (~ 41%) groups, had decreased relative
muscle mass compared to the isograft (Figure 6.5). Additionally, groups with growth factor,
except NGF (no DS), had increased relative muscle mass compared to the empty conduit
group.
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Figure 6.5. Relative muscle mass of EDL for groups with nerve regeneration 12 weeks after
injury. EDL muscles (experimental and contralateral sides) were harvested and weighed, and the
experimental muscle mass normalized to the contralateral mass. Groups with growth factor were
similar to the isograft in relative muscle mass. Data represents mean ± S.E.M., * indicates statistical
significance (p<0.05) compared to the isograft, and # indicates statistical significance (p<0.05)
compared to empty.

6.4.4 Retrograde labeling
Experimental and contralateral (for normalization) sciatic nerves were labeled with
Fluorogold solution to stain ventral horn and DRG neurons for animals with nerve
regeneration. Cell counts of labeled axons in both regions allow quantification of
regenerating motor and sensory neurons, respectively. The number of animals with
regeneration and tested for this portion of the study is summarized in Table 1. Neither
NGF (no DS) nor GDNF (no DS) had more than one animal with nerve regeneration for
this portion of the study; therefore, these groups were omitted from the analysis as statistics
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could not be performed for these groups. Differences in cell sizes, such as diameter, or
locations within the spinal cord or DRG between experimental groups could indicate
differences in neuronal populations and fiber types regenerating. However, no qualitative
differences in labeled neurons were observed between GDNF DS, NGF DS, and isograft
groups (Figure 6.6).

Figure 6.6. Representative sections of retrograde labeled ventral horn SC and DRG neurons
12 weeks after injury. The experimental and contralateral sciatic nerves were labeled with 4%
fluorogold to stain sensory (DRG) and motor (ventral horn SC) neurons. No qualitative differences
in cell sizes within the SC (A – C) or DRG (D – F) between experimental groups were observed
between isograft (A, D), GDNF DS (B, E), or NGF DS (C, F) groups. Scale bar represents 200 µm.

Normal, uninjured sciatic nerve had 3200 ± 180 ventral horn neurons and 11,000 ±
560 total L4 & L5 DRG neurons labeled. All experimental group ventral horn and DRG
neuron counts were normalized to contralateral (uninjured side) nerve counts in their
respective region to yield a percentage of regenerating neurons. GDNF DS (62 ± 11%) and
NGF DS (62 ± 7.1%) groups were comparable to the isograft (57 ± 4.5%) in the percentage
of normalized ventral horn neurons (Figure 6.7A). These three groups all had greater
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percentages of normalized ventral horn neurons compared to empty (1.4 ± 1.4%) and DS
(no GF) (23 ± 7.5%) groups. The percentage of normalized DRG neurons were similar for
GDNF DS (44 ± 4.7%), NGF DS (41 ± 7.2%), and DS (no GF) (44 ± 6.9%) groups
compared to the isograft (45 ± 2.9%). Additionally, these groups had increased percentages
of normalized DRG neurons compared to the empty conduit (14 ± 14%) group (Figure
6.7B). No differences between GDNF DS or NGF DS groups were found in either
percentage of normalized ventral horn or DRG neurons.

Figure 6.7. Percentage of normalized ventral horn SC and DRG neurons retrograde labeled
12 weeks after injury. The experimental and contralateral sciatic nerves were labeled distal to the
conduit or graft with 4% fluorogold to stain regenerating motor (ventral horn SC; A) and sensory
(DRG; B) neurons. DRG (L4 & L5) and spinal cords (ventral horn region) were harvested 10 days
after labeling, and 20 µm sections were evaluated for total cell numbers using stereology techniques.
GDNF DS and NGF DS were comparable to the isograft in percentages of normalized ventral horn
and DRG neurons. Additionally, these three groups contained more labeled ventral horn and DRG
neurons compared to empty conduit groups. Data represents mean ± S.E.M. where all cell counts
were normalized to the contralateral side, and * indicates statistical significance (p<0.05) compared to
the isograft.

6.5

Discussion
This study investigated whether the delivery of growth factors using affinity-based

delivery can affect modality specific nerve regeneration and functional recovery. Diffusionbased delivery systems have utilized growth factor delivery to promote nerve regeneration
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and modality specific nerve regeneration (Fine, Decosterd et al. 2002). We considered an
affinity-based DS, which uses non-covalent interactions to sequester and slow the release of
growth factor leaving it available for cell-mediated release. Cell-mediated processes, such as
neurite outgrowth induced protease activation (e.g. plasminogen to plasmin), cleave fibrin
into smaller fragments, which can regulate growth factor release from fibrin matrices
(Kalderon 1984; Krystosek and Seeds 1984; Alvarez-Buylla and Valinsky 1985; Pittman and
Buettner 1989; Pittman, Ivins et al. 1989; Herbert, Bittner et al. 1996). Therefore, this study
investigated whether a different delivery method, our affinity-based DS, could stimulate
modality specific nerve regeneration.
Regardless of growth factor used, the effectiveness of nerve regeneration or
frequency of neural regeneration across the 13 mm nerve gap, in the form of a nerve cable
spanning the conduit, was increased with the presence of the DS (see Table 6.1). Nerve
regeneration effectiveness decreased in groups without growth factor or DS establishing that
both are essential to improve effectiveness. Others have observed similar increases in nerve
regeneration effectiveness with controlled growth factor delivery but decreased effectiveness
without controlled growth factor delivery (Barras, Pasche et al. 2002; Fine, Decosterd et al.
2002; Dodla and Bellamkonda 2008). Previously, an initial burst was observed in vitro from
fibrin matrices with free growth factor (either NGF (Wood and Sakiyama-Elbert 2008) or
GDNF (Wood, Borschel et al. 2009)), while sequestered growth factor improved neurite
outgrowth compared to free growth factor with no DS (Sakiyama-Elbert and Hubbell 2000a;
Wood and Sakiyama-Elbert 2008; Wood, Borschel et al. 2009). A possible reason that fibrin
matrices with free growth factor (no DS) did not improve regeneration effectiveness could
be due to an initial burst of growth factor from the conduit, which has been cited by others
as detrimental to nerve regeneration (Barras, Pasche et al. 2002). An initial burst would also
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leave less growth factor remaining to promote regeneration for migrating cells and axons
growing into the conduit. A need for sustained growth factor release could also explain the
low regeneration effectiveness in groups without growth factor.
Two behavioral analyses were performed to detect differences in functional recovery
between groups. No differences in behavioral recovery were observed between groups as
measured by SFI scores. The lack of differences in SFI scores determined by walking track
analysis was likely due to frequent foot contractures observed in animals, which decreases
the number of animals that could be assessed using this method and has been cited by
others (Hare, Evans et al. 1992; Hare, Evans et al. 1993), Conversely, in the second analysis,
grid-grip, contracture formation analysis does not prevent measurements and is therefore
beneficial compared to walking track analysis in this regard.
In grid-grip analysis, groups with fibrin were similar to the isograft in behavioral
recovery. The overall improvement in successful grid-grip in groups with a fibrin matrix
could be due to the inclusion of a substrate for cellular adhesion, which is lacking in empty
conduits. Initial experiments in the rat sciatic nerve revealed that at one week a fibrin matrix
spans a silicone conduit used to contain nerve stumps, which is later followed by nerve
regeneration (Williams, Longo et al. 1983). Furthermore, fibrin has been used as a
biomaterial to support nerve regeneration within a NGC (Lee, Yu et al. 2003a; Galla,
Vedecnik et al. 2004; Marcol, Kotulska et al. 2005) and can promote cell adhesion because it
contains binding sites for integrins (Thiagarajan, Rippon et al. 1996) and Schwann cells
(Chernousov and Carey 2003), Therefore, a fibrin matrix can promote neural regeneration.
We observed faster behavioral recovery for the isograft group compared to conduit
groups, as the isograft had a higher successful grid-grip percentage at 8 weeks. However, the

154

GDNF DS group had improved behavioral recovery compared to the isograft at 12 weeks.
The improved recovery for the isograft group at 8 weeks may be due to a previous observed
increase in nerve fibers compared to other groups at 6 weeks (Wood, Moore et al. 2009),
which correlates with improved function (Aydin, Mackinnon et al. 2004; Lien, Cederna et al.
2008). However, in the same studies, GDNF DS had a greater number of larger (5 – 7 µm)
mature fibers than the isograft (Wood, Moore et al. 2009), which can correlate with greater
return in function compared to smaller fibers (Williams and Wendell-Smith 1971; Fraher and
Dockery 1998). Additionally, increases in EDL twitch and tetanic specific forces for the
GDNF DS group correlated with an increase in grid-gripping ability.
There were no differences between experimental groups in measured CNAPs or
current amplitude thresholds to elicit motor responses. The largest contributing factor to
this outcome was high variance in recording, likely due to tissue scarring near the nerve and
blood from the surrounding tissue interfering with neural electrode contact. However,
CNAP recordings do not clearly indicate return of function because the peroneal nerve
contains a mixture of sensory and motor fibers. Therefore, measured CNAPs are the
summation of all nerve fiber types generating action potentials and recording muscle force
production can better indicate functional recovery.
EDL specific force production measurements demonstrated that treatment with
growth factor produced muscle force that was comparable to the isograft. Most groups with
growth factor (except NGF (no DS)) also had decreased muscle atrophy compared to
groups without growth factor. Taken together, these results indicate that muscle
reinnervation may generally improve due to growth factor release. While the empty and DS
(no GF) conduit groups produced similar specific forces as the isograft, this result is likely
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due to high variation in nerve regeneration between animals. Rats have superior neural
regeneration compared to humans, as the rat is able to spontaneously regenerate into an
unfilled 4.5 cm nerve gap to a distance of 2.4 cm after 5 months (Mackinnon, Hudson et al.
1985). Therefore, negative controls in this injury model tend to have high biological
variance, which compounded with low regeneration effectiveness in these groups, results in
poor statistical comparisons.
A significant outcome in the study was increased twitch and tetanic specific EDL
forces for GDNF, with or without the DS, compared to groups without growth factor or
the isograft. These results suggest superior muscle reinnervation in groups that received
GDNF. GDNF is upregulated in Schwann cells in the distal nerve stump and skeletal
muscle after injury (Nagano and Suzuki 2003; Zhao, Veltri et al. 2004) and regulates
presynaptic differentiation and neuromuscular junction connections (Nagano and Suzuki
2003; Yang and Nelson 2004). Therefore, in our study, exogenous delivery of GDNF at the
site of injury could have amplified the existing endogenous mechanism for motor nerve
regeneration and resulted in improved functional reinnervation of the muscle. This
hypothesis may explain why groups with GDNF regardless of controlled delivery performed
better than the isograft in EDL twitch and tetanic specific force production. Furthermore,
normalized motor neuron counts for the GDNF DS were comparable to the isograft, which
would indicate that the motor neurons available are establishing more meaningful functional
connections with muscles.
It was not anticipated that the NGF DS would have been similar to the isograft in
functional recovery as well as motor neuron counts because NGF cannot target motor
neurons due to a lack of receptors. Previous studies using NGCs with growth factors that
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targeted motor neurons or axons, such as GDNF, have increased motor axon counts
(Barras, Pasche et al. 2002) or retrograde labeled motor neuron counts (Fine, Decosterd et al.
2002) compared to other growth factors such as NGF and NT-3. We observed no
differences in retrograde labeled motor neuron counts between GDNF or NGF delivered
with the DS but did observe functional differences, as GDNF performed better than the
isograft in functional recovery measures. The differences in our study results compared to
the previous studies could be the inclusion of a material for cellular migration and axonal
growth within the NGC and the delivery of growth factors from the material, as opposed to
diffusion-based delivery from the NGC. We hypothesize that the inclusion of the DS with
growth factors within the material facilitates both modality specific nerve regeneration and
Schwann cell migration into the conduit, promoting neural regeneration. The Mackinnon
lab has demonstrated that isografts facilitate better nerve regeneration compared to
decellularized nerve allografts based on measures of nerve regeneration effectiveness and
histomorphometry (Whitlock, Tuffaha et al. 2009). They attributed the enhanced nerve
regeneration in part to Schwann cells retained in isografts promoting nerve regeneration.
Additionally, Schwann cells contain receptors for both NGF (Taniuchi, Clark et al. 1988;
Anton, Weskamp et al. 1994) and GDNF (Iwase, Jung et al. 2005), which can facilitate cell
signaling leading to increased cell proliferation and migration (Anton, Weskamp et al. 1994).
Therefore, our DS may target motor axons with GDNF, explaining the improvement in
functional recovery compared to the isograft, while also encouraging Schwann cell
migration, explaining similarities in functional recovery and motor neuron counts between
NGF DS and the isograft.
Silicone conduits serve as a useful model to study nerve regeneration, but clinically
have associated morbidities. Silicone conduits have been reported to cause chronic nerve
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compression, irritation at the implantation site requiring removal, and inflammatory
reactions impacting nerve regeneration (Merle, Dellon et al. 1989; Dellon 1994; Battiston,
Geuna et al. 2005). We examined our DS within a silicone NGC because of the
biocompatibility of the product, the mechanical stability of the conduit wall thickness
chosen, and well characterized critical defect length in our surgical model. The combination
of our DS with a biodegradable conduit would be more desirable for clinical peripheral
nerve injury repairs. Based on the positive functional outcomes observed in our study, work
directed toward this goal would be beneficial in translating our DS into clinical practice.

6.6

Conclusions
In summary, the goal of this study was to determine if sensory or motor nerve fibers

regenerated and the functionality of regeneration due to growth factor delivery with an
affinity-based DS to the regenerative site in a rat sciatic nerve critical defect. We examined
behavioral outcomes and electrophysiological responses including evoked motor responses
and compared the measures to controls. We found similar functional outcomes as the
isograft with the delivery of NGF, but superior functional outcomes with the delivery of
GDNF, both supported by histological counts of regenerating motor and sensory neurons.
Due to the observed improved functional measures, we believe that affinity-based delivery
of growth factors offers insight into potential future alternatives for the treatment of
peripheral nerve injuries.
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Chapter 7
Summary and Future Directions
7.1

Summary of Findings
The results of this thesis work indicated that a fibrin affinity-based delivery system

(ABDS) delivering growth factors can promote peripheral nerve regeneration. These results
were determined through five studies. These objectives of the studies were: to assess the
role of peptide binding affinity for heparin in nerve regeneration through the delivery of
nerve growth factor (NGF); to assess the ability of a different growth factor, glial-derived
neurotrophic factor (GDNF), to promote nerve regeneration when delivered from the
ABDS; and to determine the effect of growth factor delivery from the ABDS in promoting
functional recovery following injury.
The first and second study of this thesis work addressed the role of peptide binding
affinity for heparin in promoting nerve regeneration. The first study determined if peptide
binding affinity for heparin and the molar ratio of peptide to heparin affected the release rate
and biological activity of NGF. Mathematically modeling of the delivery system and in vitro
experiments confirmed that release rates could be controlled by both peptide binding affinity
for heparin and the molar ratio of peptide to heparin. The ABDS was also found to present
biologically active NGF as assayed by chick embryo dorsal root ganglia (DRG) neurite
extension, regardless of peptide binding affinity for heparin. Thus release rate appeared to be
the main mechanism controlling the biological activity of released NGF.
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The second study extended the first study to evaluate the efficacy of the ABDS in
vivo to promote nerve regeneration in a rat sciatic nerve critical defect and determine if
peptide binding affinity for heparin affected nerve regeneration. Histological outcomes
demonstrated that the ABDS with any affinity peptide and NGF was similar to the isograft
in aspects of nerve regeneration including: nerve fiber density, the quality of nerve
regeneration, nerve fiber maturity, and the neural fiber organization of the regenerating
nerve 6 weeks after treatment. Additionally, no differences in nerve regeneration due to
heparin-binding affinity were observed, but general trends indicated that stronger peptide
binding affinity for heparin promoted superior nerve regeneration.
Based on the results of the first and second studies, the third and fourth study
addressed the role of GDNF in the context of the ABDS. These studies focused on the
delivery of GDNF from the ABDS incorporating the strongest heparin-binding peptide,
ATIII. The ABDS effectively sequestered and slowed the release of GDNF, and the ratio of
peptide to heparin was found to modulate the rate of GDNF release in vitro. The ABDS and
GDNF were found to promote neurite extension comparable to GDNF and fibrin matrices
alone at specific concentrations.
The fourth study evaluated the efficacy of affinity-based delivery of GDNF in a rat
sciatic nerve critical defect. Histological outcomes of nerve fiber density, the quality of
nerve regeneration, nerve fiber maturity, myelination, and the neural fiber organization of
the regenerating nerve demonstrated that the ABDS and GDNF were similar to the isograft
6 weeks after treatment. Therefore, the ABDS can promote peripheral nerve regeneration
following injury.
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Based on the outcome in short-term (6 week) in vivo studies, the objective of the fifth
study was to assess functional recovery and modality specific nerve regeneration with the
ABDS and growth factor in a rat sciatic nerve critical defect over 12 weeks following
treatment. Behavioral outcomes and electrophysiological responses including evoked motor
responses were similar to functional outcomes in the isograft with the delivery of NGF, but
superior to the isograft with the delivery of GDNF. Additionally, both GDNF and NGF
delivery supported the regeneration of motor and sensory neurons equivalent to the isograft,
as assessed by retrograde labeling. Overall, this work indicates that affinity-based growth
factor delivery from fibrin matrices enhances nerve regeneration.

7.2

Recommendations for Future Direction
This thesis work evaluated the role of peptide affinity and growth factor delivery

with an ABDS for peripheral nerve injury. Based on the observed histological outcomes and
functional measures, affinity-based delivery of growth factors offers potential alternatives for
the treatment of peripheral nerve injuries. During the evaluation in the short-term animal
studies (6 weeks), all experimental groups with a conduit for treatment of nerve injury
demonstrated decreased regenerating nerve fiber counts compared to the isograft. This may
be due to the silicone conduit limiting the area of nerve regeneration. This limitation could
be addressed with a new conduit material (or structure) to contain the luminal fibrin matrix
and ABDS. Additionally in the 6 week animal studies, the ABDS with GDNF or NGF were
similar to the negative control (empty conduits) in regenerating nerve fiber counts. This
result could again be due to the above mentioned silicone issue, which could limit the ability
to demonstrate differences in fiber counts within the conduit. Alternatively, the fibrin
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matrix and ABDS could be modulated to provide additional guidance cues for axons. As
observed in the final study, GDNF promoted better functional recovery than even the
isograft while NGF promoted functional recovery similar to the isograft. This result with
NGF delivery was not anticipated due to limitations of NGF in stimulating and targeting
motor neurons, which do not express the major receptor for NGF (TrkA). Overall, this
result may indicate that growth factor delivery in general has a synergistic effect on nerve
regeneration. Therefore, incorporating other known therapies for peripheral nerve injury,
such as the incorporation of cells into a fibrin scaffold with the ABDS, may further effect
nerve regeneration.

7.2.1 Advanced material and delivery strategies for nerve regeneration
In this thesis work, both GDNF and NGF promoted nerve regeneration. Although
it is not clear from this work, either growth factor may have promoted nerve regeneration to
an extent due to targeting and stimulating axonal growth in different neuronal populations,
as sensory and motor neurons express different receptors. An interesting extension of this
work would be to simultaneously present these growth factors to target the neuronal
populations. Deister et al. demonstrated that presenting multiple growth factors to DRG can
produce synergistic effects on neurite extension in vitro (Deister and Schmidt 2006). This
ABDS is capable of binding multiple growth factors simultaneously (Willerth, Rader et al.
2008), which could allow for delivery of both NGF and GDNF from the same scaffold or
other growth factor combinations.
This ABDS could alternatively include additional cell adhesion molecules or peptides
that interact with heparin. For example, the peptide sequence IKVAV is the neurite binding
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sequence contained on laminin (Tashiro, Sephel et al. 1989), and as a synthetic peptide could
be chemically modified to include a heparin-binding domain. The incorporation of both
cellular adhesive molecules and growth factors could have a synergistic or additive effect on
nerve regeneration. For example, adding laminin to agarose gels improved nerve
regeneration compared to agarose gels alone; however, combining laminin and NGF to
agarose gels improved nerve regeneration more than laminin alone in agarose gels (Yu and
Bellamkonda 2003). One consideration when incorporating additional growth factors or
proteins that interact with heparin would be the availability of binding sites for these
proteins, which limits the concentration of bound proteins. Based on the mathematical
modeling done in this work, the use of multiple growth factors would be reasonable. The
ratio of heparin to growth factor in the ABDS was on the order of thousands for the
sustained and controlled release of a single growth factor. Cellular adhesion molecules and
proteins are typically used at greater concentrations than growth factors; therefore, their use
would be limited to lower concentrations with this delivery system.
The fibrin matrices used in this study form via an enzymatic reaction that covalently
links randomly oriented fibrin monomers. Consequently, during polymerization fibrinogen
fibers within a fibrin matrix possess the ability to be aligned by a magnetic field. Parallel,
longitudinal arrangements of fibers in a material can promote nerve regeneration better than
random oriented fibers. Work from the Bellamkonda laboratory recently demonstrated that
synthetic polymer fibers oriented in a magnetic field to run parallel to regenerating nerve
fibers enhanced nerve regeneration compared to randomly-oriented, synthetic polymer fibers
(Kim, Haftel et al. 2008). Additionally, in vitro studies have demonstrated that similar
alignment can increase neurite outgrowth two-fold over randomly oriented fibers in a fibrin
matrix (Dubey, Letourneau et al. 2001). Incorporating the ABDS into a fibrin matrix with
163

aligned, parallel fibers could positively affect nerve regeneration. While it is unclear how the
delivery of growth factor would be affected by the alignment, the presentation of growth
factors from aligned fibers within the fibrin matrix would better mimic native nerve, which
contains parallel, longitudinally-oriented basal lamina tubes.
Alternatively, the ABDS could be used to create a concentration gradient of growth
factors or proteins that interact with heparin. In vivo concentration gradients of neurotrophic
factors promote enhanced nerve regeneration compared to isotropic presentation of the
same factors (Dodla and Bellamkonda 2008). Commonly for a concentration gradient of
growth factors to exist in an implantable material, the growth factors are immobilized within
the material. The ABDS sequesters growth factors due to a fast binding constant (kf), which
prevents long-term diffusion. Therefore, this ABDS could potentially sequester a gradient
of a number of growth factors to construct an implantable material to promote nerve
regeneration.

7.2.2 Alternative structure to contain the material for nerve regeneration
Although the ABDS with either GDNF or NGF promoted nerve regeneration
equivalent to the isograft by many histological measures, this result could be improved. The
silicone conduit used to contain the system proved detrimental in nerve regeneration as
measured by a decrease in the total number of regenerating nerve fibers for any experimental
groups with a conduit. Other researches have noticed this effect on nerve regeneration as
well (Lundborg, Dahlin et al. 1982b). Additionally, the implantation of a permanent conduit
could result in adverse tissue reactions, as noted by others (Dellon 1994), which could
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require a second surgery to remove it. Therefore, a different structure to house the material
would be useful to eliminate the need to permanently implant a device and potentially
improve nerve regeneration due to an increase in area available for nerve regeneration.
Loading the scaffold into a biodegradable nerve guidance conduit (NGC) would
eliminate the safety concerns of permanently implanting a medical device. It also capitalizes
on the natural degradation of the fibrin scaffold to construct a device that completely
degrades over time leaving behind the regenerated nervous tissue. While this ABDS is
capable of delivering multiple growth factors, as previously discussed, a biodegradable NGC
offers the potential to deliver growth factors as well. Growth factor delivery from the NGC
and the luminal scaffold would permit greater degrees of freedom in modulating release
rates, which can affect nerve regeneration. Previously Piquilloud et al. designed collagen
NGCs with layers of poly(lactide-coglycolide) that varied in thickness to produce conduits
that can deliver GDNF at variable rates based on layer thickness. The NGCs with highest
release rate of GDNF resulted in improved histological outcomes compared to delivery at
slower release rates (Piquilloud, Christen et al. 2007). Therefore, an additional release vehicle
could allow release rates of growth factors to be modulated to best promote nerve
regeneration. Additionally, the ABDS used in this work is limited in its ability to deliver
growth factors over long periods by degradation of the fibrin matrix, which completely
degrades by 2-4 weeks (unpublished data from the Sakiyama-Elbert lab). Delivery from a
NGC could provide growth factor delivery for periods beyond the fibrin degradation limit.
Overall, biodegradable NGCs have benefits compared to non-resorbable NGCs; however,
biodegradable NGCs still demonstrate problematic issues similar to silicone, where the
available area for nerve regeneration is limited in the NGC before the NGC degrades
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(Francel, Smith et al. 2003), and the NGC can cause compression on the nerve as the
conduit degrades (Borkenhagen, Stoll et al. 1998).
Materials, such as fibrin, are not limited to a NGC, and due to its ability to
polymerize to a stable hydrogel, it could be incorporated into other structures, such as
biological grafts. In particular, this scaffold could be utilized in decellularized biological
grafts to possibly improve their outcome. For example, decellularized muscle grafts do not
produce nerve regeneration similar to autografts, but can match autografts in some
histomorphometric measures of nerve regeneration when beneficial cues for nerve
regeneration, such as Schwann cells (SCs), are loaded into the muscle graft (Fansa and
Keilhoff 2004). Therefore, the use of both an inductive material, a fibrin matrix with an
ABDS as demonstrated in this work, and decellularized biological graft could produce
additive or synergistic effects on nerve regeneration. Perhaps the ideal structure would be a
decellularized nerve allograft, which would combine the alignment and natural structure of
nerve with a vehicle to deliver growth factors.

7.2.3 Cell transplantation for nerve regeneration
The migration of SCs into the NGC was not studied in this thesis work, but may
have played a role in promoting nerve regeneration as they are known to secrete trophic
support and can adhere to a fibrin scaffold. This ABDS has been used for many other
applications including a scaffold for cellular growth, specifically with embryonic stem cellderived neural progenitor cells (Willerth, Rader et al. 2008). Furthermore, the fibrin scaffold
with the ABDS was capable of promoting these cells to differentiate due to controlled
growth factor release from the ABDS. Therefore, SCs cultured within the scaffolds with
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controlled growth factor delivery may enhance their proliferation, migration, and myelination
capabilities. The transplantation of such a scaffold could enhance peripheral nerve
regeneration.
Previous work with the transplantation of SCs has shown mixed success. For
example, SCs loaded into biological grafts have proven beneficial (Fansa and Keilhoff 2004),
but others have not observed beneficial aspects. Specifically, Evans et al. loaded SCs into a
collagen scaffold in a degradable NGC to treat rat sciatic nerve injury. However, the
combination approach did not perform better in nerve regeneration measures than collagen
alone (Evans, Brandt et al. 2002); therefore, care must be taken to optimize SC growth
parameters with that of axonal regeneration in order to promote additive or synergistic
effects on nerve regeneration due to their transplantation.
Another aspect of SC transplantation that would be of interest to study would be the
effect of modality specific SC transplantation. Hoke et al. determined that SCs from
primarily sensory or motor specific nerve branches express different levels of growth factors,
indicating that SCs have specific phenotypes (Hoke, Redett et al. 2006). This result could be
further extrapolated to explore modality specific regeneration. For example, motor branches
may contain SCs that guide motor axons to the correct parent target (Brushart 1988).
Therefore, the transplantation of phenotypic specific SCs within a conduit or graft could
affect nerve regeneration modalities.
Although the proposed future work focuses on the use of the ABDS for treatment
of peripheral nerve injury, there could be potential for treatment of other diseases and
injuries. As already mentioned, this ABDS can be employed using a variety of growth
factors that interact non-covalently with heparin and to culture cells. It has been used for a
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variety of potential treatment applications, which include flexor tendon repair (Gelberman,
Thomopoulos et al. 2007) and spinal cord injury (Taylor, McDonald et al. 2004; Taylor and
Sakiyama-Elbert 2006). Due to the positive outcomes demonstrated in this thesis work,
future work with this biomaterial for local drug delivery and cell culture would be beneficial.
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